<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Curr Neuropharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Neuropharmacol</journal-id>
<journal-id journal-id-type="publisher-id">CN</journal-id>
<journal-title-group>
<journal-title>Current Neuropharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1570-159X</issn>
<issn pub-type="epub">1875-6190</issn>
<publisher>
<publisher-name>Bentham Science Publishers</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27296643</article-id>
<article-id pub-id-type="pmc">4983752</article-id>
<article-id pub-id-type="publisher-id">CN-14-514</article-id>
<article-id pub-id-type="doi">10.2174/1570159X13666150515234920</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Peterlik</surname>
<given-names>Daniel</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Flor</surname>
<given-names>Peter J.</given-names>
</name>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Uschold-Schmidt</surname>
<given-names>Nicole</given-names>
</name>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<aff id="aff1">Faculty of Biology and Preclinical Medicine, Laboratory of Molecular and Cellular Neurobiology, University of Regensburg, <country>Germany</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>Address correspondence to these authors at the Faculty of Biology and Preclinical Medicine, University of Regensburg, D-93053 Regensburg, Germany; Tel: +49 941 943 3079; Fax: +49 941 943 3052;, E-mail: <email xlink:href="peter.flor@ur.de">peter.flor@ur.de</email> and Faculty of Biology and Preclinical Medicine, University of Regensburg, D-93053 Regensburg, Germany; Tel: +49 941 943 2123; Fax: +49 941 943 3052; E-mail: <email xlink:href="nicole.uschold@ur.de">nicole.uschold@ur.de</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<month>7</month>
<year>2016</year>
</pub-date>
<volume>14</volume>
<issue>5</issue>
<fpage>514</fpage>
<lpage>539</lpage>
<history>
<date date-type="received">
<day>14</day>
<month>2</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>04</day>
<month>4</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>5</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>© 2016 Bentham Science Publishers</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>J. Flor and Uschold-Schmidt</copyright-holder>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/legalcode">
<license-p>This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) <uri xlink:href="https://creativecommons.org/licenses/by-nc/4.0/legalcode" xlink:type="simple">(https://creativecommons.org/licenses/by-nc/4.0/legalcode</uri>), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>Chronic stress-related psychiatric conditions such as anxiety, depression, and alcohol abuse are an enormous public health concern. The etiology of these pathologies is complex, with psychosocial stressors being among the most frequently discussed risk factors. The brain glutamatergic neurotransmitter system has often been found involved in behaviors and pathophysiologies resulting from acute stress and fear. Despite this, relatively little is known about the role of glutamatergic system components in chronic psychosocial stress, neither in rodents nor in humans. Recently, drug discovery efforts at the metabotropic receptor subtypes of the glutamatergic system (mGlu1-8 receptors) led to the identification of pharmacological tools with emerging potential in psychiatric conditions. But again, the contribution of individual mGlu subtypes to the manifestation of physiological, molecular, and behavioral consequences of chronic psychosocial stress remains still largely unaddressed. The current review will describe animal models typically used to analyze acute and particularly chronic stress conditions, including models of psychosocial stress, and there we will discuss the emerging roles for mGlu receptor subtypes. Indeed, accumulating evidence indicates relevance and potential therapeutic usefulness of mGlu2/3 ligands and mGlu5 receptor antagonists in chronic stress-related disorders. In addition, a role for further mechanisms, <italic>e.g</italic>. mGlu7-selective compounds, is beginning to emerge. These mechanisms are important to be analyzed in chronic psychosocial stress paradigms, <italic>e.g</italic>. in the chronic subordinate colony housing (CSC) model. We summarize the early results and discuss necessary future investigations, especially for mGlu5 and mGlu7 receptor blockers, which might serve to suggest improved therapeutic strategies to treat stress-related disorders.</p>
</abstract>
<kwd-group>
<title>Keywords</title>
<kwd>Animal models</kwd>
<kwd>anxiety</kwd>
<kwd>chronic stress</kwd>
<kwd>depression</kwd>
<kwd>mGlu receptors</kwd>
<kwd>stress-related disorders</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec>
<title>The glutamate system is implicated in stress-related physiology and disorders</title>
<p>Major depression, anxiety, and drug abuse disorders represent the most prevalent stress-related psychiatric conditions and are an enormous health concern worldwide [<xref ref-type="bibr" rid="R1">1</xref>-<xref ref-type="bibr" rid="R3">3</xref>]. The etiology of these pathologies is complex, with chronic psychosocial stressors being the most acknowledged risk factors [<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R4">4</xref>-<xref ref-type="bibr" rid="R8">8</xref>]. These factors include continuing adverse conditions, such as social decline along with poverty, or life events that possess a high degree of chronic threat (<italic>e.g</italic>. medical disabilities), long lasting negative emotions and experience of personal loss [<xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R7">7</xref>-<xref ref-type="bibr" rid="R9">9</xref>]. The majority of these types of factors has been demonstrated to increase both anxiety- and depression-related behavior, but also alcohol and drug abuse [<xref ref-type="bibr" rid="R10">10</xref>-<xref ref-type="bibr" rid="R13">13</xref>]. Indeed, and not surprisingly, there’s a high comorbidity between anxiety and depression/mood disorders, with approximately half of the patients suffering from major depression also meeting criteria for comorbid anxiety [<xref ref-type="bibr" rid="R14">14</xref>].</p>
<p>As disorders of mood and emotion may show a common excessive or inappropriate brain excitability within crucial brain circuits, the L-glutamate system, which represents the primary excitatory neurotransmitter system in emotion and cognition circuits, is increasingly considered to play an important role in mental disease etiology and persistence. Several lines of evidence from human clinical studies link dysfunction in the L-glutamate system to the pathogenesis of psychiatric disorders [<xref ref-type="bibr" rid="R15">15</xref>]. For instance, changes in glutamate levels have been found in plasma, cerebrospinal fluid (CSF), and in the brain of patients suffering from mood and anxiety disorders [<xref ref-type="bibr" rid="R16">16</xref>-<xref ref-type="bibr" rid="R18">18</xref>]. Interestingly, recent postmortem studies showed significant increases in glutamate levels in the frontal cortex and dorsolateral prefrontal cortex of depressed and bipolar patients, respectively [<xref ref-type="bibr" rid="R19">19</xref>, <xref ref-type="bibr" rid="R20">20</xref>]. Furthermore, various clinical neuroimaging studies have consistently demonstrated volumetric changes in brain regions, in which glutamatergic neurons predominate, such as the hippocampus, amygdala and several cortical regions [<xref ref-type="bibr" rid="R21">21</xref>].</p>
<p>The L-glutamate neurotransmitter system of the emotion and cognition circuitry of mammalian brains is composed of a large diversity of genetically regulated factors: a group of vesicular, glial and synaptic glutamate transporters [<xref ref-type="bibr" rid="R22">22</xref>] as well as two families of glutamate receptors: ligand-gated ionotropic glutamate receptors (iGlu) comprising (2R)-2-(methylamino)butanedioic acid (NMDA)-, 2-amino-3-(5-methyl-3-oxo-2,3-dihydro-1,2-oxazol-4-yl)propanoic acid (AMPA)- and (2S,3S,4S)-3-(carboxylatomethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylate (kainate, KA)-receptors [<xref ref-type="bibr" rid="R23">23</xref>-<xref ref-type="bibr" rid="R26">26</xref>], and the G protein-coupled metabotropic glutamate receptor (mGlu) subtypes -1 to -8 (mGlu1-8, [<xref ref-type="bibr" rid="R26">26</xref>-<xref ref-type="bibr" rid="R29">29</xref>]). Throughout the last three decades, several drug discovery efforts were made targeting iGlu receptors, with preclinical and clinical data demonstrating NMDA and AMPA receptors to be promising targets in controlling cognitive and emotional changes observed in stress-related disorders [<xref ref-type="bibr" rid="R30">30</xref>-<xref ref-type="bibr" rid="R33">33</xref>]. In this regard, a major breakthrough came from clinical studies using the NMDA receptor antagonist ketamine by showing clinical efficacy in treatment-resistant depression (TRD) and major depressive disorder (MDD) patients. Interestingly, ketamine administered intravenously showed strong decreases in the Hamilton Depression Rating Scale (HDRS) analysis, with an improvement observed 2 h after infusion that remained significant for more than 1 week [<xref ref-type="bibr" rid="R34">34</xref>, <xref ref-type="bibr" rid="R35">35</xref>]. However, this iGlu receptor-based strategy is not devoid of limitations and risks, as ketamine administration has also been shown to be associated with cognitive and dissociative adverse effects, which thus limits ketamine’s widespread application for the treatment of mood disorders [<xref ref-type="bibr" rid="R36">36</xref>, <xref ref-type="bibr" rid="R37">37</xref>]. In contrast, therapeutic strategies targeting mGlu receptors represent a more subtle alternative in regulating excitatory (and possibly inhibitory) neurotransmission and are therefore considered to have a more favorable side-effect profile than ligand-gated ion channel modulation [<xref ref-type="bibr" rid="R38">38</xref>, <xref ref-type="bibr" rid="R39">39</xref>]. Indeed, signaling <italic>via</italic> mGlu receptors is slower and longer lasting than <italic>via</italic> iGlu receptors, allowing fine-tuning of glutamate regulation and its cellular responses, which could eventually avoid the adverse effects associated with direct modulation of iGlu receptors. In addition to that, growing evidence gives rise to mGlu-based compounds to be effective in regulating iGlu receptor signaling, further emphasizing the modulatory potential of mGlu receptors.</p>
<p>By summarizing the findings from preclinical and recent clinical studies, the present review will illustrate the involvement of different mGlu receptor subtypes in the pathophysiology of stress-related emotional disorders. Here, we especially focus on the role of the different mGlu receptors in the development of depressive and anxiety disorders and largely neglect their role in somatic disorders and substance abuse, allowing us to go more into depth with respect to the former two. Moreover, we show that the discovery of selective ligands for these receptors created potentially new strategies for the therapy of psychiatric disorders and their comorbid somatic syndromes. We will summarize in detail the growing evidence for mGlu receptors to serve as promising molecular targets for the treatment of chronic stress-related disorders in man. We will first introduce animal models typically used to analyze acute and particularly chronic stress conditions on a preclinical basis. To this end, we compare different acute and chronic stress models and eventually focus on one distinct animal model that most appropriately mimics chronic psychosocial stress, the CSC model [<xref ref-type="bibr" rid="R40">40</xref>, <xref ref-type="bibr" rid="R41">41</xref>]. Applying this preclinically validated model, we will also report on recent findings obtained by our group and others to provide first evidence for a role of mGlu subtypes in chronic psychosocial stress, which further emphasizes the importance of this receptor family as promising drug targets towards ensuring mental health.</p>
</sec>
<sec>
<title>Glutamate signaling <italic>via</italic> mGlu receptors in the CNS</title>
<p>The existence of neuromodulatory glutamate receptors, namely the mGlu receptors, provides a mechanism by which binding of glutamate, in contrast to the fast synaptic responses mediated by iGlu receptors, slowly modulates cell excitability, synaptic neurotransmission and plasticity; mGlu receptors perform this modulation <italic>via</italic> second messenger signaling pathways and their interactions with ion channels [<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R42">42</xref>-<xref ref-type="bibr" rid="R44">44</xref>]. According to sequence homology, second messenger coupling and pharmacological properties, the mGlu receptor family is subdivided into three groups. The group I members, mGlu1 and mGlu5, are coupled to G<sub>q/11</sub> proteins and primarily elevate {[(1R,2S,3R,4R,5S,6R)-2,3,5-trihydroxy-4,6-bis(phosphonooxy)cyclohexyl]oxy}phosphonic acid (IP<sub>3</sub>), diacylglycerol (DAG), and Ca<sup>2+</sup> signal transduction. In general, these receptor subtypes function to enhance glutamate-mediated postsynaptic excitation [<xref ref-type="bibr" rid="R38">38</xref>, <xref ref-type="bibr" rid="R45">45</xref>-<xref ref-type="bibr" rid="R49">49</xref>]. In contrast, group II (mGlu2 and mGlu3) and group III (mGlu4, -6, -7, and -8) receptors inhibit adenylyl cyclase activity and other effector proteins <italic>via</italic> coupling to G<sub>i/o</sub> proteins and thereby negatively modulate excitatory neurotransmitter efflux and neuronal excitability upon activation [<xref ref-type="bibr" rid="R38">38</xref>, <xref ref-type="bibr" rid="R50">50</xref>-<xref ref-type="bibr" rid="R55">55</xref>]. Interestingly, various mGlu receptors are expressed in both neurons and glial cells of the central nervous system (CNS), as well as in peripheral tissue like the enteric nervous system or adrenal gland cells [<xref ref-type="bibr" rid="R56">56</xref>]. In neurons, group I receptors show predominantly postsynaptic location and modulate cell excitability, while group II and III members are mainly expressed at the presynapse and are involved in regulating neurotransmitter release, mostly inhibiting release [<xref ref-type="bibr" rid="R57">57</xref>, <xref ref-type="bibr" rid="R58">58</xref>]. As they are members of class C GPCR, all mGlus are characterized by a large extracellular N-terminal “Venus flytrap domain” (VFTD), which is known to serve as the orthosteric ligand binding site and shows abundant homology between the different mGlu receptor subtypes. The binding site for allosteric modulators of the mGlus is located topographically distinct within the transmembrane domain [<xref ref-type="bibr" rid="R59">59</xref>-<xref ref-type="bibr" rid="R64">64</xref>]. As the allosteric binding site has a higher level of sequence diversity between the receptor subtypes, allosteric ligands typically show greater subtype selectivity [<xref ref-type="bibr" rid="R65">65</xref>, <xref ref-type="bibr" rid="R66">66</xref>]. Importantly, the widespread distribution of mGlu subtypes suggests that these modulatory receptors have the ability to participate in a broad array of physiological functions throughout the CNS and may represent suitable targets for therapeutic intervention in a variety of CNS disorders. Thus, the therapeutic potential of the mGlu receptors is increasingly receiving attention as possible treatment strategies for CNS diseases such as Parkinson’s disease (PD), Fragile X syndrome (FXS), schizophrenia, addiction, and in particular depression and anxiety-related disorders [<xref ref-type="bibr" rid="R67">67</xref>-<xref ref-type="bibr" rid="R71">71</xref>].</p>
<sec>
<title>Group I mGlu Receptors: Neurobiochemistry and Distribution</title>
<p>In general, the group I members mGlu1 and mGlu5 couple to G<sub>q/11</sub> proteins and activate phospholipase C, a process that results in the formation of IP<sub>3</sub> and DAG (see Fig. <bold>1</bold>). This classical pathway leads to intracellular Ca<sup>2+</sup> mobilization and activation of protein kinase C (PKC). Apart from this, group I receptors can also activate a range of further downstream effectors, most notably proteins involved in synaptic plasticity, such as mitogen-activated protein kinase/extracellular receptor kinase (MAPK/ERK) and mammalian target of rapamycin (mTOR) [<xref ref-type="bibr" rid="R72">72</xref>-<xref ref-type="bibr" rid="R74">74</xref>]. With respect to their distribution, expression of both mGlu1 and mGlu5 primarily overlaps within brain regions implicated in mood disorders [<xref ref-type="bibr" rid="R36">36</xref>]. However, there are also distinct differences, with mGlu1’s expression being abundant in cerebellum, olfactory bulb, the CA3 region of the hippocampus, in thalamus, dentate gyrus and substantia nigra, whereas mGlu5 is highly expressed in telencephalic regions, CA1 and CA3 regions of the hippocampus, septum, basal ganglia, striatum, amygdala and nucleus accumbens [<xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R75">75</xref>]. In addition, mGlu5 is also expressed in glial cells (see Fig. <bold>1</bold>), particularly in astrocytes, where its expression has been highlighted with respect to a number of potential physiological roles, <italic>e.g</italic>. neuroprotection [<xref ref-type="bibr" rid="R76">76</xref>-<xref ref-type="bibr" rid="R80">80</xref>].</p>
</sec>
<sec>
<title>Group II mGlu Receptors: Neurobiochemistry and Distribution</title>
<p>In contrast to group I, the group II members mGlu2 and mGlu3 are coupled predominantly to G<sub>i/o</sub> proteins negatively modulating adenylyl cyclase activity and directly regulating ion channels and other downstream signaling components <italic>via</italic> the release of the G<sub>βγ</sub> subunit. In addition, group II mGlus also couple to MAPK and phosphatidyl inositol  3- (PI3-) kinase pathways which are implicated in synaptic plasticity [<xref ref-type="bibr" rid="R39">39</xref>, <xref ref-type="bibr" rid="R81">81</xref>, <xref ref-type="bibr" rid="R82">82</xref>]. Both mGlu2 and mGlu3 are presynaptically localized in rather preterminal than terminal axonal portions, distant from the active zone of neurotransmitter release, where they are potentially activated by synaptic glutamate spillover [<xref ref-type="bibr" rid="R83">83</xref>]. mGlu2 mRNA is observed to be highly expressed in pyramidal neurons in the enthorhinal and parasubicular cortical regions and in granule cells of the dentate gyrus [<xref ref-type="bibr" rid="R84">84</xref>, <xref ref-type="bibr" rid="R85">85</xref>]. In contrast, mGlu3 mRNA is highly expressed in neurons of the cerebral cortex and the caudate-putamen and in the granule cells of the dentate gyrus [<xref ref-type="bibr" rid="R86">86</xref>, <xref ref-type="bibr" rid="R87">87</xref>]. In addition, the mGlu3 receptor subtype (see Fig. <bold>1</bold>) is also prominently expressed in glial cells throughout the whole brain, and its activation provides robust neuroprotection <italic>in vitro</italic> and <italic>in vivo</italic> [<xref ref-type="bibr" rid="R88">88</xref>-<xref ref-type="bibr" rid="R91">91</xref>].</p>
</sec>
<sec>
<title>Group III mGlu Receptors: Neurobiochemistry and Distribution</title>
<p>Group III represents the largest family of mGlu receptors and comprises the subtypes mGlu4, mGlu6, mGlu7, and mGlu8. Like group II, group III members are predominantly expressed presynaptically (see Fig. <bold><xref ref-type="fig" rid="F1">1</xref></bold>) [<xref ref-type="bibr" rid="R92">92</xref>], where they regulate neurotransmitter release [<xref ref-type="bibr" rid="R28">28</xref>, <xref ref-type="bibr" rid="R93">93</xref>-<xref ref-type="bibr" rid="R97">97</xref>]. By coupling to G<sub>i/o</sub> proteins, their activation inhibits cAMP formation and indirectly affects synaptic transmission and neurotransmitter release by modulating membrane Ca<sup>2+</sup>- and K<sup>+</sup>-channels [<xref ref-type="bibr" rid="R51">51</xref>, <xref ref-type="bibr" rid="R55">55</xref>, <xref ref-type="bibr" rid="R98">98</xref>]. As with group II mGlu receptors, the group III subtypes also couple to other signaling pathways, including MAPK and PI3-kinase, providing further complexity to the mechanisms by which they regulate synaptic transmission [<xref ref-type="bibr" rid="R99">99</xref>-<xref ref-type="bibr" rid="R101">101</xref>]. Except for the mGlu6 receptor subtype, whose expression is restricted to the retina, all other group III mGlus are widely expressed throughout the mammalian brain and also in peripheral tissue [<xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R56">56</xref>]. In detail, in the CNS the mGlu4 receptor subtype is highly expressed in the cerebellum, the olfactory bulb and thalamus as well as in the hippocampus, the cerebral cortex and basal ganglia in pre- and post-synaptical position [<xref ref-type="bibr" rid="R92">92</xref>, <xref ref-type="bibr" rid="R103">102</xref>, <xref ref-type="bibr" rid="R104">103</xref>]. In addition, widespread peripheral mGlu4 expression has been shown also in the pancreas, adrenal glands and gastrointestinal tract [<xref ref-type="bibr" rid="R105">104</xref>-<xref ref-type="bibr" rid="R108">107</xref>]. The mGlu7 receptor is highly localized in the presynaptic active zone and abundantly expressed in brain regions such as neocortex, hippocampus, amygdala, locus coeruleus, thalamus and hypothalamus [<xref ref-type="bibr" rid="R109">108</xref>-<xref ref-type="bibr" rid="R111">110</xref>]. In the periphery, mGlu7 expression has been reported in the adrenal glands, the colon and stomach – among other areas [<xref ref-type="bibr" rid="R112">111</xref>-<xref ref-type="bibr" rid="R114">113</xref>]. The mGlu8 receptor is found predominantly in the CNS in presynaptic terminals in the olfactory bulb, hippocampus, cerebellum and cortical areas [<xref ref-type="bibr" rid="R75">75</xref>], but also in peripheral tissue such as pancreas and testis [<xref ref-type="bibr" rid="R56">56</xref>]. Interestingly, general expression levels of mGlu8 receptors seem considerably lower than those of mGlu4 and mGlu7 [<xref ref-type="bibr" rid="R39">39</xref>].</p>
</sec>
</sec>
<sec>
<title>Established rodent models for the evaluation of stress</title>
<p>In general, “stress” can defined either as an activation of a stress response, a stressful stimulus itself, and/or the consequences of a stressful experience [<xref ref-type="bibr" rid="R115">114</xref>-<xref ref-type="bibr" rid="R120">119</xref>]. Undoubtedly, exposure to stress or even trauma (experience or witness of a terrifying event and difficulty in coping with it for a long time) has been shown to be amongst the predisposing factors for developing emotional disorders in man, such as depression and anxiety, which are often viewed as manifestations of an inability to cope with stress [<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R121">120</xref>, <xref ref-type="bibr" rid="R122">121</xref>]. Albeit the biological basis of the stress response is not clearly defined, its understanding is essential for a better comprehension of the etiology of those disorders. Animal models have turned out to be instrumental in this respect and, like in humans, animals use coping strategies when exposed to stress. They can express both active coping mechanisms manifested by aggressive behaviors as well as exploratory activity or passive coping manifested by freezing, immobility and submission [<xref ref-type="bibr" rid="R123">122</xref>]. All these behaviors can be reliably measured in different animal models. In the following, various animal models are discussed in which the animal’s stress response is reflected either upon exposure to acute  or to chronic stress. Paradigms that employ acute stressor exposure include stress-induced hyperthermia (SIH), the forced swim test (FST), the tail suspension test (TST), elevated plus maze (EPM) and learned helplessness (LH), to name a few. On the other hand, chronic mild stress/chronic unpredictable stress (CMS/CUS), chronic social defeat stress (CSDS) and chronic subordinate colony housing (CSC) represent chronic stress models, all of which employ relatively long-term exposure to inescapable or uncontrollable stress events.</p>
<sec>
<title>Assessment of Acute Stress in Rodent Animals</title>
<sec>
<title>The SIH Test</title>
<p>In general, SIH is known to be a physiological phenomenon when a mammalian organism is confronted with an either physical or psychological stress situation [<xref ref-type="bibr" rid="R124">123</xref>-<xref ref-type="bibr" rid="R128">127</xref>]. In the SIH test, modified from the version originally described by Borsini <italic>et al.</italic> [<xref ref-type="bibr" rid="R129">128</xref>], the basal temperature is measured rectally (T1), followed by a second rectal measurement 15 minutes later (T2). During these 15 minutes the temperature usually rises due to physical stress the animal is undergoing (handling, rectal measurement). Conveniently, potential anxiolytic-like effects of drugs are measured by a decrease in the SIH response [<xref ref-type="bibr" rid="R126">125</xref>]. Those measurements of the body temperature are not dependent on the animal’s motoric activity, which makes SIH different from other mild stress models/anxiety tests that depend on locomotor performance of the animal, for instance the EPM or open field tests.</p>
</sec>
</sec>
<sec>
<title>The FST and TST</title>
<p>The FST and TST are the two most widely used preclinical screening tests that allow rapid detection of substances with potential antidepressant-like activity (good predictive validity). In general, both tests are based on the same principle, which is the measurement of the duration of immobility while rodents are exposed to an acute, short-term (minutes) inescapable situation. In the FST, first described by Porsolt <italic>et al.</italic> [<xref ref-type="bibr" rid="R130">129</xref>, <xref ref-type="bibr" rid="R131">130</xref>], a mouse or a rat is placed in a water-filled cylinder, in which the animal is unable to escape from. Following an initial period of escape-oriented movements, the animal will eventually display an immobile posture, a passive behavior characterized by the absence of movements except those necessary to keep the head above the water level. By contrast, in the TST, immobility is scored while mice are suspended by their tails and, as water is not required, this test is not confounded by challenges of thermoregulation [<xref ref-type="bibr" rid="R132">131</xref>]. In both tests, the immobility is typically interpreted as an expression of behavioral despair [<xref ref-type="bibr" rid="R133">132</xref>-<xref ref-type="bibr" rid="R135">134</xref>], which can be reversed by the acute administration of compounds with antidepressant potential. So, testing of new substances in these stress models allows a simple and rapid screening of potential antidepressant activity by the measurement of their acute effect on immobility. However, this poses a problem for the model, as antidepressants used in depressed humans in the clinics generally require many weeks of administration to elevate mood. Nevertheless, both, the FST and TST are currently popular models, mostly due to their low cost of experiments, their ease of use and their reliability across laboratories [<xref ref-type="bibr" rid="R128">127</xref>, <xref ref-type="bibr" rid="R136">135</xref>].</p>
<sec>
<title>The EPM Test</title>
<p>The EPM represents one of the most widely used anxiety models, in which anxiety is typically measured by indices of open-arm avoidance and locomotion by the frequency of closed-arm entries [<xref ref-type="bibr" rid="R137">136</xref>, <xref ref-type="bibr" rid="R138">137</xref>]. In principle, this test exploits the balance between the preference of rodents for avoiding open exposure to potential predators <italic>versus</italic> exploration for possible rewards. When placed in the center portion of the plus-maze and allowed to explore each of the arms freely, mice with higher anxiety will show reduced open-arm activity and <italic>vice versa</italic>. This tendency can be, for instance, suppressed by anxiolytics and potentiated by anxiogenic agents [<xref ref-type="bibr" rid="R139">138</xref>]. As short-term exposing of animals to heights and bright open spaces demonstrates an acutely stressful situation, the EPM can also be used and interpreted as a test for mild stressor exposure [<xref ref-type="bibr" rid="R140">139</xref>, <xref ref-type="bibr" rid="R141">140</xref>].</p>
</sec>
<sec>
<title>The LH Model</title>
<p>The LH model can be basically viewed as analogous to the abovementioned tests, with the difference that it involves a series of stressors over a few hours or even days [<xref ref-type="bibr" rid="R142">141</xref>]. Following an uncontrollable stressor such as exposure to inescapable electric foot shocks, animals eventually will either display increased escape latency or completely fail to escape from a subsequent situation in which escape is possible [<xref ref-type="bibr" rid="R143">142</xref>-<xref ref-type="bibr" rid="R145">144</xref>]. Importantly, the escape deficits can be reversed by a variety of antidepressants [<xref ref-type="bibr" rid="R146">145</xref>]. Following one or more sessions of inescapable shock, animals have been shown to develop persistent changes that are reminiscent of depression, including weight loss, alterations in sleep pattern, hypothalamic-pituitary-adrenal (HPA) axis activity and loss of spines in hippocampal regions [<xref ref-type="bibr" rid="R132">131</xref>, <xref ref-type="bibr" rid="R147">146</xref>, <xref ref-type="bibr" rid="R148">147</xref>]. The attractiveness of LH is that the model is based on the consideration that cognitive functions (<italic>e.g</italic>. learning) are linked to other behavioral outcomes (<italic>e.g</italic>., neurovegetative modalities), and thus, this model helps to provide a reasonably integrated and broad picture of depressive symptomatology that are analogous to the human situation. However, the major drawback of the model is that most  of the depression-like symptomatology does not persist beyond 2-3 days following cessation of the uncontrollable shock. Moreover, another limitation is – in contrast to  the FST and TST - the difficulty to replicate between laboratories, particularly in mice. Until today, these acute stress models clearly represent the first line of behavioral tests used to rapidly screen putative antidepressant and anxiolytic compounds and to phenotype transgenic animals. Even though direct links to emotional disorders in man are obviously weak due to utilizing only acute stressors and testing only acute antidepressant/anxiolytic responses, these acute stress models have helped enormously to reveal important molecular players within the CNS emotion circuitry [<xref ref-type="bibr" rid="R149">148</xref>-<xref ref-type="bibr" rid="R152">151</xref>].</p>
</sec>
</sec>
<sec>
<title>Chronic Mild Stress (CMS), Chronic Social Defeat Stress (CSDS) and Chronic Subordinate Colony Housing (CSC)</title>
<p>While acute stress paradigms are used broadly for their ease, automation potential, and rapid phenotyping abilities, they offer singular readouts that often cannot be unambiguously interpreted. For instance, increased immobility in the FST is often interpreted as an expression of despair. However, it can also be understood as a successful and adaptive behavioral response that functions to conserve energy [<xref ref-type="bibr" rid="R153">152</xref>]. Today’s chronic stress models are distinguished by their remarkable ability to simultaneously produce a set of behavioral alterations with strong face validity for depression and anxiety disorders (behavioral manifestations that should be similar to the symptoms observed in affected humans). Based on the clinical evidence that chronic stress significantly increases pathogenesis of affective diseases, these stress models are potentially of high value to better understand the underlying physiological mechanisms [<xref ref-type="bibr" rid="R41">41</xref>, <xref ref-type="bibr" rid="R149">148</xref>]. Basically, they are composed of repeated and/or permanent applications of an uncontrollable and unpredictable stressor that is associated with quantifiable molecular, behavioral and physiological changes.</p>
<sec>
<title>The CMS Model</title>
<p>In the CMS model, also referred to as chronic unpredictable stress (CUS) paradigm [<xref ref-type="bibr" rid="R154">153</xref>, <xref ref-type="bibr" rid="R155">154</xref>], rodents are exposed to a variety of relatively mild, mostly physical, stressors such as restraint, isolation housing, disruption of light-dark cycles, intermittently for relatively prolonged time periods (<italic>e.g</italic>. several weeks). Typically, a variety of stressors is used within the CMS schedule in order to prevent or delay habituation, which can occur rapidly when a single stressor is presented repeatedly [<xref ref-type="bibr" rid="R154">153</xref>, <xref ref-type="bibr" rid="R155">154</xref>]. In addition to a reduction in sucrose preference [<xref ref-type="bibr" rid="R156">155</xref>], CMS has also been shown to result in a number of other changes that are difficult to objectively quantify, such as grooming deficits and changes in aggressive and sexual behavior. Interestingly, however, many of these changes can be reversed by chronic antidepressants applied either during the stress procedure or as a post-stress treatment [<xref ref-type="bibr" rid="R157">156</xref>, <xref ref-type="bibr" rid="R158">157</xref>]. However, as the CMS model only employs physical stressors and often lacks cross-laboratory reliability, other approaches to develop chronic psychosocial stress-based models, more reminiscent of human depression, have emerged in recent years.</p>
</sec>
<sec>
<title>The CSDS Model</title>
<p>The stress models described above are based exclusively on physical stressors, and thus, are lacking the relevance of mimicking most important situations that human beings encounter in everyday life – i.e. social interactions [<xref ref-type="bibr" rid="R159">158</xref>-<xref ref-type="bibr" rid="R162">161</xref>]. As opposed to CMS, the CSDS model clearly includes an important social stress component, and thus displays remarkable strength as it relies on innate social behavior. The model is based on the principle that two animals interact socially and physically such that one achieves dominant status and the other becomes subordinate. Much of the preclinical aggression research has been conducted so far in territorial male resident rats or mice confronting an intruder conspecific. As a consequence of territoriality, the resident will attack unfamiliar males intruding in its home cage. However, there are many versions of CSDS for mice and rats. For example, a typical procedure in mice lasts for 21 days where the experimental animal is (repeatedly) exposed to 10 intermittent bouts (5-10 min, once daily; see Fig. <bold><xref ref-type="fig" rid="F2">2A</xref></bold>)</p>
<p>of social defeat. Here, the experimental mice are forced  to intrude into cage space occupied by a larger mouse of a more aggressive strain, leading to subordination of the experimental mice. In addition to the short-time physical stress during direct contact with the dominant male, the experimental mice are exposed to additional psychological stress in form of prolonged “not physical” contact by housing them for 24 h in the same cage as the residents, but with a transparent partition allowing only sensory interaction [<xref ref-type="bibr" rid="R163">162</xref>, <xref ref-type="bibr" rid="R164">163</xref>]. Other laboratories expose the experimental mice also daily to 10 min of physical interaction with a resident followed by 24 h of sensory contact, but only for 10 consecutive days [<xref ref-type="bibr" rid="R165">164</xref>-<xref ref-type="bibr" rid="R167">166</xref>]. For rats there are protocols where the experimental animals are placed in a resident’s home cage for 5 min physical interaction, followed by 10 min of sensory threat for 4 consecutive days [<xref ref-type="bibr" rid="R168">167</xref>, <xref ref-type="bibr" rid="R169">168</xref>], or where the intruders are placed in the cage of the resident for intermittent physical interaction until submission, followed by 30 min of sensory threat for 1 to 3 consecutive days [<xref ref-type="bibr" rid="R170">169</xref>-<xref ref-type="bibr" rid="R172">171</xref>]. Although there are many more versions and mentioning all of them would go beyond the scope of this article, following repeated exposure to a dominant encounter, independent of the protocol used, animals reliably show decreased sucrose preference, indicative of an anhedonia-like state, and show reduced social interaction/sociability, as well as alterations in HPA axis and autonomic function [<xref ref-type="bibr" rid="R173">172</xref>-<xref ref-type="bibr" rid="R175">174</xref>]. Importantly, many of these changes can be reversed by chronic, but not acute, antidepressant drug administration, illustrating pharmacological validity of this stress model [<xref ref-type="bibr" rid="R176">175</xref>-<xref ref-type="bibr" rid="R178">177</xref>].</p>
</sec>
<sec>
<title>The CSC Model</title>
<p>The CSC paradigm was established by Reber <italic>et al.</italic> [<xref ref-type="bibr" rid="R40">40</xref>] and represents a chronic psychosocial stress model with similarities to the CSDS model, but with the difference of applying psychosocial stress not only intermittently but permanently over a period of 19 days (24 h per day; see  Fig. <bold>2 B</bold>). This chronic stress model is a very reliable animal model in combining chronic, psychological and social aspects of stress. In doing so, and as compared to the other stress models of above, it more comprehensively mimics the type of health compromising stressors that humans are exposed to. Typically, four male mice are housed together with a larger male resident in its homecage for 19 consecutive days. This results in immediate subordination of the four intruder CSC mice, and a hierarchy within each colony is formed, in which the resident clearly obtains the dominant position. To avoid habituation to the dominant mouse, the four CSC mice are transferred into the homecage of a novel larger male resident mouse on days 8 and 15. Single-housed (SHC) mice that remain undisturbed serve as unstressed controls [<xref ref-type="bibr" rid="R179">178</xref>]. Importantly, studies by the group of Reber clearly demonstrate that CSC stressor exposure leads to the development of affective, immunological and somatic changes and also results in reduced glucocorticoid (GC) signaling (see Fig. <bold><xref ref-type="fig" rid="F3">3</xref></bold>, [<xref ref-type="bibr" rid="R41">41</xref>]), and thus provides a powerful experimental tool to study the mechanisms underlying several relevant stress-induced conditions. In detail, is has been shown that exposure to CSC alters several parameters indicative of chronic stress, including reduced body weight gain, decreased thymus weight and increased pituitary and adrenal weight [<xref ref-type="bibr" rid="R40">40</xref>, <xref ref-type="bibr" rid="R141">140</xref>]. The latter finding is accompanied by a reduced responsiveness of adrenal explants to adrenocorticotropic hormone (ACTH) challenge <italic>in vitro</italic>. Importantly, adrenal ACTH sensitivity seems to be not only diminished under <italic>in vitro</italic> conditions,  as CSC mice show unaffected basal morning plasma corticosterone (CORT) despite elevated plasma ACTH levels in comparison with SHC mice. Moreover, CSC mice show basal evening hypocorticism, suggested by decreased basal evening plasma CORT levels compared with SHC mice [<xref ref-type="bibr" rid="R40">40</xref>, <xref ref-type="bibr" rid="R141">140</xref>, <xref ref-type="bibr" rid="R180">179</xref>]. The decline in GC signaling is further amplified by a reduced GC sensitivity seen in lipopolysaccharide-stimulated splenocytes [<xref ref-type="bibr" rid="R40">40</xref>] and plate-bound anti-CD3-stimulated T helper (Th) 2 cells from peripheral lymph nodes [<xref ref-type="bibr" rid="R181">180</xref>] of 19-day CSC compared with SHC mice. These are interesting findings, as an insufficient GC signaling can be observed in numerous affective and somatic disorders in man following chronic psychosocial stressor exposure [<xref ref-type="bibr" rid="R182">181</xref>-<xref ref-type="bibr" rid="R185">184</xref>]. In addition, CSC-stressed mice develop a spontaneous colonic inflammation, indicated by an increased secretion of proinflammatory cytokines from mesenteric lymph node cells <italic>in vitro</italic> and an increased histological damage score of colonic tissue [<xref ref-type="bibr" rid="R40">40</xref>, <xref ref-type="bibr" rid="R186">185</xref>, <xref ref-type="bibr" rid="R187">186</xref>]. Moreover, CSC exposure was also shown to increase the risk for the development of inflammation-induced colorectal cancer (CRC), indicated by the development of macroscopic suspect lesions, as well as a trend towards an increased incidence of low- and/or high-grade colonic dysplasia [<xref ref-type="bibr" rid="R187">186</xref>]. Interestingly, in humans, inflammatory bowel disease (IBD) has been shown to be a consequence of chronic life stress and colorectal cancer poses one of the most serious complications in these patients [<xref ref-type="bibr" rid="R188">187</xref>-<xref ref-type="bibr" rid="R192">191</xref>]. Furthermore, IBD was also shown to be comorbid in patients suffering from depression [<xref ref-type="bibr" rid="R193">192</xref>-<xref ref-type="bibr" rid="R195">194</xref>]. These findings further indicate that the CSC paradigm is an appropriate model of chronic psychosocial stress with high construct validity (i.e. high disease relevance of methods by which the animal model is constructed; [<xref ref-type="bibr" rid="R142">141</xref>]).</p>
<p>With respect to their behavior, CSC mice show reduced open-arm activity on the EPM and reduced center-activity in an open field after 19 days of CSC, further illustrating that chronic stressor exposure increases anxiety-related behavior, a phenomenon that co-occurs with depression in humans [<xref ref-type="bibr" rid="R14">14</xref>]. Moreover, CSC mice spend a similar time investigating an empty cage and a cage with an unknown conspecific during the social preference/avoidance test (SPAT) on day 20 of CSC, suggesting a lack of social preference [<xref ref-type="bibr" rid="R196">195</xref>]. In addition, CSC mice also show an increased ethanol (EtOH) preference and total intake, which was already shown following 14 days of CSC exposure [<xref ref-type="bibr" rid="R197">196</xref>]. Interestingly, in humans chronic psychosocial stress represents a strong risk factor for the development of substance abuse such as alcoholism, which is often co-morbid with anxiety disorders [<xref ref-type="bibr" rid="R198">197</xref>-<xref ref-type="bibr" rid="R200">199</xref>].</p>
<p>Taken together, the CSC paradigm represents an animal model that utilizes a chronic psychosocial stress component and results in decreased GC signaling and concomitant affective and somatic pathologies, in particular the  stress-induced anxiogenic phenotype and the systemic proinflammatory phenotypes. Thus, the CSC model is likely to have more translational value than other stress models in animals, <italic>e.g</italic>. when compared to the CMS or CSDS model, which lack either social or truly chronic components. Most interestingly, CSC exposure is associated with hypocorticism, a phenomenon that is not apparent after CMS or CSDS, but occurs in human mood disorders. In contrast, CMS and CSDS are associated with greatly elevated plasma CORT levels (hypercorticism). Interestingly, in addition to mice, the CSC paradigm was also established in rats [<xref ref-type="bibr" rid="R201">200</xref>]. However, to date the effects of CSC exposure in rats are not that well characterized as compared to mice. Overall, the CSC paradigm is a promising animal model that makes it also possible to gain further insight into how stress-induced pathophysiological changes (<italic>e.g</italic>. HPA axis alterations) eventually lead to affective and somatic disorders.</p>
<p>Taken together, the rodent models explained above can be performed in mice as well as in rats and which species to use probably depends on the particular research question  to be answered. However, in case of the CSC model,  mice will be the choice for future projects to gain more knowledge about the role of the brain glutamatergic neurotransmitter system in the development of affective and somatic changes, as the effects of chronic psychosocial stressor exposure using this model are much better characterized and robust in mice. Other advantages of mouse models are lower costs and less space necessary. Moreover, mouse models also offer the possibility to use transgenic animals, <italic>e.g</italic>. knockout mice, in order to analyze the underlying mechanisms.</p>
</sec>
</sec>
<sec>
<title>Dysregulation of Brain mGlu Receptor Gene Expression after CSC Stressor Exposure and in Related Models</title>
<p>Recent findings clearly have sparked interest in neurobiological systems that were previously little explored in mood disorders, such as the glutamatergic system. In particular the clinical findings with ketamine have inspired new lines of preclinical research to explore the glutamate system in more detail, including modulatory receptors that could be targeted to achieve better side-effect profiles [<xref ref-type="bibr" rid="R202">201</xref>], and to investigate the underlying neural mechanisms. To our knowledge, only few studies have dealt with chronic stress and the involvement of mGlu receptors in the manifestation of stress-induced changes. But some promising results have already emerged. Wieronska <italic>et al.</italic> [<xref ref-type="bibr" rid="R203">202</xref>] addressed changes of mGlu5 expression in response to CMS exposure and reported an increase of mGlu5 protein expression in CA1 and a decrease in CA3 of the rat hippocampus. Furthermore, O’Connor and co-workers [<xref ref-type="bibr" rid="R204">203</xref>] found no changes of hippocampal group III mGlu receptor mRNA expression upon either chronic immobilization stress or chronic social defeat and concluded that hippocampal group III mGlu receptors may not be involved in the manifestation of behavioral and physiological changes observed in these models. However, early-life stress, which was induced by maternal separation, specifically reduced the expression of mGlu4 mRNA in the hippocampus, whereas mGlu7 and mGlu8 mRNA remained unaffected [<xref ref-type="bibr" rid="R205">204</xref>]. Taken together, they could demonstrate that there were only very few, but selective changes to group III mGlu receptors under early-life stress conditions. These findings ask for further research efforts to study mGlu receptors as potentially important players in chronic stress-induced pathology.</p>
<p>To extend and specify the range of these findings, we evaluated the molecular changes that occur within the mGlu receptor system upon chronic psychosocial stressor exposure in mice using the CSC animal model. We investigated the consequences of chronic psychosocial stress on gene expression of distinct mGlu receptor subtypes in several brain regions. Indeed, we found that mGlu7 mRNA was downregulated in the prefrontal cortex (PFC) of CSC mice (see Fig. <bold><xref ref-type="fig" rid="F4">4</xref></bold>), suggesting that the mGlu7 receptor subtype is potentially involved in PFC-mediated emotional and/or cognitive processes that could be altered by CSC exposure. It is interesting to note that mGlu7 receptors are also located on GABAergic neurons, on which they negatively regulate release of this inhibitory neurotransmitter. It is possible that the stress-induced reduction of mGlu7 mRNA levels potentially lead to enhanced excitatory transmission in the PFC, which may be part of the pathology observed in depression disorders [<xref ref-type="bibr" rid="R206">205</xref>]. Furthermore, we showed that mGlu5 mRNA was upregulated in the hypothalamus (see Fig. <bold>4</bold>), possibly suggesting that the mGlu5 receptor subtype is rather associated with mediating functionalities of the HPA axis’ responses to CSC, which is consistent with mGlu5’s postulated roles in physiological stress-regulation systems in mammals [<xref ref-type="bibr" rid="R207">206</xref>-<xref ref-type="bibr" rid="R210">209</xref>]. Interestingly, no CSC stress-induced changes were found in either mGlu2 or mGlu3 mRNA in neither brain region investigated (PFC, hypothalamus, or hippocampus; see Fig. <bold><xref ref-type="fig" rid="F4">4</xref></bold>), possibly indicating that group II mGlu receptors may play a less prominent role in CSC-induced pathophysiology. Overall, the results discussed here represent very early evidence towards a role of mGlu receptor subtypes in chronic stress-induced pathophysiology. At least, our data suggest that there is possibly a controlling role of the mGlu7 receptor in the PFC and of the mGlu5 receptor subtype in the hypothalamus, indicating that these receptor subtypes should be pursued as further research topics in chronic stress-induced conditions. Of course, much future work is required to fully elucidate the roles these receptor subtypes play in chronic stress-induced behavioral and physiological symptomatology (see below).</p>
</sec>
</sec>
<sec>
<title>
<bold>Current knowledge of mGlu receptor</bold> genetic and pharmacological modulation <bold>in acute and chronic stress</bold></title>
<p>A possible aim of pharmacological intervention targeting glutamate neurotransmission in stress-related disorders  could be that excessive glutamate exposure in specific brain areas should be blocked, whereas normal glutamatergic neurotransmission should be kept unaffected. New ways of fine-tuning the glutamatergic system are now emerging <italic>via</italic> the pharmacological modulation of mGlu receptor subtypes [<xref ref-type="bibr" rid="R36">36</xref>, <xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R58">58</xref>, <xref ref-type="bibr" rid="R212">211</xref>]. The wide functional diversity and distinct distribution patterns of mGlu receptor subtypes provide an opportunity for selectively targeting individual mGlu subtypes in order to attempt the development of novel treatment strategies for emotional disorders. A large body of preclinical studies suggests that ligands for specific mGlu subtypes have potential in multiple mood disorders, including anxiety disorders and depression (Table <xref ref-type="table" rid="T1">1</xref>). More recently, data from clinical studies with mGlu subtype-selective ligands are beginning to emerge and are providing remarkable clinical efficacy of some of these compounds, which we discuss below.</p>
<sec>
<title>Role of Group I mGlu Receptors in the Physiology of Stress</title>
<p>Group I mGlu receptors are broadly distributed within the peripheral and central nervous system and are expressed at post- and perisynaptic sites in several areas implicated in anxiety and emotional processing, and there is evidence for the involvement of these receptors in the pathophysiology of different emotional and somatic disorders. For example, human post-mortem studies reported specific reductions of total mGlu5 protein and mRNA levels in the lateral cerebellum [<xref ref-type="bibr" rid="R213">212</xref>, <xref ref-type="bibr" rid="R214">213</xref>] and prefrontal cortex [<xref ref-type="bibr" rid="R215">214</xref>] in MDD patients [<xref ref-type="bibr" rid="R216">215</xref>]. Furthermore, a study by Wieronska <italic>et al.</italic> [<xref ref-type="bibr" rid="R203">202</xref>] showed an increase of mGlu5 expression in CA1 and a decrease in CA3 of rat hippocampus in response to CMS, an animal model showing symptoms related to human depression, supporting the involvement of mGlu5 in the pathophysiology of mood disorders in response to chronic stress.</p>
<p>Very interestingly, the mGlu5 receptor subtype is known to functionally interact with NMDA receptors by indirect physical and positive feedback linkage <italic>via</italic> a variety of intracellular mechanisms, including Homer, Shank and PSD-95 proteins [<xref ref-type="bibr" rid="R164">163</xref>, <xref ref-type="bibr" rid="R217">216</xref>-<xref ref-type="bibr" rid="R222">221</xref>] (see Fig. <bold><xref ref-type="fig" rid="F1">1</xref></bold>). This close functional association and positive reciprocal regulation between mGlu5 and NMDA makes the mGlu5 receptor subtype an attractive target for the indirect modulation of NMDA receptor function, which is known to be dysregulated in a variety of neuropsychiatric pathologies including mood disorders [<xref ref-type="bibr" rid="R223">222</xref>-<xref ref-type="bibr" rid="R226">225</xref>]. Importantly, as pharmacological activation of mGlu5 is shown to cause neurotoxicity  and neurodegeneration [<xref ref-type="bibr" rid="R80">80</xref>, <xref ref-type="bibr" rid="R227">226</xref>, <xref ref-type="bibr" rid="R228">227</xref>], the activating mode of action will not be considered in the context of  mGlu5’s potential therapeutic application. In contrast, pharmacological blockade of mGlu5 function has emerged to be one of the most promising and quite advanced therapeutic strategies for the treatment of psychiatric conditions [<xref ref-type="bibr" rid="R164">163</xref>, <xref ref-type="bibr" rid="R229">228</xref>-<xref ref-type="bibr" rid="R234">233</xref>]. This approach has demonstrated anti-stress efficacy in a number of animal and human studies. For instance, 3-(3-chlorophenyl)-1-(1-methyl-4-oxo-5H-imidazol-2-yl)urea (fenobam), a compound shown to be a clinically active anxiolytic already in the early 1980s [<xref ref-type="bibr" rid="R235">234</xref>, <xref ref-type="bibr" rid="R236">235</xref>], was more recently described to exert its pharmacological effects <italic>via</italic> inverse receptor agonist activity at the mGlu5 receptor [<xref ref-type="bibr" rid="R237">236</xref>]. Moreover, allosteric blockade of mGlu5 with the prototypical allosteric receptor antagonist 2-methyl-6-(2-phenylethynyl)pyridine (MPEP) showed broad anxiolytic and antidepressant-like profiles in acute rodent animal models [<xref ref-type="bibr" rid="R238">237</xref>-<xref ref-type="bibr" rid="R242">241</xref>]. Li <italic>et al.</italic> [<xref ref-type="bibr" rid="R240">239</xref>] reported that administration of MPEP and the tricyclic antidepressant (TCA) imipramine resulted in a synergistic antidepressant-like effect in the FST and that this effect was even persistent after sub-chronic treatment (once daily, for five consecutive days). A further study revealed that MPEP remained equally active in reducing the SIH response in mice after sub-chronic dosing for five consecutive days, with comparable efficacy as after acute administration [<xref ref-type="bibr" rid="R243">242</xref>]. Those studies provided the first evidence that longer-term administration of mGlu5 blockers may have the potential to ameliorate stress-induced pathophysiology. Moreover, MPEP’s anxiolytic activity could be confirmed in a battery of further acute animal models, such as the EPM, Vogel conflict- and marble burying-tests and the fear-potentiated startle paradigm [<xref ref-type="bibr" rid="R238">237</xref>, <xref ref-type="bibr" rid="R239">238</xref>, <xref ref-type="bibr" rid="R244">243</xref>-<xref ref-type="bibr" rid="R246">245</xref>]. Another selective mGlu5 receptor antagonist, 3-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP), turned out to be a good pharmacological tool to confirm anti-stress activity in several behavioral models [<xref ref-type="bibr" rid="R72">72</xref>, <xref ref-type="bibr" rid="R247">246</xref>-<xref ref-type="bibr" rid="R251">250</xref>]. MTEP showed activity in the FST, TST and olfactory bulbectomy (OB) model [<xref ref-type="bibr" rid="R252">251</xref>, <xref ref-type="bibr" rid="R253">252</xref>]. In the latter, repeated administration of MTEP attenuated the OB-related hyperactivity of rats in the open field test, a finding that resembles the action of typical antidepressants in the OB model of depression [<xref ref-type="bibr" rid="R253">252</xref>]. Obviously, both MPEP and MTEP have been studied in a wide range of preclinical animal models for different therapeutic indications, however, both compounds are not suitable drug candidates for clinical development due to pharmacokinetic constraints [<xref ref-type="bibr" rid="R254">253</xref>]. Beside the above mentioned, acute administration of the recently discovered mGlu5-selective negative allosteric modulator (NAM) 2-{2-[2-(difluoromethoxy)-5-({5H,6H,7H-pyrrolo[3,4-b]pyridin-6-yl}carbonyl)phenyl]ethynyl}pyridine (GRN-529) showed dose-dependent efficacy across a broad battery of animal models including the FST and TST, in anxiety tests (attenuation of SIH response and increased punished crossings in the four plate test) and in pain models (reversal of hyperalgesia due to sciatic nerve ligation or inflammation) [<xref ref-type="bibr" rid="R255">254</xref>]. Another novel and highly selective mGlu5 receptor antagonist, methyl (3aR,4S,7aR)-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-3,3a,5,6,7,7a-hexahydro-2H-indole-1-carboxylate (AFQ056, mavoglurant), showed an improved pharmacokinetic profile in rodents and better efficacy in SIH tests in mice as compared to the prototypic mGlu5 antagonist MPEP [<xref ref-type="bibr" rid="R256">255</xref>]. Interestingly, efficacy of AFQ056 has been reported also in L-dopa induced dyskinesia in Parkinson's disease and Fragile X syndrome in proof-of-principle clinical studies [<xref ref-type="bibr" rid="R256">255</xref>-<xref ref-type="bibr" rid="R259">258</xref>]. The mGlu5-selective NAM 2-chloro-4-{[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-yl]ethynyl}pyridine (basimglurant) turned out to be very promising in a phase II clinical study by demonstrating efficacy and safety as an adjunctive therapy in MDD patients using multiple read-outs. For instance, this study showed that a 6-week double-blind treatment of basimglurant versus placebo reached significant improvements in patient-rated Montgomery-Asberg depression rating scale (MADRS) results, in remission assessment and further ratings [<xref ref-type="bibr" rid="R232">231</xref>, <xref ref-type="bibr" rid="R234">233</xref>, <xref ref-type="bibr" rid="R260">259</xref>]. The consistency of the efficacy findings combined with good tolerability warrants further investigation with basimglurant in depressive disorders. Furthermore, the recently discovered mGlu5 NAM 2-chloro-4-[2-[2,5-dimethyl-1-[4-(trifluoromethoxy)phenyl]imidazol-4-yl]ethynyl]pyridine (CTEP), a compound chemically derived from basimglurant and optimized for utility in rodent studies, was shown to be active in acute rodent models, such as the SIH in mice and the Vogel conflict test in rats [<xref ref-type="bibr" rid="R229">228</xref>]. CTEP is the first reported mGlu5 inhibitor with both, very long half-life of approximately 18 h and high oral bioavailability in rodents, classifying as useful pharmacological tool for long-term treatment. CTEP thus allows the exploration of the full therapeutic potential of mGlu5 inhibition for indications requiring chronic receptor blockade. Indeed, Michalon <italic>et al.</italic> [<xref ref-type="bibr" rid="R230">229</xref>, <xref ref-type="bibr" rid="R261">260</xref>] found out that chronic treatment with CTEP in a mouse model of Fragile X rescued learning and memory deficits, elevated locomotor activity and increased spine density, suggesting that this mGlu5 NAM treatment may be effective in correcting multiple neurological symptoms [<xref ref-type="bibr" rid="R234">233</xref>]. Furthermore, a more recent study reported that chronic administration of CTEP was able to improve various behavioral alterations induced by chronic social defeat stress, such as reduced locomotion and an anhedonic phenotype [<xref ref-type="bibr" rid="R164">163</xref>]. Importantly, studies using mGlu5-deficient mice elegantly support the functional roles of mGlu5 in anxiety- and depression-related behaviors [<xref ref-type="bibr" rid="R240">239</xref>, <xref ref-type="bibr" rid="R246">245</xref>].</p>
<p>One can speculate that these beneficial effects of mGlu5 blockade may result from a combination of different neurophysiological mechanism. First, disruption of thalamic-lateral amygdala long-term potentiation is observed with intra-amygdala injection of MPEP [<xref ref-type="bibr" rid="R262">261</xref>], which is a likely mechanism for the reduced acquisition of learned fear observed with MPEP in conditioned anxiety paradigms [<xref ref-type="bibr" rid="R262">261</xref>, <xref ref-type="bibr" rid="R263">262</xref>]. Second, interference with hippocampal mGlu5 function and possibly dysregulation of expression by allosteric mGlu5 antagonists are also likely to contribute to anxiolytic activity [<xref ref-type="bibr" rid="R58">58</xref>, <xref ref-type="bibr" rid="R264">263</xref>]. Third, mGlu5 blockade is known to interfere with functional parameters of the HPA axis, which represents the principal stress-response and -regulation system in mammals [<xref ref-type="bibr" rid="R207">206</xref>-<xref ref-type="bibr" rid="R209">208</xref>, <xref ref-type="bibr" rid="R265">264</xref>]. Taken together, the reported findings substantiate the hypothesis that mGlu5 receptor antagonism is associated with anxiolytic and antidepressant-like effects and that this approach represents one of the most promising and advanced mGlu receptor strategies towards future treatment of chronic stress-related disabilities such as mood disorders.</p>
<p>Modulation of the second group I receptor, mGlu1, has originally been considered also as an attractive target for the treatment of anxiety. For instance, anxiolytic-like activities of mGlu1 receptor antagonists have been documented in various animal models, including, for example, the Vogel conflict- and SIH test [<xref ref-type="bibr" rid="R266">265</xref>-<xref ref-type="bibr" rid="R270">269</xref>]. Several other studies have also illustrated effects of mGlu1 receptor antagonists on fear memory [<xref ref-type="bibr" rid="R271">270</xref>-<xref ref-type="bibr" rid="R274">273</xref>]. However, as compared to mGlu5, the mGlu1 receptor subtype has been evaluated much less in the context of emotion, stress physiology and behavior, which may be due to reports on cognitive dysfunctions in mice lacking mGlu1 [<xref ref-type="bibr" rid="R275">274</xref>-<xref ref-type="bibr" rid="R277">276</xref>] or potentially induced by mGlu1-selective antagonist [<xref ref-type="bibr" rid="R267">266</xref>, <xref ref-type="bibr" rid="R274">273</xref>, <xref ref-type="bibr" rid="R278">277</xref>].</p>
</sec>
<sec>
<title>Role of Group II mGlu Receptors in the Physiology of Stress</title>
<p>Group II mGlu subtypes show localization in key forebrain and limbic areas, such as the PFC, thalamus, hippocampus, and amygdala [<xref ref-type="bibr" rid="R279">278</xref>] and their ability to fine-tune glutamatergic neurotransmission makes these receptors attractive targets for the development of improved medication for emotional disorders. Recent studies showed that hippocampal mGlu2/3 receptor expression is reduced in the mouse OB model of depression and spontaneously depressed Flinders-sensitive line (FSL) rats [<xref ref-type="bibr" rid="R280">279</xref>, <xref ref-type="bibr" rid="R281">280</xref>]. Moreover, recent human postmortem brain analysis demonstrated an increase in mGlu2/3 protein levels in depressed patients [<xref ref-type="bibr" rid="R282">281</xref>]. Particularly the mGlu2/3 activating ligands seem to be drugs with promising therapeutic potential and good safety profiles. For example, the mGlu2/3 receptor agonists such as (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0.]hexane-4,6 dicarboxylic acid (LY404039) and (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740) demonstrated neurochemical and behavioral effects in a very broad spectrum of models predictive of anxiolytic and anti-stress activity [<xref ref-type="bibr" rid="R58">58</xref>, <xref ref-type="bibr" rid="R269">268</xref>, <xref ref-type="bibr" rid="R283">282</xref>-<xref ref-type="bibr" rid="R287">286</xref>]. These mGlu2/3 receptor agonists have even progressed into phase II clinical trial, in which there was good efficacy in preventing CO<sub>2</sub>-induced anxiety in panic attack patients [<xref ref-type="bibr" rid="R288">287</xref>]. Furthermore, strong preclinical evidence for potential antidepressant effects upon chronic dosing came from a study showing that 3-days of treatment with the mGlu2/3 agonist 2-amino-4-oxabicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY379268) induced a decrease of total immobility time in the FST in FSL rats [<xref ref-type="bibr" rid="R289">288</xref>, <xref ref-type="bibr" rid="R290">289</xref>]. Interestingly, combination of the antidepressant chlorimipramine and LY379268 for 3 days substantially reduced the immobility time, supporting the hypothesis that antidepressants have a shorter latency of action if mGlu2/3 receptors are activated at the same time [<xref ref-type="bibr" rid="R281">280</xref>]. Especially the latter finding raises the intriguing possibility for mGlu2/3 agonists to be used as adjunctive drugs to shorten the latency of antidepressant medication,  an issue that should receive strong attention, as suicide attempts are often increased particularly during the initial period of antidepressant treatment. In addition, LY379268 significantly decreased SIH responses, indicating its anti-anxiety potential [<xref ref-type="bibr" rid="R270">269</xref>, <xref ref-type="bibr" rid="R291">290</xref>]. Interestingly, it has been shown that mGlu2, and not mGlu3, mediated the actions of LY404039 and LY379268 in mouse models predictive of antipsychotic activity [<xref ref-type="bibr" rid="R292">291</xref>, <xref ref-type="bibr" rid="R293">292</xref>], suggesting a dominant role of the mGlu2 receptor subtype in triggering antipsychotic effects. In recent years, the number of reports about mGlu2 receptor-selective positive allosteric modulators (PAMs) has increased substantially and some of these compounds have been extensively characterized in a number of animal models [<xref ref-type="bibr" rid="R294">293</xref>, <xref ref-type="bibr" rid="R295">294</xref>]. For instance, a recent study using the mGlu2 receptor PAM N-({4-[3-hydroxy-4-(2-methylpropanoyl)-2-(trifluoromethyl)phenoxymethyl]phenyl}methyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC) showed robust activity in three assays detecting antidepressant-like activity, including the FST in mice, the differential reinforcement of low rate 72-s (DRL-72) assay and the dominant-submissive test in rats, with a maximal response similar to that of imipramine [<xref ref-type="bibr" rid="R296">295</xref>]. Moreover, this mGlu2 PAM showed anxiolytic- like efficacy in the SIH test in rats and the marble-burying test in mice, suggesting an important role for mGlu2 in  the pathophysiology of anxiety. In addition, 1-(4-chloro- 2-fluorobenzyl)-5-(4-methoxyphenyl)-2(1H)-pyridinone (ADX71149), another highly mGlu2-selective PAM, demonstrated safety and efficacy not only in phase IIa clinical testing for schizophrenia but also in anxious depression [<xref ref-type="bibr" rid="R297">296</xref>, <xref ref-type="bibr" rid="R298">297</xref>]. The mGlu2 PAMs 2,2,2-trifluoro- N-[4-(2-methoxyphenoxy)phenyl]-N-(pyridin-3-ylmethyl) ethanesulfonamide (LY487379) and 4-[3-[(2-cyclopentyl-6,7-dimethyl-1-oxo-2,3-dihydroinden-5-yl)oxymethyl]phenyl] benzoic acid (biphenylindanone A, BINA) also exhibited anxiolytic effects when assessed in rodent models of anxiety such as SIH and EPM tests [<xref ref-type="bibr" rid="R291">290</xref>, <xref ref-type="bibr" rid="R299">298</xref>].</p>
<p>Interestingly, and in some way paradoxically, there are also studies demonstrating antidepressant-like and anxiolytic efficacies of mGlu2/3 receptor antagonists. Early findings were obtained in the FST in rats and TST in mice after  acute administration of (1R,2R,3R,5R,6R)-2-amino-3-[(3, 4-dichlorophenyl)methoxy]-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039) and (1S,2S)-2-[(2S)-2-amino-3-(2,6-dioxo-3H-purin-9-yl)-1-hydroxy-1-oxopropan-2-yl]cyclopropane-1-carboxylic acid (LY341495) [<xref ref-type="bibr" rid="R300">299</xref>]. Importantly, several studies revealed that repeated administration of the mGlu2/3 receptor antagonist MGS0039 exhibited remarkable antidepressant-like efficacy. In this context, Palucha-Poniewiera <italic>et al.</italic> [<xref ref-type="bibr" rid="R301">300</xref>] could show that repeated administration of MGS0039 attenuated deficits in the OB model of depression in rats. Furthermore, treatment with MGS0039 for 7 days elicited a significant reduction in escape failures in the LH paradigm [<xref ref-type="bibr" rid="R302">301</xref>]. Additionally, MGS0039’s antidepressant-like potential was demonstrated by reversing the increase of immobility in the FST induced by chronic social isolation-reared mice [<xref ref-type="bibr" rid="R303">302</xref>] and by reducing the increase of immobility in the FST after chronic corticosterone treatment [<xref ref-type="bibr" rid="R304">303</xref>]. Moreover, this mGlu2/3 receptor antagonist significantly attenuated freezing behavior in a conditioned fear stress (CFS) model [<xref ref-type="bibr" rid="R302">301</xref>], dose-dependently reduced SIH [<xref ref-type="bibr" rid="R305">304</xref>] and inhibited marble-burying behavior [<xref ref-type="bibr" rid="R306">305</xref>], indicating also strong anxiolytic-like potential. It was further demonstrated that systemic blockade of mGlu2/3 with LY341495 prevented stress-induced autonomic hyperactivity [<xref ref-type="bibr" rid="R305">304</xref>] and reduced immobility in the mouse FST and in the TST of a line of Helpless (H) mice [<xref ref-type="bibr" rid="R301">300</xref>, <xref ref-type="bibr" rid="R304">303</xref>, <xref ref-type="bibr" rid="R307">306</xref>, <xref ref-type="bibr" rid="R308">307</xref>], a putative model for depression symptoms. A more recent study demonstrated that a single administration of LY341495 produced a rapid and long-lasting reversal of decreased sucrose preference caused by CUS in rats [<xref ref-type="bibr" rid="R309">308</xref>]. In addition, the recently developed mGlu2/3-selective NAM 4-[3-(2,6-dimethylpyridin-4-yl)phenyl]-7-methyl-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one (RO4491533) also showed strong antidepressant-like efficacy in mouse FST and TST models [<xref ref-type="bibr" rid="R308">307</xref>], underpinning the anti-stress potential of mGlu2/3 receptor antagonists – at least in some relevant experimental animal models.</p>
<p>As clearly demonstrated by the recent advances above, mGlu2/3 receptors are critically involved in stress physiology and their modulation holds promise for the treatment of mood disorders such as depression and anxiety [<xref ref-type="bibr" rid="R310">309</xref>], and several pharmaceutical companies are interested in advancing mGlu2- and/or mGlu3 modulators (positive  and negative) from discovery research into clinical development.</p>
</sec>
<sec>
<title>Role of Group III mGlu Receptors in the Physiology of Stress</title>
<p>Group III mGlu receptors have received somewhat less attention than those of group I or group II, mostly due to the obvious paucity of pharmacological tools available to study them [<xref ref-type="bibr" rid="R51">51</xref>, <xref ref-type="bibr" rid="R55">55</xref>, <xref ref-type="bibr" rid="R61">61</xref>, <xref ref-type="bibr" rid="R311">310</xref>]. Nevertheless, they are thought to be involved in a number of disease states and physiological conditions, consistent with their role in the regulation of both glutamatergic and GABAergic neurotransmission throughout the brain [<xref ref-type="bibr" rid="R312">311</xref>-<xref ref-type="bibr" rid="R318">317</xref>]. Much of our current knowledge still relies on studies performed by direct central application of compounds and on the characterization of genetically manipulated animals under basal and under stress conditions. For instance, Tatarczynska <italic>et al.</italic> [<xref ref-type="bibr" rid="R319">318</xref>] found out that intraventricular injection of the group III mGlu receptor agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) produced both anxiolytic- and antidepressant-like effects. Its anxiolytic action was shown in both the  SIH and EPM tests in mice, and in the Vogel conflict test in rats. Its antidepressant-like action was evaluated in the  FST [<xref ref-type="bibr" rid="R319">318</xref>, <xref ref-type="bibr" rid="R320">319</xref>]. Interestingly, another study showed that the antidepressant-like effects of centrally applied ACPT-I could be reversed by the group III mGlu receptor antagonist  2-amino-2-cyclopropyl-2-(4-phosphonophenyl)acetic acid (CPPG) [<xref ref-type="bibr" rid="R321">320</xref>]. However, these compounds are not subtype-selective, as they act at all members of group III receptors, making it impossible to allocate these effects to a specific receptor subtype. Addressing the influence of mGlu4, Klak <italic>et al.</italic> [<xref ref-type="bibr" rid="R322">321</xref>] could show that the combined administration of the mGlu4-selective PAM 7-hydroxyimino-N-phenyl-1,7a-dihydrocyclopropa[b]chromene-1a-carboxamide (PHCCC) and a non-effective dose of ACPT-1 produced antidepressant-like efficacy in the rat FST. A further study demonstrated that administration of PHCCC into the basolateral amygdala resulted in dose-dependent anti-conflict effects in the rat Vogel conflict test, indicating that positive allosteric modulation of mGlu4 receptors may be a useful therapeutic approach for anxiety [<xref ref-type="bibr" rid="R323">322</xref>]. More recently, the peripheral use of (1R,2S)-2-[(3,5-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid (VU0155041), an mGlu4 PAM [<xref ref-type="bibr" rid="R324">323</xref>], demonstrated anxiolytic action in the elevated zero maze [<xref ref-type="bibr" rid="R325">324</xref>]. In addition, the novel mGlu4 PAMs (1S,2R)- 2-[(aminooxy)methyl]-N-(3,4-dichlorophenyl)cyclohexane-1-carboxamide (Lu AF21934) and 4-methyl-N-[5-methyl- 4-(1H-pyrazol-4-yl)-1,3-thiazol-2-yl]pyrimidin-2-amine (ADX88178) have been reported to also induce an anxiolytic-like affect in acute rodent models including SIH, four-plate and marble-burying test, in addition to being active in multiple models of Parkinson’s disease [<xref ref-type="bibr" rid="R326">325</xref>, <xref ref-type="bibr" rid="R327">326</xref>]. Interestingly, mGlu4-deficient mice exerted increased measures of anxiety in acute models, including the open field and elevated zero maze, and impaired sensorimotor function on the rotarod test [<xref ref-type="bibr" rid="R328">327</xref>]. Consistent with this, they also showed enhanced amygdala-dependent cued-fear conditioning [<xref ref-type="bibr" rid="R329">328</xref>]. Similar to these findings, mice lacking mGlu8 showed higher measures of anxiety as compared to control animals [<xref ref-type="bibr" rid="R330">329</xref>, <xref ref-type="bibr" rid="R331">330</xref>] and when exposed to novel, aversive environments, they exhibit greater neuronal activation in stress-related brain regions [<xref ref-type="bibr" rid="R332">331</xref>]. These studies suggest enhanced reactivity to stressors in mice deficient for mGlu4 or mGlu8. To go on with mGlu8, acute pharmacological stimulation with its agonist 4-[(1S)-1-amino-2-hydroxy-2-oxoethyl]phthalic acid (DCPG) reduced innate anxiety in the open field and EPM tests [<xref ref-type="bibr" rid="R333">332</xref>] and reduced the expression of contextual fear without affecting the acquisition and expression of cued fear [<xref ref-type="bibr" rid="R334">333</xref>]. Furthermore, 2-amino-2-(4-phosphonophenyl)acetic acid (RS-PPG), an mGlu8 receptor-preferring agonist, induced dose-dependent antidepressant-like effects in the FST after central administration [<xref ref-type="bibr" rid="R321">320</xref>]. Moreover, the mGlu8-selective PAM 2-[(4-bromophenyl)methyl-sulfanyl]-N-(4-butan-2-ylphenyl)acetamide (AZ12216052) reduced measures of anxiety in the open field and EPM tests [<xref ref-type="bibr" rid="R333">332</xref>].</p>
<p>Abbreviations: NAM, negative allosteric modulator; PAM, positive allosteric modulator; EPM, elevated plus maze; SIH, stress-induced hyperthermia; FST, forced swim test; TST, tail suspension test; LH, learned helplessness; CMS, chronic mild stress; CSDS, chronic social defeat stress.</p>
<p>However, as this anxiolytic effect was still present in mGlu8-KO mice, the effect of 2-{[(4-bromophenyl)methyl] sulfanyl}-N-[4-(butan-2-yl)phenyl]acetamide (AZ12216052) on measures of anxiety likely involves molecular targets other than mGlu8, too [<xref ref-type="bibr" rid="R325">324</xref>]. Nevertheless, the behavioral data so far suggest that mGlu4 and mGlu8 receptor activation may render anxiolytic, anti-stress as well as antidepressant-like effects [<xref ref-type="bibr" rid="R335">334</xref>].</p>
<p>With respect to mGlu7, there is clear evidence for a role of this receptor in fear and stress physiology from studies using mGlu7-KO mice [<xref ref-type="bibr" rid="R334">333</xref>, <xref ref-type="bibr" rid="R336">335</xref>, <xref ref-type="bibr" rid="R337">336</xref>]. Ablation of mGlu7 in mice was shown to result in reduced amygdala-dependent conditioned fear and aversion. The phenotype of reduced anxiety- and stress-related behaviors and physiology of mGlu7-deficient mice extends also to tests for innate anxiety and despair [<xref ref-type="bibr" rid="R336">335</xref>, <xref ref-type="bibr" rid="R337">336</xref>]. In addition, these mice also show an upregulated glucocorticoid receptor-dependent feedback suppression of the HPA axis [<xref ref-type="bibr" rid="R210">209</xref>], further supporting mGlu7’s critical role in stress physiology. Mitsukawa <italic>et al.</italic> [<xref ref-type="bibr" rid="R338">337</xref>] characterized an mGlu7-selective agonist, namely N,N'-bis[di(phenyl)methyl]ethane-1,2-diamine (AMN082), as a compound which is orally active and penetrates the blood-brain barrier, that enabled to further study mGlu7’s potential role in stress physiology. In the fear-potentiated startle paradigm, a model of acute stress, AMN082 impaired acquisition but enhanced extinction of conditioned fear, while mGlu7 knockdown using short interfering RNA attenuated extinction [<xref ref-type="bibr" rid="R339">338</xref>, <xref ref-type="bibr" rid="R340">339</xref>]. In another study, Dobi <italic>et al.</italic> [<xref ref-type="bibr" rid="R341">340</xref>] demonstrated that direct AMN082-injection into the basolateral complex of the amygdala also facilitated extinction of contextual fear. Together, these data support a clear role for mGlu7 in both acquisition and extinction of conditioned fear. Moreover, AMN082 elevated plasma levels of the stress hormones ACTH and CORT [<xref ref-type="bibr" rid="R338">337</xref>], induced antidepressant-like effects in the FST and TST [<xref ref-type="bibr" rid="R72">72</xref>, <xref ref-type="bibr" rid="R342">341</xref>-<xref ref-type="bibr" rid="R345">344</xref>], and demonstrated robust anxiolytic efficacy in the SIH response, four-plate- and EPM test [<xref ref-type="bibr" rid="R346">345</xref>, <xref ref-type="bibr" rid="R347">346</xref>]. At a first glance, these effects seem to be in contradiction with the anxiolytic- and antidepressant-like behavioral changes observed in mice lacking mGlu7 or after siRNA-mediated knockdown of the receptor [<xref ref-type="bibr" rid="R348">347</xref>]. However, AMN082 has been shown also to induce a rapid and lasting internalization of mGlu7 protein, which could well translate into functional antagonism of the receptor [<xref ref-type="bibr" rid="R349">348</xref>]. A further explanation for AMN082’s antidepressant-like profile in rodents would be that AMN082 not only binds to mGlu7 but with weaker affinity also to monoamine transporters, similar to its primary metabolite, <italic>N</italic>-benzhydrylethane-1,2-diamine (Met-1), which inhibits serotonin and norepinephrine reuptake transporters with a physiologically relevant affinity [<xref ref-type="bibr" rid="R350">349</xref>].</p>
<p>Two systemically active mGlu7 NAMs have yielded divergent results in behavioral tests despite displaying very similar pharmacological properties <italic>in vitro</italic>. 6-(2,4-dimethylphenyl)-2-ethyl-4,5,6,7-tetrahydro-1,3-benzoxazol-4-one (ADX71743) was shown to have robust anxiolytic effects in the EPM and the marble burying test [<xref ref-type="bibr" rid="R351">350</xref>]. In contrast, 6-(4-methoxyphenyl)-5-methyl-3-(pyridin-4-yl)-4H,5H-[<xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref>]oxazolo[4,5-c]pyridin-4-one (MMPIP) was reported to have little anxiolytic activity but reversed antidepressant-like effects of AMN082 in rats [<xref ref-type="bibr" rid="R344">343</xref>, <xref ref-type="bibr" rid="R352">351</xref>]. In addition, various behavioral studies also revealed that MMPIP impaired cognitive performances in the object recognition and the object location test [<xref ref-type="bibr" rid="R353">352</xref>]. As opposed to <italic>e.g</italic>. MMPIP, the recently discovered and first mGlu7-selective orthosteric antagonist 7-hydroxy-3-(4-iodophenoxy)-4H-chromen-4-one (XAP044) was shown to display binding within the VFTD of mGlu7 and a quite broad mode of functional mGlu7-blockade across multiple <italic>in vitro</italic> tests [<xref ref-type="bibr" rid="R354">353</xref>]. XAP044 is systemically active and demonstrates a wide spectrum of anti-stress-, antidepressant-, and anxiolytic-like efficacy <italic>in vivo</italic> [<xref ref-type="bibr" rid="R354">353</xref>]. This supports the view that pharmacological blockade of mGlu7 <italic>in vivo</italic> might be a viable path forward attempting to reverse stress-related pathophysiological states in psychiatric illness. In line with this, human genetic studies with depressed siblings and recurrent MDD patients pointed at GRM7 (the gene coding for mGlu7 receptors) as a gene potentially involved in human depression [<xref ref-type="bibr" rid="R355">354</xref>, <xref ref-type="bibr" rid="R356">355</xref>]. Taken together, considerable progress has been made in recent years in increasing our understanding of group III mGlu receptors within the CNS, and has remarkably revealed key roles for these receptors in acute stress, fear- and depression-related behavior, thereby emphasizing the therapeutic potential of group III-directed ligands and asking for future studies under chronic stress conditions (see below).</p>
</sec>
</sec>
<sec>
<title>Conclusion and Outlook</title>
<p>Encouraging evidence has emerged from both preclinical and clinical research in recent years, supporting key roles for the brain glutamatergic neurotransmitter system in the physiology of psychiatric disorders. However, only little is known about the contribution of the glutamate system to the pathophysiology following chronic psychosocial stress, which is the most acknowledged risk factor for emotion disorders, such as anxiety and depression [<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R4">4</xref>-<xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R9">9</xref>]. Moreover, current drug discovery efforts targeting the mGlu receptors led to the identification of pharmacological tools with promising efficacy in psychiatric conditions [<xref ref-type="bibr" rid="R51">51</xref>, <xref ref-type="bibr" rid="R55">55</xref>, <xref ref-type="bibr" rid="R58">58</xref>, <xref ref-type="bibr" rid="R65">65</xref>, <xref ref-type="bibr" rid="R71">71</xref>, <xref ref-type="bibr" rid="R232">231</xref>, <xref ref-type="bibr" rid="R234">233</xref>, <xref ref-type="bibr" rid="R359">358</xref>]. The potential of these pharmacological tools in the manifestation of physiological and behavioral consequences of chronic psychosocial stress still needs to  be investigated. On a preclinical basis, the CSC paradigm might be an appropriate animal model, as it utilizes chronic psychosocial stressor exposure and results in decreased GC signaling and concomitant somatic, immunological, and affective pathologies, such as an overall proinflammatory- and cancer-prone phenotype and an anxiogenic and substance abuse phenotype [<xref ref-type="bibr" rid="R40">40</xref>, <xref ref-type="bibr" rid="R41">41</xref>, <xref ref-type="bibr" rid="R141">140</xref>, <xref ref-type="bibr" rid="R180">179</xref>, <xref ref-type="bibr" rid="R181">180</xref>, <xref ref-type="bibr" rid="R187">186</xref>, <xref ref-type="bibr" rid="R197">196</xref>, <xref ref-type="bibr" rid="R359">359</xref>]. All these consequences are relevant for the development of somatic, <italic>e.g</italic>. gastrointestinal, and/or psychiatric disorders and the question whether mGlu receptors have the potential to exert control on these consequences is of great interest. Early evidence for the potential involvement of mGlu receptor subtypes in chronic psychosocial stress pathology comes from recent studies described above, suggesting that the mGlu7 receptor might play a controlling role in the PFC and the mGlu5 receptor in the hypothalamus. The recent development of CTEP and basimglurant, two compounds with markedly improved pharmacokinetic and safety profiles as compared to previous mGlu5 NAMs, such as MPEP and MTEP, may be most suitable to study the long-term effects of mGlu5-blockade <italic>in vivo</italic> following chronic stress exposure. Most notably, CTEP’s sufficiently long half-life amenable for once daily administration in rodents and its high <italic>in vivo</italic> potency to achieve a low application dose makes it a suitable compound for chronic application and for the study of mGlu5’s role in chronic stress conditions. Indeed, first evidence of efficacy already comes from a very recent study conducted by Wagner <italic>et al.</italic> [<xref ref-type="bibr" rid="R164">163</xref>], who demonstrated that sustained mGlu5 receptor blockade <italic>via</italic> chronic administration of CTEP was able to recover CSDS-induced behavioral alterations [<xref ref-type="bibr" rid="R164">163</xref>]. The finding, that CTEP did not reverse the stress-induced physiological changes, requires further investigation. A potentially profitable approach in this regard may be to investigate whether chronic CTEP administration can attenuate the various physiological, immunological, and also behavioral consequences of chronic psychosocial stress induced by CSC exposure. Such studies may suggest future application routes for mGlu5 NAMs in chronic clinical conditions, including somatoform psychiatric disorders.</p>
<p>The mGlu7 receptor is also a promising target in chronic stress physiology, but the question still remains, which mechanism of action – its activation or blockade – might be effective in ameliorating the detrimental consequences of chronic psychosocial stress. Considerable progress has been made with the discovery of the mGlu7 agonist AMN082 [<xref ref-type="bibr" rid="R338">337</xref>] and the mGlu7 NAM ADX71743 [<xref ref-type="bibr" rid="R351">350</xref>], two compounds that have already shown robust efficacy in animal models for anxiety and depression, but have not yet been investigated in any context of chronic or even psychosocial stress. For the present time, it is very difficult to speculate whether activation or inhibition of the mGlu7 receptor would be more efficacious in reversing the consequences of chronic stress in man. However, the characterization of the recently discovered orthosteric-like mGlu7 antagonist XAP044 [<xref ref-type="bibr" rid="R354">353</xref>], which shows wide spectrum anti-stress (acute), antidepressant-, and anxiolytic-like efficacy <italic>in vivo</italic>, might provide an additional and suitable tool compound to elucidate the role of mGlu7 under chronic psychosocial stress conditions, at least in rodents. Taken together, there is emerging evidence that makes it worthwhile to further investigate in detail the potentially beneficial roles of especially mGlu5 and mGlu7 subtype-selective modulation in the context of chronic psychosocial stress and to provide a better understanding of the neural mechanisms involved and regulated by mGlu receptors. Besides providing fundamental neurophysiological insights, these investigations will hopefully stimulate drug development towards mGlu5- and mGlu7-targeted therapies aiming at the large panel of human chronic stress-induced neuropsychiatric disorders.</p>
</sec>
</body>
<back>
<ack>
<title>ACKNOWLEDGEMENTS</title>
<p>Dr. Peter J. Flor is supported by Grant FL 729/2-1 from the German Research Foundation (DFG).</p>
</ack>
<sec>
<title>CONFLICT OF INTEREST</title>
<p>All three authors who contributed to this manuscript state that they have no conflict of interest with this work.</p>
</sec>
<ref-list>
<title>REFERENCES</title>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneiderman</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ironson</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>S. D.</given-names>
</name>
</person-group>
<article-title>Stress and health: psychological, behavioral, and biological determinants.</article-title>
<source/>Annu. Rev Clin. Psychol
          <year>2005</year>
<volume>1</volume>
<fpage>607</fpage>
<lpage>628.</lpage>
<pub-id pub-id-type="pmid">17716101</pub-id>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The ascent of mouse: advances in modelling human depression and anxiety.</article-title>
<source/>Nat. Rev. Drug Discov.
          <year>2005</year>
<volume>4</volume>
<issue>9</issue>
<fpage>775</fpage>
<lpage>790</lpage>
<pub-id pub-id-type="doi">10.1038/nrd1825</pub-id>
<pub-id pub-id-type="pmid">16138108</pub-id>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Steen</surname>
<given-names>N.E.</given-names>
</name>
<name>
<surname>Agartz</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Aminoff</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Lorentzen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sundet</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Andreassen</surname>
<given-names>O.A.</given-names>
</name>
<name>
<surname>Melle</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Is cognitive impairment following early life stress in severe mental disorders based on specific or general cognitive functioning?</article-title>
<source/>Psychiatry Res.
          <year>2012</year>
<volume>198</volume>
<issue>3</issue>
<fpage>495</fpage>
<lpage>500</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2011.12.045</pub-id>
<pub-id pub-id-type="pmid">22472845</pub-id>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caspi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sugden</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Moffitt</surname>
<given-names>T.E.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Craig</surname>
<given-names>I.W.</given-names>
</name>
<name>
<surname>Harrington</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>McClay</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mill</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Martin, J.; Braithwaite, A.; Poulton, R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.</article-title>
<source/>Science
          <year>2003</year>
<volume>301</volume>
<issue>5631</issue>
<fpage>386</fpage>
<lpage>389</lpage>
<pub-id pub-id-type="doi">10.1126/science.1083968</pub-id>
<pub-id pub-id-type="pmid">12869766</pub-id>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Kloet</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Joëls</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Holsboer</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Stress and the brain: from adaptation to disease.</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2005</year>
<volume>6</volume>
<issue>6</issue>
<fpage>463</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="doi">10.1038/nrn1683</pub-id>
<pub-id pub-id-type="pmid">15891777</pub-id>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Slattery</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Animal models of mood disorders: Recent developments.</article-title>
<source/>Curr. Opin. Psychiatry
          <year>2007</year>
<volume>20</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1097/YCO.0b013e3280117733</pub-id>
<pub-id pub-id-type="pmid">17143074</pub-id>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Virtanen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kivimäki</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Saved by the bell: does working too much increase the likelihood of depression?</article-title>
<source/>Expert Rev. Neurother.
          <year>2012</year>
<volume>12</volume>
<issue>5</issue>
<fpage>497</fpage>
<lpage>499</lpage>
<pub-id pub-id-type="doi">10.1586/ern.12.29</pub-id>
<pub-id pub-id-type="pmid">22550976</pub-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Virtanen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nyberg</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Batty</surname>
<given-names>G.D.</given-names>
</name>
<name>
<surname>Jokela</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Heikkilä</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fransson</surname>
<given-names>E.I.</given-names>
</name>
<name>
<surname>Alfredsson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bjorner</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Borritz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Burr</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Casini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Clays</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>De Bacquer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dragano</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Elovainio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Erbel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ferrie</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Hamer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jöckel</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Kittel</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Knutsson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Koskenvuo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koskinen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lunau</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Madsen</surname>
<given-names>I.E.</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Nordin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Oksanen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pahkin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pejtersen</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Pentti</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rugulies</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Salo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Shipley</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Siegrist</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Steptoe</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Suominen</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Theorell</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Toppinen-Tanner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Väänänen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vahtera</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Westerholm</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Westerlund</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Slopen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kawachi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Singh-Manoux</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kivimäki</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Perceived job insecurity as a risk factor for incident coronary heart disease: systematic review and meta-analysis.</article-title>
<source/>BMJ
          <year>2013</year>
<volume>347</volume>
<fpage>f4746</fpage>
<pub-id pub-id-type="pmid">23929894</pub-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hammen</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Stress and depression.</article-title>
<source/>Annu. Rev. Clin. Psychol.
          <year>2005</year>
<volume>1</volume>
<fpage>293</fpage>
<lpage>319</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.clinpsy.1.102803.143938</pub-id>
<pub-id pub-id-type="pmid">17716090</pub-id>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Blanchard</surname>
<given-names>E. B.</given-names>
</name>
<name>
<surname>Rowell</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wittrock</surname>
<given-names>D.</given-names>
</name>
</person-group>
<source/>Posttraumatic stress and depressive symptoms in a college population one year after the September 11 attacks: the effect of proximity.
          <year>2005</year>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Blanchard</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Eisen</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Alpern</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Karlinsky</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Toomey</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Reda</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>F. M.</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>L. W.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>H. K.</given-names>
</name>
</person-group>
<source/>Chronic multisymptom illness complex in Gulf War I veterans  10 years later.
          <year>2006</year>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Häuser</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Giese</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Stallmach</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Irritable pouch syndrome is associated with depressiveness and can be differentiated from pouchitis by quantification of mucosal levels of proinflammatory gene transcripts.</article-title>
<source/>Inflamm. Bowel Dis.
          <year>2007</year>
<volume>13</volume>
<issue>12</issue>
<fpage>1502</fpage>
<lpage>1508</lpage>
<pub-id pub-id-type="doi">10.1002/ibd.20241</pub-id>
<pub-id pub-id-type="pmid">17712839</pub-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kotov</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gamez</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Linking “big” personality traits to anxiety, depressive, and substance use disorders: a meta-analysis.</article-title>
<source/>Psychol. Bull.
          <year>2010</year>
<volume>136</volume>
<issue>5</issue>
<fpage>768</fpage>
<lpage>821</lpage>
<pub-id pub-id-type="doi">10.1037/a0020327</pub-id>
<pub-id pub-id-type="pmid">20804236</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kennedy</surname>
<given-names>S.H.</given-names>
</name>
</person-group>
<article-title>Core symptoms of major depressive disorder: relevance to diagnosis and treatment.</article-title>
<source/>Dialogues Clin. Neurosci.
          <year>2008</year>
<volume>10</volume>
<issue>3</issue>
<fpage>271</fpage>
<lpage>277</lpage>
<pub-id pub-id-type="pmid">18979940</pub-id>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cortese</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Phan</surname>
<given-names>K.L.</given-names>
</name>
</person-group>
<article-title>The role of glutamate in anxiety and related disorders.</article-title>
<source/>CNS Spectr.
          <year>2005</year>
<volume>10</volume>
<issue>10</issue>
<fpage>820</fpage>
<lpage>830</lpage>
<pub-id pub-id-type="pmid">16400245</pub-id>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mauri</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Ferrara</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Boscati</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bravin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zamberlan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Alecci</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Invernizzi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment.</article-title>
<source/>Neuropsychobiology
          <year>1998</year>
<volume>37</volume>
<issue>3</issue>
<fpage>124</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="pmid">9597668</pub-id>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levine</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Panchalingam</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rapoport</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gershon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McClure</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Pettegrew</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>Increased cerebrospinal fluid glutamine levels in depressed patients.</article-title>
<source/>Biol. Psychiatry
          <year>2000</year>
<volume>47</volume>
<issue>7</issue>
<fpage>586</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="pmid">10745050</pub-id>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitani</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shirayama</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ashby</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Kawahara</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Correlation between plasma levels of glutamate, alanine and serine with severity of depression.</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2006</year>
<volume>30</volume>
<issue>6</issue>
<fpage>1155</fpage>
<lpage>1158</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2006.03.036</pub-id>
<pub-id pub-id-type="pmid">16707201</pub-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Iyo</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Increased levels of glutamate in brains from patients with mood disorders.</article-title>
<source/>Biol. Psychiatry
          <year>2007</year>
<volume>62</volume>
<issue>11</issue>
<fpage>1310</fpage>
<lpage>1316</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2007.03.017</pub-id>
<pub-id pub-id-type="pmid">17574216</pub-id>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>McLoughlin</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Tsang</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Manji</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bahn</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder.</article-title>
<source/>Mol. Psychiatry
          <year>2009</year>
<volume>14</volume>
<issue>3</issue>
<fpage>269</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4002130</pub-id>
<pub-id pub-id-type="pmid">18256615</pub-id>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lorenzetti</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>N.B.</given-names>
</name>
<name>
<surname>Fornito</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yücel</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies.</article-title>
<source/>J. Affect. Disord.
          <year>2009</year>
<volume>117</volume>
<issue>1-2</issue>
<fpage>1</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2008.11.021</pub-id>
<pub-id pub-id-type="pmid">19237202</pub-id>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheldon</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>M.B.</given-names>
</name>
</person-group>
<article-title>The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention.</article-title>
<source/>Neurochem. Int.
          <year>2007</year>
<volume>51</volume>
<issue>6-7</issue>
<fpage>333</fpage>
<lpage>355</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2007.03.012</pub-id>
<pub-id pub-id-type="pmid">17517448</pub-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakanishi</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Molecular diversity of glutamate receptors and implications for brain function.</article-title>
<source/>Science
          <year>1992</year>
<volume>258</volume>
<issue>5082</issue>
<fpage>597</fpage>
<lpage>603</lpage>
<pub-id pub-id-type="pmid">1329206</pub-id>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Planells-Cases</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lerma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ferrer-Montiel</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Pharmacological intervention at ionotropic glutamate receptor complexes.</article-title>
<source/>Curr. Pharm. Des.
          <year>2006</year>
<volume>12</volume>
<issue>28</issue>
<fpage>3583</fpage>
<lpage>3596</lpage>
<pub-id pub-id-type="pmid">17073661</pub-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>A.Y.</given-names>
</name>
<name>
<surname>Homma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S.P.</given-names>
</name>
</person-group>
<article-title>Role of K(+) efflux in apoptosis induced by AMPA and kainate in mouse cortical neurons.</article-title>
<source/>Neuroscience
          <year>2001</year>
<volume>108</volume>
<issue>1</issue>
<fpage>61</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="pmid">11738131</pub-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willard</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Koochekpour</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Glutamate, glutamate receptors, and downstream signaling pathways.</article-title>
<source/>Int. J. Biol. Sci.
          <year>2013</year>
<volume>9</volume>
<issue>9</issue>
<fpage>948</fpage>
<lpage>959</lpage>
<pub-id pub-id-type="doi">10.7150/ijbs.6426</pub-id>
<pub-id pub-id-type="pmid">24155668</pub-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conn</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Physiological roles and therapeutic potential of metabotropic glutamate receptors.</article-title>
<source/>Ann. N. Y. Acad. Sci.
          <year>2003</year>
<volume>1003</volume>
<fpage>12</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">14684432</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinheiro</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Mulle</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Presynaptic glutamate receptors: physiological functions and mechanisms of action.</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2008</year>
<volume>9</volume>
<issue>6</issue>
<fpage>423</fpage>
<lpage>436</lpage>
<pub-id pub-id-type="doi">10.1038/nrn2379</pub-id>
<pub-id pub-id-type="pmid">18464791</pub-id>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bockaert</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Collingridge</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Conn</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Ferraguti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Schoepp</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Wroblewski</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Pin</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptors: from the workbench to the bedside.</article-title>
<source/>Neuropharmacology
          <year>2011</year>
<volume>60</volume>
<issue>7-8</issue>
<fpage>1017</fpage>
<lpage>1041</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2010.10.022</pub-id>
<pub-id pub-id-type="pmid">21036182</pub-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Foy</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>R.F.</given-names>
</name>
</person-group>
<article-title>Behavioral stress modifies hippocampal plasticity through N-methyl-D-aspartate receptor activation.</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1996</year>
<volume>93</volume>
<issue>10</issue>
<fpage>4750</fpage>
<lpage>4753</lpage>
<pub-id pub-id-type="pmid">8643474</pub-id>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyce-Rustay</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Ethanol-related behaviors in mice lacking the NMDA receptor NR2A subunit.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>2006</year>
<volume>187</volume>
<issue>4</issue>
<fpage>455</fpage>
<lpage>466</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-006-0448-6</pub-id>
<pub-id pub-id-type="pmid">16835771</pub-id>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graybeal</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kiselycznyk</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Stress-induced deficits in cognition and emotionality: a role of glutamate.</article-title>
<source/>Curr. Top. Behav. Neurosci.
          <year>2012</year>
<volume>12</volume>
<fpage>189</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="doi">10.1007/7854_2011_193</pub-id>
<pub-id pub-id-type="pmid">22261703</pub-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watanabe</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Weiland</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>McEwen</surname>
<given-names>B.S.</given-names>
</name>
</person-group>
<article-title>Effects of adrenal steroid manipulations and repeated restraint stress on dynorphin mRNA levels and excitatory amino acid receptor binding in hippocampus.</article-title>
<source/>Brain Res.
          <year>1995</year>
<volume>680</volume>
<issue>1-2</issue>
<fpage>217</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="pmid">7663979</pub-id>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berman</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Cappiello</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Anand</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Oren</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Heninger</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Charney</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Krystal</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>Antidepressant effects of ketamine in depressed patients.</article-title>
<source/>Biol. Psychiatry
          <year>2000</year>
<volume>47</volume>
<issue>4</issue>
<fpage>351</fpage>
<lpage>354</lpage>
<pub-id pub-id-type="pmid">10686270</pub-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zarate</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Brutsche</surname>
<given-names>N.E.</given-names>
</name>
<name>
<surname>Ameli</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Luckenbaugh</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Charney</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Manji</surname>
<given-names>H.K.</given-names>
</name>
</person-group>
<article-title>A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2006</year>
<volume>63</volume>
<issue>8</issue>
<fpage>856</fpage>
<lpage>864</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.63.8.856</pub-id>
<pub-id pub-id-type="pmid">16894061</pub-id>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Witkin</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Marek</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>B.G.</given-names>
</name>
<name>
<surname>Schoepp</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptors in the control of mood disorders.</article-title>
<source/>CNS Neurol. Disord. Drug Targets
          <year>2007</year>
<volume>6</volume>
<issue>2</issue>
<fpage>87</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="pmid">17430147</pub-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Witkin</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Mood disorders: regulation by metabotropic glutamate receptors.</article-title>
<source/>Biochem. Pharmacol.
          <year>2008</year>
<volume>75</volume>
<issue>5</issue>
<fpage>997</fpage>
<lpage>1006</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2007.09.021</pub-id>
<pub-id pub-id-type="pmid">18164691</pub-id>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cartmell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schoepp</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>Regulation of neurotransmitter release by metabotropic glutamate receptors.</article-title>
<source/>J. Neurochem.
          <year>2000</year>
<volume>75</volume>
<issue>3</issue>
<fpage>889</fpage>
<lpage>907</lpage>
<pub-id pub-id-type="pmid">10936169</pub-id>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niswender</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Conn</surname>
<given-names>P. J.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptors: physiology, pharmacology, and disease.</article-title>
<source/>Annu. Rev. Pharmacol Toxicol.
          <year>2010</year>
<volume>50</volume>
<fpage>295</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="pmid">20055706</pub-id>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reber</surname>
<given-names>S.O.</given-names>
</name>
<name>
<surname>Birkeneder</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Veenema</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Obermeier</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Falk</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Straub</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>I.D.</given-names>
</name>
</person-group>
<article-title>Adrenal insufficiency and colonic inflammation after a novel chronic psycho-social stress paradigm in mice: implications and mechanisms.</article-title>
<source/>Endocrinology
          <year>2007</year>
<volume>148</volume>
<issue>2</issue>
<fpage>670</fpage>
<lpage>682</lpage>
<pub-id pub-id-type="doi">10.1210/en.2006-0983</pub-id>
<pub-id pub-id-type="pmid">17110427</pub-id>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langgartner</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Füchsl</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Uschold-schmidt</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Slattery</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Reber</surname>
<given-names>S. O.</given-names>
</name>
</person-group>
<source/>Chronic subordinate colony housing paradigm : A mouse model to characterize the consequences of insufficient glucocorticoid signalling.
          <year>2015</year>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J-Y.</given-names>
</name>
<name>
<surname>Roche</surname>
<given-names>K.W.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptors: phosphorylation and receptor signaling.</article-title>
<source/>J. Neurosci. Res.
          <year>2008</year>
<volume>86</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.21437</pub-id>
<pub-id pub-id-type="pmid">17663464</pub-id>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Niswender</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications.</article-title>
<source/>Cell. Signal.
          <year>2014</year>
<volume>26</volume>
<issue>10</issue>
<fpage>2284</fpage>
<lpage>2297</lpage>
<pub-id pub-id-type="doi">10.1016/j.cellsig.2014.04.022</pub-id>
<pub-id pub-id-type="pmid">24793301</pub-id>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rondard</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pin</surname>
<given-names>J-P.</given-names>
</name>
</person-group>
<article-title>Dynamics and modulation of metabotropic glutamate receptors.</article-title>
<source/>Curr. Opin. Pharmacol.
          <year>2015</year>
<volume>20C</volume>
<fpage>95</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1016/j.coph.2014.12.001</pub-id>
<pub-id pub-id-type="pmid">25529199</pub-id>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sugihara</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shigemoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction.</article-title>
<source/>J. Biol. Chem.
          <year>1992</year>
<volume>267</volume>
<issue>19</issue>
<fpage>13361</fpage>
<lpage>13368</lpage>
<pub-id pub-id-type="pmid">1320017</pub-id>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bordi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ugolini</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Group I metabotropic glutamate receptors: implications for brain diseases.</article-title>
<source/>Prog. Neurobiol.
          <year>1999</year>
<volume>59</volume>
<issue>1</issue>
<fpage>55</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="pmid">10416961</pub-id>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Worley</surname>
<given-names>P.F.</given-names>
</name>
<name>
<surname>Linden</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>Transient upregulation of postsynaptic IP3-gated Ca release underlies short-term potentiation of metabotropic glutamate receptor 1 signaling in cerebellar Purkinje cells.</article-title>
<source/>J. Neurosci.
          <year>2008</year>
<volume>28</volume>
<issue>17</issue>
<fpage>4350</fpage>
<lpage>4355</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0284-08.2008</pub-id>
<pub-id pub-id-type="pmid">18434513</pub-id>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Youn</surname>
<given-names>D-H.</given-names>
</name>
</person-group>
<article-title>Long-term potentiation by activation of group I metabotropic glutamate receptors at excitatory synapses in the spinal trigeminal subnucleus oralis.</article-title>
<source/>Neurosci. Lett.
          <year>2014</year>
<volume>560</volume>
<fpage>36</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2013.11.056</pub-id>
<pub-id pub-id-type="pmid">24321406</pub-id>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Youn</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Differential roles of signal transduction mechanisms in long-term potentiation of excitatory synaptic transmission induced by activation of group I mGluRs in the spinal trigeminal subnucleus oralis.</article-title>
<source/>Brain Res. Bull
          <year>2014</year>
<volume>108</volume>
<fpage>37</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">25149878</pub-id>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schoepp</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system.</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2001</year>
<volume>299</volume>
<issue>1</issue>
<fpage>12</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">11561058</pub-id>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lavreysen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dautzenberg</surname>
<given-names>F.M.</given-names>
</name>
</person-group>
<article-title>Therapeutic potential of group III metabotropic glutamate receptors.</article-title>
<source/>Curr. Med. Chem.
          <year>2008</year>
<volume>15</volume>
<issue>7</issue>
<fpage>671</fpage>
<lpage>684</lpage>
<pub-id pub-id-type="pmid">18336281</pub-id>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McMullan</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Phanavanh</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.G.</given-names>
</name>
<name>
<surname>Barger</surname>
<given-names>S.W.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptors inhibit microglial glutamate release.</article-title>
<source/>ASN Neuro
          <year>2012</year>
<volume>4</volume>
<issue>5</issue>
<fpage>e00094</fpage>
<pub-id pub-id-type="doi">10.1042/AN20120044</pub-id>
<pub-id pub-id-type="pmid">22770428</pub-id>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kintscher</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Breustedt</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Miceli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wozny</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Group II metabotropic glutamate receptors depress synaptic transmission onto subicular burst firing neurons.</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<issue>9</issue>
<fpage>e45039</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0045039</pub-id>
<pub-id pub-id-type="pmid">22984605</pub-id>
</element-citation>
</ref>
<ref id="R54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>Z-Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y-W.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Dinh</surname>
<given-names>E.H.</given-names>
</name>
<name>
<surname>Hamlet</surname>
<given-names>W.R.</given-names>
</name>
<name>
<surname>Curry</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Activation of synaptic group II metabotropic glutamate receptors induces long-term depression at GABAergic synapses in CNS neurons.</article-title>
<source/>J. Neurosci.
          <year>2013</year>
<volume>33</volume>
<issue>40</issue>
<fpage>15964</fpage>
<lpage>15977</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0202-13.2013</pub-id>
<pub-id pub-id-type="pmid">24089501</pub-id>
</element-citation>
</ref>
<ref id="R55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mercier</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Lodge</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Group III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential.</article-title>
<source/>Neurochem. Res.
          <year>2014</year>
<volume>39</volume>
<issue>10</issue>
<fpage>1876</fpage>
<lpage>1894</lpage>
<pub-id pub-id-type="doi">10.1007/s11064-014-1415-y</pub-id>
<pub-id pub-id-type="pmid">25146900</pub-id>
</element-citation>
</ref>
<ref id="R56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Julio-Pieper</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Flor</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Exciting times beyond the brain: metabotropic glutamate receptors in peripheral and non-neural tissues.</article-title>
<source/>Pharmacol. Rev.
          <year>2011</year>
<volume>63</volume>
<issue>1</issue>
<fpage>35</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1124/pr.110.004036</pub-id>
<pub-id pub-id-type="pmid">21228260</pub-id>
</element-citation>
</ref>
<ref id="R57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conn</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Pin</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Pharmacology and functions of metabotropic glutamate receptors.</article-title>
<source/>Annu. Rev. Pharmacol. Toxicol.
          <year>1997</year>
<volume>37</volume>
<fpage>205</fpage>
<lpage>237</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.pharmtox.37.1.205</pub-id>
<pub-id pub-id-type="pmid">9131252</pub-id>
</element-citation>
</ref>
<ref id="R58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swanson</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Bures</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Linden</surname>
<given-names>A-M.</given-names>
</name>
<name>
<surname>Monn</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Schoepp</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.</article-title>
<source/>Nat. Rev. Drug Discov.
          <year>2005</year>
<volume>4</volume>
<issue>2</issue>
<fpage>131</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1038/nrd1630</pub-id>
<pub-id pub-id-type="pmid">15665858</pub-id>
</element-citation>
</ref>
<ref id="R59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christopoulos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kenakin</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>G protein-coupled receptor allosterism and complexing.</article-title>
<source/>Pharmacol. Rev.
          <year>2002</year>
<volume>54</volume>
<issue>2</issue>
<fpage>323</fpage>
<lpage>374</lpage>
<pub-id pub-id-type="pmid">12037145</pub-id>
</element-citation>
</ref>
<ref id="R60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wood</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Brogan</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Conn</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Lindsley</surname>
<given-names>C.W.</given-names>
</name>
</person-group>
<article-title>“Molecular switches” on mGluR allosteric ligands that modulate modes of pharmacology.</article-title>
<source/>Biochemistry
          <year>2011</year>
<volume>50</volume>
<issue>13</issue>
<fpage>2403</fpage>
<lpage>2410</lpage>
<pub-id pub-id-type="doi">10.1021/bi200129s</pub-id>
<pub-id pub-id-type="pmid">21341760</pub-id>
</element-citation>
</ref>
<ref id="R61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flor</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Acher</surname>
<given-names>F.C.</given-names>
</name>
</person-group>
<article-title>Orthosteric versus allosteric GPCR activation: the great challenge of group-III mGluRs.</article-title>
<source/>Biochem. Pharmacol.
          <year>2012</year>
<volume>84</volume>
<issue>4</issue>
<fpage>414</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2012.04.013</pub-id>
<pub-id pub-id-type="pmid">22554564</pub-id>
</element-citation>
</ref>
<ref id="R62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gregory</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Noetzel</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Niswender</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Pharmacology of metabotropic glutamate receptor allosteric modulators: structural basis and therapeutic potential for CNS disorders.</article-title>
<source/>Prog. Mol. Biol. Transl. Sci.
          <year>2013</year>
<volume>115</volume>
<fpage>61</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="doi">10.1016/B978-0-12-394587-7.00002-6</pub-id>
<pub-id pub-id-type="pmid">23415092</pub-id>
</element-citation>
</ref>
<ref id="R63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nickols</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Conn</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Development of allosteric modulators of GPCRs for treatment of CNS disorders.</article-title>
<source/>Neurobiol. Dis.
          <year>2014</year>
<volume>61</volume>
<fpage>55</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2013.09.013</pub-id>
<pub-id pub-id-type="pmid">24076101</pub-id>
</element-citation>
</ref>
<ref id="R64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gregory</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>G.W.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>H.P.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Niswender</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Katritch</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Meiler</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cherezov</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Conn</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>R.C.</given-names>
</name>
</person-group>
<article-title>Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator.</article-title>
<source/>Science
          <year>2014</year>
<volume>344</volume>
<issue>6179</issue>
<fpage>58</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1126/science.1249489</pub-id>
<pub-id pub-id-type="pmid">24603153</pub-id>
</element-citation>
</ref>
<ref id="R65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conn</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Christopoulos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lindsley</surname>
<given-names>C.W.</given-names>
</name>
</person-group>
<article-title>Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.</article-title>
<source/>Nat. Rev. Drug Discov.
          <year>2009</year>
<volume>8</volume>
<issue>1</issue>
<fpage>41</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1038/nrd2760</pub-id>
<pub-id pub-id-type="pmid">19116626</pub-id>
</element-citation>
</ref>
<ref id="R66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conn</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>C.K.</given-names>
</name>
<name>
<surname>Lindsley</surname>
<given-names>C.W.</given-names>
</name>
</person-group>
<article-title>Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.</article-title>
<source/>Trends Pharmacol. Sci.
          <year>2009</year>
<volume>30</volume>
<issue>3</issue>
<fpage>148</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="doi">10.1016/j.tips.2008.12.002</pub-id>
<pub-id pub-id-type="pmid">19201489</pub-id>
</element-citation>
</ref>
<ref id="R67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picconi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Calabresi</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson’s disease?</article-title>
<source/>Mov. Disord.
          <year>2014</year>
<volume>29</volume>
<issue>6</issue>
<fpage>715</fpage>
<lpage>719</lpage>
<pub-id pub-id-type="doi">10.1002/mds.25851</pub-id>
<pub-id pub-id-type="pmid">24591264</pub-id>
</element-citation>
</ref>
<ref id="R68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scharf</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Jaeschke</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wettstein</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Lindemann</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.</article-title>
<source/>Curr. Opin. Pharmacol.
          <year>2014</year>
<volume>20C</volume>
<fpage>124</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1016/j.coph.2014.11.004</pub-id>
<pub-id pub-id-type="pmid">25488569</pub-id>
</element-citation>
</ref>
<ref id="R69">
<label>69</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Herman</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Bubser</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Conn</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>C. K.</given-names>
</name>
</person-group>
<year>2012</year>
</element-citation>
</ref>
<ref id="R70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pomierny-Chamioło</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rup</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pomierny</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Niedzielska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kalivas</surname>
<given-names>P.W.</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamatergic receptors and their ligands in drug addiction.</article-title>
<source/>Pharmacol. Ther.
          <year>2014</year>
<volume>142</volume>
<issue>3</issue>
<fpage>281</fpage>
<lpage>305</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.12.012</pub-id>
<pub-id pub-id-type="pmid">24362085</pub-id>
</element-citation>
</ref>
<ref id="R71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ngomba</surname>
<given-names>R. T.</given-names>
</name>
<name>
<surname>Gradini</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Battaglia</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptors as drug targets: what’s new?</article-title>
<source/>Curr. Opin. Pharmacol.
          <year>2015</year>
<volume>20</volume>
<fpage>89</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="pmid">25506748</pub-id>
</element-citation>
</ref>
<ref id="R72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pałucha-Poniewiera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Szewczyk</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats.</article-title>
<source/>Neuropharmacology
          <year>2014</year>
<volume>82</volume>
<fpage>59</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="pmid">24631968</pub-id>
</element-citation>
</ref>
<ref id="R73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fieblinger</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sebastianutto</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Alcacer</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bimpisidis</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Maslava</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sandberg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Engblom</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cenci</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5.</article-title>
<source/>J. Neurosci.
          <year>2014</year>
<volume>34</volume>
<issue>13</issue>
<fpage>4728</fpage>
<lpage>4740</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2702-13.2014</pub-id>
<pub-id pub-id-type="pmid">24672017</pub-id>
</element-citation>
</ref>
<ref id="R74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>X-R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H-Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z-J.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>Y-W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X-Y.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sang</surname>
<given-names>S-S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>Anti-Cancer Effect of Metabotropic Glutamate Receptor 1 Inhibition in Human Glioma U87 Cells: Involvement of PI3K/Akt/mTOR Pathway.</article-title>
<source/>Cell. Physiol. Biochem.
          <year>2015</year>
<volume>35</volume>
<issue>2</issue>
<fpage>419</fpage>
<lpage>432</lpage>
<pub-id pub-id-type="doi">10.1159/000369707</pub-id>
<pub-id pub-id-type="pmid">25613036</pub-id>
</element-citation>
</ref>
<ref id="R75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferraguti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Shigemoto</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptors.</article-title>
<source/>Cell Tissue Res.
          <year>2006</year>
<volume>326</volume>
<issue>2</issue>
<fpage>483</fpage>
<lpage>504</lpage>
<pub-id pub-id-type="doi">10.1007/s00441-006-0266-5</pub-id>
<pub-id pub-id-type="pmid">16847639</pub-id>
</element-citation>
</ref>
<ref id="R76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wierońska</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs.</article-title>
<source/>Neurochem. Int.
          <year>2009</year>
<volume>55</volume>
<issue>1-3</issue>
<fpage>85</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2009.02.019</pub-id>
<pub-id pub-id-type="pmid">19428811</pub-id>
</element-citation>
</ref>
<ref id="R77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verkhratsky</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kirchhoff</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Glutamate-mediated neuronal-glial transmission.</article-title>
<source/>J. Anat
          <year>2007</year>
<volume>210</volume>
<issue>6</issue>
<fpage>651</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">17504269</pub-id>
</element-citation>
</ref>
<ref id="R78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruno</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Battaglia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kingston</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Catania</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Di Grezia</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors.</article-title>
<source/>Neuropharmacology
          <year>1999</year>
<volume>38</volume>
<issue>2</issue>
<fpage>199</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="pmid">10218860</pub-id>
</element-citation>
</ref>
<ref id="R79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruno</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Battaglia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Copani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>D'Onofrio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Di Iorio</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>De Blasi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Melchiorri</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Flor</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs.</article-title>
<source/>J. Cereb. Blood Flow Metab.
          <year>2001</year>
<volume>21</volume>
<issue>9</issue>
<fpage>1013</fpage>
<lpage>1033</lpage>
<pub-id pub-id-type="doi">10.1097/00004647-200109000-00001</pub-id>
<pub-id pub-id-type="pmid">11524608</pub-id>
</element-citation>
</ref>
<ref id="R80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruno</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Battaglia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Copani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cespédes</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>Galindo</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Ceña</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Sánchez-Prieto</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gasparini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Flor</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>An activity-dependent switch from facilitation to inhibition in the control of excitotoxicity by group I metabotropic glutamate receptors.</article-title>
<source/>Eur. J. Neurosci.
          <year>2001</year>
<volume>13</volume>
<issue>8</issue>
<fpage>1469</fpage>
<lpage>1478</lpage>
<pub-id pub-id-type="pmid">11328342</pub-id>
</element-citation>
</ref>
<ref id="R81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Onofrio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cuomo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Battaglia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ngomba</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Storto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kingston</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Orzi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>De Blasi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Di Iorio</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways.</article-title>
<source/>J. Neurochem.
          <year>2001</year>
<volume>78</volume>
<issue>3</issue>
<fpage>435</fpage>
<lpage>445</lpage>
<pub-id pub-id-type="pmid">11483646</pub-id>
</element-citation>
</ref>
<ref id="R82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>C.-H.</given-names>
</name>
<name>
<surname>You</surname>
<given-names>J.-R.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>K.-C.</given-names>
</name>
<name>
<surname>Gean</surname>
<given-names>P.-W.</given-names>
</name>
</person-group>
<article-title>Stimulating
ERK/PI3K/NFκB signaling pathways upon activation of mGluR2/3
restores OGD-induced impairment in glutamate clearance in
astrocytes.</article-title>
<source/>Eur. J. Neurosci.
          <year>2014</year>
<volume>39</volume>
<issue>1</issue>
<fpage>83</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="pmid">24206109</pub-id>
</element-citation>
</ref>
<ref id="R83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamaru</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nomura</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shigemoto</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites.</article-title>
<source/>Neuroscience
          <year>2001</year>
<volume>106</volume>
<issue>3</issue>
<fpage>481</fpage>
<lpage>503</lpage>
<pub-id pub-id-type="pmid">11591452</pub-id>
</element-citation>
</ref>
<ref id="R84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohishi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shigemoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat.</article-title>
<source/>Neuroscience
          <year>1993</year>
<volume>53</volume>
<issue>4</issue>
<fpage>1009</fpage>
<lpage>1018</lpage>
<pub-id pub-id-type="pmid">8389425</pub-id>
</element-citation>
</ref>
<ref id="R85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Momiyama</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ohishi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ogawa-Meguro</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shigemoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Role of a metabotropic glutamate receptor in synaptic modulation in the accessory olfactory bulb.</article-title>
<source/>Nature
          <year>1993</year>
<volume>366</volume>
<issue>6456</issue>
<fpage>687</fpage>
<lpage>690</lpage>
<pub-id pub-id-type="doi">10.1038/366687a0</pub-id>
<pub-id pub-id-type="pmid">7903116</pub-id>
</element-citation>
</ref>
<ref id="R86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohishi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shigemoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study.</article-title>
<source/>J. Comp. Neurol.
          <year>1993</year>
<volume>335</volume>
<issue>2</issue>
<fpage>252</fpage>
<lpage>266</lpage>
<pub-id pub-id-type="doi">10.1002/cne.903350209</pub-id>
<pub-id pub-id-type="pmid">8227517</pub-id>
</element-citation>
</ref>
<ref id="R87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanabe</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nomura</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Masu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shigemoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4.</article-title>
<source/>J. Neurosci.
          <year>1993</year>
<volume>13</volume>
<issue>4</issue>
<fpage>1372</fpage>
<lpage>1378</lpage>
<pub-id pub-id-type="pmid">8463825</pub-id>
</element-citation>
</ref>
<ref id="R88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciceroni</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mosillo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mastrantoni</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sale</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ricci-Vitiani</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Biagioni</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Stocchi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Melchiorri</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>mGLU3 metabotropic glutamate receptors modulate the differentiation of SVZ-derived neural stem cells towards the astrocytic lineage.</article-title>
<source/>Glia
          <year>2010</year>
<volume>58</volume>
<issue>7</issue>
<fpage>813</fpage>
<lpage>822</lpage>
<pub-id pub-id-type="doi">10.1002/glia.20965</pub-id>
<pub-id pub-id-type="pmid">20091783</pub-id>
</element-citation>
</ref>
<ref id="R89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durand</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Carniglia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Caruso</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lasaga</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>mGlu3 receptor and astrocytes: partners in neuroprotection.</article-title>
<source/>Neuropharmacology
          <year>2013</year>
<volume>66</volume>
<fpage>1</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.04.009</pub-id>
<pub-id pub-id-type="pmid">22564439</pub-id>
</element-citation>
</ref>
<ref id="R90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durand</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Carniglia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Beauquis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Caruso</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Saravia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lasaga</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Astroglial mGlu3 receptors promote alpha-secretase-mediated amyloid precursor protein cleavage.</article-title>
<source/>Neuropharmacology
          <year>2014</year>
<volume>79</volume>
<fpage>180</fpage>
<lpage>189</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.11.015</pub-id>
<pub-id pub-id-type="pmid">24291464</pub-id>
</element-citation>
</ref>
<ref id="R91">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Battaglia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Riozzi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bucci</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Di Menna</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Molinaro</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pallottino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis.</article-title>
<source/>Neurobiol. Dis.
          <year>2014</year>
<volume>74C</volume>
<fpage>126</fpage>
<lpage>136</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2014.11.012</pub-id>
<pub-id pub-id-type="pmid">25434487</pub-id>
</element-citation>
</ref>
<ref id="R92">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shigemoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kinoshita</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wada</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nomura</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ohishi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Flor</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Neki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus.</article-title>
<source/>J. Neurosci.
          <year>1997</year>
<volume>17</volume>
<issue>19</issue>
<fpage>7503</fpage>
<lpage>7522</lpage>
<pub-id pub-id-type="pmid">9295396</pub-id>
</element-citation>
</ref>
<ref id="R93">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Panatier</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Poulain</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Oliet</surname>
<given-names>S.H.</given-names>
</name>
</person-group>
<article-title>Regulation of transmitter release by high-affinity group III mGluRs in the supraoptic nucleus of the rat hypothalamus.</article-title>
<source/>Neuropharmacology
          <year>2004</year>
<volume>47</volume>
<issue>3</issue>
<fpage>333</fpage>
<lpage>341</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2004.05.003</pub-id>
<pub-id pub-id-type="pmid">15275822</pub-id>
</element-citation>
</ref>
<ref id="R94">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grueter</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Winder</surname>
<given-names>D. G.</given-names>
</name>
</person-group>
<article-title></article-title>
<source/>Group II and III metabotropic glutamate receptors suppress excitatory synaptic transmission in the dorsolateral bed nucleus of the stria terminalis.
          <year>2005</year>
<volume>30</volume>
<issue>7</issue>
<fpage>1302</fpage>
<lpage>13011</lpage>
</element-citation>
</ref>
<ref id="R95">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woodhall</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Ayman</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>Differential control of two forms of glutamate release by group III metabotropic glutamate receptors at rat entorhinal synapses.</article-title>
<source/>Neuroscience
          <year>2007</year>
<volume>148</volume>
<issue>1</issue>
<fpage>7</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2007.06.002</pub-id>
<pub-id pub-id-type="pmid">17630217</pub-id>
</element-citation>
</ref>
<ref id="R96">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Rover</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Meye</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Ramakers</surname>
<given-names>G.M.</given-names>
</name>
</person-group>
<article-title>Presynaptic metabotropic glutamate receptors regulate glutamatergic input to dopamine neurons in the ventral tegmental area.</article-title>
<source/>Neuroscience
          <year>2008</year>
<volume>154</volume>
<issue>4</issue>
<fpage>1318</fpage>
<lpage>1323</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2008.04.055</pub-id>
<pub-id pub-id-type="pmid">18534761</pub-id>
</element-citation>
</ref>
<ref id="R97">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antflick</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Hampson</surname>
<given-names>D.R.</given-names>
</name>
</person-group>
<article-title>Modulation of glutamate release from parallel fibers by mGlu4 and pre-synaptic GABA(A) receptors.</article-title>
<source/>J. Neurochem.
          <year>2012</year>
<volume>120</volume>
<issue>4</issue>
<fpage>552</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2011.07611.x</pub-id>
<pub-id pub-id-type="pmid">22145864</pub-id>
</element-citation>
</ref>
<ref id="R98">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pin</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Duvoisin</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>The metabotropic glutamate receptors: structure and functions.</article-title>
<source/>Neuropharmacology
          <year>1995</year>
<volume>34</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="pmid">7623957</pub-id>
</element-citation>
</ref>
<ref id="R99">
<label>99</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iacovelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Salvatore</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Melchiorri</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gradini</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Caricasole</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Barletta</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>De Blasi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways.</article-title>
<source/>J. Neurochem.
          <year>2002</year>
<volume>82</volume>
<issue>2</issue>
<fpage>216</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="pmid">12124422</pub-id>
</element-citation>
</ref>
<ref id="R100">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iacovelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Capobianco</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Iula</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Di Giorgi Gerevini</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Picascia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Blahos</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Melchiorri</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>De Blasi</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Regulation of mGlu4 metabotropic glutamate receptor signaling by type-2 G-protein coupled receptor kinase (GRK2).</article-title>
<source/>Mol. Pharmacol.
          <year>2004</year>
<volume>65</volume>
<issue>5</issue>
<fpage>1103</fpage>
<lpage>1110</lpage>
<pub-id pub-id-type="doi">10.1124/mol.65.5.1103</pub-id>
<pub-id pub-id-type="pmid">15102938</pub-id>
</element-citation>
</ref>
<ref id="R101">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iacovelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Felicioni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nisticò</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>De Blasi</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Selective regulation of recombinantly expressed mGlu7 metabotropic glutamate receptors by G protein-coupled receptor kinases and arrestins.</article-title>
<source/>Neuropharmacology
          <year>2014</year>
<volume>77</volume>
<fpage>303</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.10.013</pub-id>
<pub-id pub-id-type="pmid">24148810</pub-id>
</element-citation>
</ref>
<ref id="R102">
<label>102</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kinoshita</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ohishi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nomura</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shigemoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Presynaptic localization of a metabotropic glutamate receptor, mGluR4a, in the cerebellar cortex: a light and electron microscope study in the rat.</article-title>
<source/>Neurosci. Lett.
          <year>1996</year>
<volume>207</volume>
<issue>3</issue>
<fpage>199</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="pmid">8728484</pub-id>
</element-citation>
</ref>
<ref id="R103">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Aldegheri</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Somogyi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ferraguti</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS.</article-title>
<source/>Neuroscience
          <year>2002</year>
<volume>110</volume>
<issue>3</issue>
<fpage>403</fpage>
<lpage>420</lpage>
<pub-id pub-id-type="pmid">11906782</pub-id>
</element-citation>
</ref>
<ref id="R104">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brice</surname>
<given-names>N.L.</given-names>
</name>
<name>
<surname>Varadi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ashcroft</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Molnar</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate and GABA(B) receptors contribute to the modulation of glucose-stimulated insulin secretion in pancreatic beta cells.</article-title>
<source/>Diabetologia
          <year>2002</year>
<volume>45</volume>
<issue>2</issue>
<fpage>242</fpage>
<lpage>252</lpage>
<pub-id pub-id-type="doi">10.1007/s00125-001-0750-0</pub-id>
<pub-id pub-id-type="pmid">11935156</pub-id>
</element-citation>
</ref>
<ref id="R105">
<label>105</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>S-B.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>S-Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>W.H.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J-G.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance.</article-title>
<source/>Clin. Cancer Res.
          <year>2005</year>
<volume>11</volume>
<issue>9</issue>
<fpage>3288</fpage>
<lpage>3295</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-1912</pub-id>
<pub-id pub-id-type="pmid">15867225</pub-id>
</element-citation>
</ref>
<ref id="R106">
<label>106</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarría</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Díez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Losada</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Doñate-Oliver</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Grandes</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Immunocytochemical localization of metabotropic (mGluR2/3 and mGluR4a) and ionotropic (GluR2/3) glutamate receptors in adrenal medullary ganglion cells.</article-title>
<source/>Histol. Histopathol.
          <year>2006</year>
<volume>21</volume>
<issue>2</issue>
<fpage>141</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="pmid">16329038</pub-id>
</element-citation>
</ref>
<ref id="R107">
<label>107</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akiba</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mizumori</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kaunitz</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Luminal L-glutamate enhances duodenal mucosal defense mechanisms via multiple glutamate receptors in rats.</article-title>
<source/>Am. J. Physiol. Gastrointest. Liver Physiol.
          <year>2009</year>
<volume>297</volume>
<issue>4</issue>
<fpage>G781</fpage>
<lpage>G791</lpage>
<pub-id pub-id-type="doi">10.1152/ajpgi.90605.2008</pub-id>
<pub-id pub-id-type="pmid">19643955</pub-id>
</element-citation>
</ref>
<ref id="R108">
<label>108</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kinoshita</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shigemoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ohishi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>van der Putten</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Immunohistochemical localization of metabotropic glutamate receptors, mGluR7a and mGluR7b, in the central nervous system of the adult rat and mouse: a light and electron microscopic study.</article-title>
<source/>J. Comp. Neurol.
          <year>1998</year>
<volume>393</volume>
<issue>3</issue>
<fpage>332</fpage>
<lpage>352</lpage>
<pub-id pub-id-type="pmid">9548554</pub-id>
</element-citation>
</ref>
<ref id="R109">
<label>109</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kosinski</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Risso Bradley</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Conn</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Levey</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Landwehrmeyer</surname>
<given-names>G.B.</given-names>
</name>
<name>
<surname>Penney</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Standaert</surname>
<given-names>D.G.</given-names>
</name>
</person-group>
<article-title>Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia.</article-title>
<source/>J. Comp. Neurol.
          <year>1999</year>
<volume>415</volume>
<issue>2</issue>
<fpage>266</fpage>
<lpage>284</lpage>
<pub-id pub-id-type="pmid">10545164</pub-id>
</element-citation>
</ref>
<ref id="R110">
<label>110</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ngomba</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Santolini</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Salt</surname>
<given-names>T.E.</given-names>
</name>
<name>
<surname>Ferraguti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Battaglia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>van Luijtelaar</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptors in the thalamocortical network: strategic targets for the treatment of absence epilepsy.</article-title>
<source/>Epilepsia
          <year>2011</year>
<volume>52</volume>
<issue>7</issue>
<fpage>1211</fpage>
<lpage>1222</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2011.03082.x</pub-id>
<pub-id pub-id-type="pmid">21569017</pub-id>
</element-citation>
</ref>
<ref id="R111">
<label>111</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scaccianoce</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Matrisciano</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Del Bianco</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Caricasole</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Di Giorgi Gerevini</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Cappuccio</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Melchiorri</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Battaglia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Endogenous activation of group-II metabotropic glutamate receptors inhibits the hypothalamic-pituitary-adrenocortical axis.</article-title>
<source/>Neuropharmacology
          <year>2003</year>
<volume>44</volume>
<issue>5</issue>
<fpage>555</fpage>
<lpage>561</lpage>
<pub-id pub-id-type="pmid">12668041</pub-id>
</element-citation>
</ref>
<ref id="R112">
<label>112</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Julio-Pieper</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hyland</surname>
<given-names>N. P.</given-names>
</name>
<name>
<surname>Bravo</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>T. G.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J. F.</given-names>
</name>
</person-group>
<source/>A novel role for the metabotropic glutamate receptor-7: modulation of faecal water content and colonic electrolyte transport in the mouse.
          <year>2010</year>
</element-citation>
</ref>
<ref id="R113">
<label>113</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakamura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kurihara</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mitsuya</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ohkubo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ohta</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Isoxazolopyridone derivatives as allosteric meta- botropic glutamate receptor 7 antagonists.</article-title>
<source/>Bioorg. Med. Chem. Lett.
          <year>2010</year>
<volume>20</volume>
<issue>2</issue>
<fpage>726</fpage>
<lpage>729</lpage>
<pub-id pub-id-type="doi">10.1016/j.bmcl.2009.11.070</pub-id>
<pub-id pub-id-type="pmid">20005101</pub-id>
</element-citation>
</ref>
<ref id="R114">
<label>114</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selye</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Stress and distress.</article-title>
<source/>Compr. Ther.
          <year>1975</year>
<volume>1</volume>
<issue>8</issue>
<fpage>9</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">1222562</pub-id>
</element-citation>
</ref>
<ref id="R115">
<label>115</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selye</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Implications of stress concept.</article-title>
<source/>N. Y. State J. Med.
          <year>1975</year>
<volume>75</volume>
<issue>12</issue>
<fpage>2139</fpage>
<lpage>2145</lpage>
<pub-id pub-id-type="pmid">1059917</pub-id>
</element-citation>
</ref>
<ref id="R116">
<label>116</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selye</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Confusion and controversy in the stress field.</article-title>
<source/>J. Human Stress
          <year>1975</year>
<volume>1</volume>
<issue>2</issue>
<fpage>37</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1080/0097840X.1975.9940406</pub-id>
</element-citation>
</ref>
<ref id="R117">
<label>117</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dhabhar</surname>
<given-names>F.S.</given-names>
</name>
</person-group>
<article-title>A hassle a day may keep the doctor away: stress and the augmentation of immune function.</article-title>
<source/>Integr. Comp. Biol.
          <year>2002</year>
<volume>42</volume>
<issue>3</issue>
<fpage>556</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="doi">10.1093/icb/42.3.556</pub-id>
<pub-id pub-id-type="pmid">21708751</pub-id>
</element-citation>
</ref>
<ref id="R118">
<label>118</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McEwen</surname>
<given-names>B.S.</given-names>
</name>
</person-group>
<article-title>Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders.</article-title>
<source/>Ann. N. Y. Acad. Sci.
          <year>2004</year>
<volume>1032</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1196/annals.1314.001</pub-id>
<pub-id pub-id-type="pmid">15677391</pub-id>
</element-citation>
</ref>
<ref id="R119">
<label>119</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joëls</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Baram</surname>
<given-names>T.Z.</given-names>
</name>
</person-group>
<article-title>The neuro-symphony of stress.</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2009</year>
<volume>10</volume>
<issue>6</issue>
<fpage>459</fpage>
<lpage>466</lpage>
<pub-id pub-id-type="doi">10.1038/nrn2632</pub-id>
<pub-id pub-id-type="pmid">19339973</pub-id>
</element-citation>
</ref>
<ref id="R120">
<label>120</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anisman</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zacharko</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Multiple neurochemical and behavioral consequences of stressors: implications for depression.</article-title>
<source/>Pharmacol. Ther.
          <year>1990</year>
<volume>46</volume>
<issue>1</issue>
<fpage>119</fpage>
<lpage>136</lpage>
<pub-id pub-id-type="pmid">2181488</pub-id>
</element-citation>
</ref>
<ref id="R121">
<label>121</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Kessler</surname>
<given-names>R. C.</given-names>
</name>
</person-group>
<source/>The effects of stressful life events on depression.
          <year>1997</year>
</element-citation>
</ref>
<ref id="R122">
<label>122</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franklin</surname>
<given-names>T.B.</given-names>
</name>
<name>
<surname>Saab</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Mansuy</surname>
<given-names>I.M.</given-names>
</name>
</person-group>
<article-title>Neural mechanisms of stress resilience and vulnerability.</article-title>
<source/>Neuron
          <year>2012</year>
<volume>75</volume>
<issue>5</issue>
<fpage>747</fpage>
<lpage>761</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2012.08.016</pub-id>
<pub-id pub-id-type="pmid">22958817</pub-id>
</element-citation>
</ref>
<ref id="R123">
<label>123</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zethof</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Van der Heyden</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Tolboom</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Olivier</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Stress-induced hyperthermia in mice: a methodological study.</article-title>
<source/>Physiol. Behav.
          <year>1994</year>
<volume>55</volume>
<issue>1</issue>
<fpage>109</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="pmid">8140153</pub-id>
</element-citation>
</ref>
<ref id="R124">
<label>124</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olivier</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zethof</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pattij</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>van Boogaert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>van Oorschot</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Leahy</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Oosting</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bouwknecht</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Veening</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>van der Gugten</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Groenink</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Stress-induced hyperthermia and anxiety: pharmacological validation.</article-title>
<source/>Eur. J. Pharmacol.
          <year>2003</year>
<volume>463</volume>
<issue>1-3</issue>
<fpage>117</fpage>
<lpage>132</lpage>
<pub-id pub-id-type="pmid">12600705</pub-id>
</element-citation>
</ref>
<ref id="R125">
<label>125</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Adriaan Bouwknecht</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Olivier</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Paylor</surname>
<given-names>R. E.</given-names>
</name>
</person-group>
<source/>The stress-induced hyperthermia paradigm as a physiological animal model for anxiety: a review of pharmacological and genetic studies in the mouse.
          <year>2007</year>
</element-citation>
</ref>
<ref id="R126">
<label>126</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vinkers</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Penning</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hellhammer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Verster</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Klaessens</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Olivier</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kalkman</surname>
<given-names>C.J.</given-names>
</name>
</person-group>
<article-title>The effect of stress on core and peripheral body temperature in humans.</article-title>
<source/>Stress
          <year>2013</year>
<volume>16</volume>
<issue>5</issue>
<fpage>520</fpage>
<lpage>530</lpage>
<pub-id pub-id-type="doi">10.3109/10253890.2013.807243</pub-id>
<pub-id pub-id-type="pmid">23790072</pub-id>
</element-citation>
</ref>
<ref id="R127">
<label>127</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borsini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Meli</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Is the forced swimming test a suitable model for revealing antidepressant activity?</article-title>
<source/>Psychopharmacology (Berl.)
          <year>1988</year>
<volume>94</volume>
<issue>2</issue>
<fpage>147</fpage>
<lpage>160</lpage>
<pub-id pub-id-type="pmid">3127840</pub-id>
</element-citation>
</ref>
<ref id="R128">
<label>128</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borsini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lecci</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Volterra</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Meli</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>A model to measure anticipatory anxiety in mice?</article-title>
<source/>Psychopharmacology (Berl.)
          <year>1989</year>
<volume>98</volume>
<issue>2</issue>
<fpage>207</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="pmid">2502791</pub-id>
</element-citation>
</ref>
<ref id="R129">
<label>129</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porsolt</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Le Pichon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jalfre</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Depression: a new animal model sensitive to antidepressant treatments.</article-title>
<source/>Nature
          <year>1977</year>
<volume>266</volume>
<issue>5604</issue>
<fpage>730</fpage>
<lpage>732</lpage>
<pub-id pub-id-type="pmid">559941</pub-id>
</element-citation>
</ref>
<ref id="R130">
<label>130</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porsolt</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Bertin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jalfre</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Behavioral despair in mice: a primary screening test for antidepressants.</article-title>
<source/>Arch. Int. Pharmacodyn. Ther.
          <year>1977</year>
<volume>229</volume>
<issue>2</issue>
<fpage>327</fpage>
<lpage>336</lpage>
<pub-id pub-id-type="pmid">596982</pub-id>
</element-citation>
</ref>
<ref id="R131">
<label>131</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Cryan</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Mombereau</surname>
<given-names>C.</given-names>
</name>
</person-group>
<source/>In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice.
          <year>2004</year>
</element-citation>
</ref>
<ref id="R132">
<label>132</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lucki</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>A prescription to resist proscriptions for murine models of depression.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>2001</year>
<volume>153</volume>
<issue>3</issue>
<fpage>395</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="pmid">11271414</pub-id>
</element-citation>
</ref>
<ref id="R133">
<label>133</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Valentino</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Lucki</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test.</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2005</year>
<volume>29</volume>
<issue>4-5</issue>
<fpage>547</fpage>
<lpage>569</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2005.03.008</pub-id>
<pub-id pub-id-type="pmid">15893822</pub-id>
</element-citation>
</ref>
<ref id="R134">
<label>134</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Mombereau</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vassout</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice.</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2005</year>
<volume>29</volume>
<issue>4-5</issue>
<fpage>571</fpage>
<lpage>625</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2005.03.009</pub-id>
<pub-id pub-id-type="pmid">15890404</pub-id>
</element-citation>
</ref>
<ref id="R135">
<label>135</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>P.V.</given-names>
</name>
</person-group>
<article-title>Rodent models of depression: reexamining validity without anthropomorphic inference.</article-title>
<source/>Crit. Rev. Neurobiol.
          <year>2003</year>
<volume>15</volume>
<issue>2</issue>
<fpage>143</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="pmid">14977368</pub-id>
</element-citation>
</ref>
<ref id="R136">
<label>136</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lister</surname>
<given-names>R.G.</given-names>
</name>
</person-group>
<article-title>The use of a plus-maze to measure anxiety in the mouse.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>1987</year>
<volume>92</volume>
<issue>2</issue>
<fpage>180</fpage>
<lpage>185</lpage>
<pub-id pub-id-type="pmid">3110839</pub-id>
</element-citation>
</ref>
<ref id="R137">
<label>137</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodgers</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Haller</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Halasz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Walton</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Brain</surname>
<given-names>P.F.</given-names>
</name>
</person-group>
<article-title>Corticosterone response to the plus-maze: high correlation with risk assessment in rats and mice.</article-title>
<source/>Physiol. Behav.
          <year>1999</year>
<volume>68</volume>
<issue>1-2</issue>
<fpage>47</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="pmid">10627061</pub-id>
</element-citation>
</ref>
<ref id="R138">
<label>138</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belzung</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Griebel</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Measuring normal and pathological anxiety-like behaviour in mice: a review.</article-title>
<source/>Behav. Brain Res.
          <year>2001</year>
<volume>125</volume>
<issue>1-2</issue>
<fpage>141</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="pmid">11682105</pub-id>
</element-citation>
</ref>
<ref id="R139">
<label>139</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salomé</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Landgraf</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Viltart</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Confinement to the open arm of the elevated-plus maze as anxiety paradigm: behavioral validation.</article-title>
<source/>Behav. Neurosci.
          <year>2006</year>
<volume>120</volume>
<issue>3</issue>
<fpage>719</fpage>
<lpage>723</lpage>
<pub-id pub-id-type="doi">10.1037/0735-7044.120.3.719</pub-id>
<pub-id pub-id-type="pmid">16768623</pub-id>
</element-citation>
</ref>
<ref id="R140">
<label>140</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uschold-Schmidt</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nyuyki</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Füchsl</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>I.D.</given-names>
</name>
<name>
<surname>Reber</surname>
<given-names>S.O.</given-names>
</name>
</person-group>
<article-title>Chronic psychosocial stress results in sensitization of the HPA axis to acute heterotypic stressors despite a reduction of adrenal in vitro ACTH responsiveness.</article-title>
<source/>Psychoneuroendocrinology
          <year>2012</year>
<volume>37</volume>
<issue>10</issue>
<fpage>1676</fpage>
<lpage>1687</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2012.02.015</pub-id>
<pub-id pub-id-type="pmid">22444976</pub-id>
</element-citation>
</ref>
<ref id="R141">
<label>141</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nestler</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Hyman</surname>
<given-names>S.E.</given-names>
</name>
</person-group>
<article-title>Animal models of neuropsychiatric disorders.</article-title>
<source/>Nat. Neurosci.
          <year>2010</year>
<volume>13</volume>
<issue>10</issue>
<fpage>1161</fpage>
<lpage>1169</lpage>
<pub-id pub-id-type="doi">10.1038/nn.2647</pub-id>
<pub-id pub-id-type="pmid">20877280</pub-id>
</element-citation>
</ref>
<ref id="R142">
<label>142</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seligman</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Rosellini</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Kozak</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Learned helplessness in the rat: time course, immunization, and reversibility.</article-title>
<source/>J. Comp. Physiol. Psychol.
          <year>1975</year>
<fpage>88</fpage>
</element-citation>
</ref>
<ref id="R143">
<label>143</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seligman</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Beagley</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Learned helplessness in the rat.</article-title>
<source/>J. Comp. Physiol. Psychol.
          <year>1975</year>
<volume>88</volume>
<issue>2</issue>
<fpage>534</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="pmid">1150935</pub-id>
</element-citation>
</ref>
<ref id="R144">
<label>144</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willner</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>The validity of animal models of depression.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>1984</year>
<volume>83</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="pmid">6429692</pub-id>
</element-citation>
</ref>
<ref id="R145">
<label>145</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henn</surname>
<given-names>F.A.</given-names>
</name>
<name>
<surname>Vollmayr</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Stress models of depression: forming genetically vulnerable strains.</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2005</year>
<volume>29</volume>
<issue>4-5</issue>
<fpage>799</fpage>
<lpage>804</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2005.03.019</pub-id>
<pub-id pub-id-type="pmid">15925700</pub-id>
</element-citation>
</ref>
<ref id="R146">
<label>146</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nestler</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Gould</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Manji</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Buncan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Duman</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Greshenfeld</surname>
<given-names>H.K.</given-names>
</name>
<name>
<surname>Hen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Koester</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lederhendler</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Meaney</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Winsky</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zalcman</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Preclinical models: status of basic research in depression.</article-title>
<source/>Biol. Psychiatry
          <year>2002</year>
<volume>52</volume>
<issue>6</issue>
<fpage>503</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="pmid">12361666</pub-id>
</element-citation>
</ref>
<ref id="R147">
<label>147</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nestler</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Barrot</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>DiLeone</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Eisch</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Gold</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Monteggia</surname>
<given-names>L.M.</given-names>
</name>
</person-group>
<article-title>Neurobiology of depression.</article-title>
<source/>Neuron
          <year>2002</year>
<volume>34</volume>
<issue>1</issue>
<fpage>13</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="pmid">11931738</pub-id>
</element-citation>
</ref>
<ref id="R148">
<label>148</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>The molecular neurobiology of depression.</article-title>
<source/>Nature
          <year>2008</year>
<volume>455</volume>
<issue>7215</issue>
<fpage>894</fpage>
<lpage>902</lpage>
<pub-id pub-id-type="doi">10.1038/nature07455</pub-id>
<pub-id pub-id-type="pmid">18923511</pub-id>
</element-citation>
</ref>
<ref id="R149">
<label>149</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Berton</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>The use of animal models in psychiatric research and treatment.</article-title>
<source/>Am. J. Psychiatry
          <year>2008</year>
<volume>165</volume>
<issue>9</issue>
<fpage>1109</fpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2008.08071076</pub-id>
<pub-id pub-id-type="pmid">18765492</pub-id>
</element-citation>
</ref>
<ref id="R150">
<label>150</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>Linking molecules to mood: new insight into the biology of depression.</article-title>
<source/>Am. J. Psychiatry
          <year>2010</year>
<volume>167</volume>
<issue>11</issue>
<fpage>1305</fpage>
<lpage>1320</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2009.10030434</pub-id>
<pub-id pub-id-type="pmid">20843874</pub-id>
</element-citation>
</ref>
<ref id="R151">
<label>151</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>Animal models of depression: molecular perspectives.</article-title>
<source/>Curr. Top. Behav. Neurosci.
          <year>2011</year>
<volume>7</volume>
<fpage>121</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="doi">10.1007/7854_2010_108</pub-id>
<pub-id pub-id-type="pmid">21225412</pub-id>
</element-citation>
</ref>
<ref id="R152">
<label>152</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>West</surname>
<given-names>A.P.</given-names>
</name>
</person-group>
<article-title>Neurobehavioral studies of forced swimming: the role of learning and memory in the forced swim test.</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>1990</year>
<volume>14</volume>
<issue>6</issue>
<fpage>863</fpage>
<lpage>877</lpage>
<pub-id pub-id-type="pmid">2277851</pub-id>
</element-citation>
</ref>
<ref id="R153">
<label>153</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willner</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Muscat</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Papp</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Chronic mild stress-induced anhedonia: a realistic animal model of depression.</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>1992</year>
<volume>16</volume>
<issue>4</issue>
<fpage>525</fpage>
<lpage>534</lpage>
<pub-id pub-id-type="pmid">1480349</pub-id>
</element-citation>
</ref>
<ref id="R154">
<label>154</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willner</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>1997</year>
<volume>134</volume>
<issue>4</issue>
<fpage>319</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="pmid">9452163</pub-id>
</element-citation>
</ref>
<ref id="R155">
<label>155</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muscat</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Willner</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Suppression of sucrose drinking by chronic mild unpredictable stress: a methodological analysis.</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>1992</year>
<volume>16</volume>
<issue>4</issue>
<fpage>507</fpage>
<lpage>517</lpage>
<pub-id pub-id-type="pmid">1480347</pub-id>
</element-citation>
</ref>
<ref id="R156">
<label>156</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strekalova</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gorenkova</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Schunk</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dolgov</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Bartsch</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Selective effects of citalopram in a mouse model of stress-induced anhedonia with a control for chronic stress.</article-title>
<source/>Behav. Pharmacol.
          <year>2006</year>
<volume>17</volume>
<issue>3</issue>
<fpage>271</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="pmid">16572005</pub-id>
</element-citation>
</ref>
<ref id="R157">
<label>157</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guidotti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Calabrese</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Anacker</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Racagni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pariante</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Riva</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Glucocorticoid receptor and FKBP5 expression is altered following exposure to chronic stress: modulation by antidepressant treatment.</article-title>
<source/>Neuropsychopharmacology
          <year>2013</year>
<volume>38</volume>
<issue>4</issue>
<fpage>616</fpage>
<lpage>627</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2012.225</pub-id>
<pub-id pub-id-type="pmid">23169346</pub-id>
</element-citation>
</ref>
<ref id="R158">
<label>158</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kouzis</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Eaton</surname>
<given-names>W.W.</given-names>
</name>
</person-group>
<article-title>Absence of social networks, social support and health services utilization.</article-title>
<source/>Psychol. Med.
          <year>1998</year>
<volume>28</volume>
<issue>6</issue>
<fpage>1301</fpage>
<lpage>1310</lpage>
<pub-id pub-id-type="pmid">9854271</pub-id>
</element-citation>
</ref>
<ref id="R159">
<label>159</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vega</surname>
<given-names>W.A.</given-names>
</name>
<name>
<surname>Sribney</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Aguilar-Gaxiola</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kolody</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>12-month prevalence of DSM-III-R psychiatric disorders among Mexican Americans: nativity, social assimilation, and age determinants.</article-title>
<source/>J. Nerv. Ment. Dis.
          <year>2004</year>
<volume>192</volume>
<issue>8</issue>
<fpage>532</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="pmid">15387155</pub-id>
</element-citation>
</ref>
<ref id="R160">
<label>160</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeVries</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Craft</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Glasper</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Neigh</surname>
<given-names>G.N.</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>J.K.</given-names>
</name>
</person-group>
<article-title>2006 Curt P. Richter award winner: Social influences on stress responses and health.</article-title>
<source/>Psychoneuroendocrinology
          <year>2007</year>
<volume>32</volume>
<issue>6</issue>
<fpage>587</fpage>
<lpage>603</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2007.04.007</pub-id>
<pub-id pub-id-type="pmid">17590276</pub-id>
</element-citation>
</ref>
<ref id="R161">
<label>161</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brinkborg</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Michanek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hesser</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Berglund</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Acceptance and commitment therapy for the treatment of stress among social workers: a randomized controlled trial.</article-title>
<source/>Behav. Res. Ther.
          <year>2011</year>
<volume>49</volume>
<issue>6-7</issue>
<fpage>389</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="doi">10.1016/j.brat.2011.03.009</pub-id>
<pub-id pub-id-type="pmid">21513917</pub-id>
</element-citation>
</ref>
<ref id="R162">
<label>162</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wagner</surname>
<given-names>K.V.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X-D.</given-names>
</name>
<name>
<surname>Liebl</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Scharf</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>M.V.</given-names>
</name>
</person-group>
<article-title>Pituitary glucocorticoid receptor deletion reduces vulnerability to chronic stress.</article-title>
<source/>Psychoneuroendocrinology
          <year>2011</year>
<volume>36</volume>
<issue>4</issue>
<fpage>579</fpage>
<lpage>587</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2010.09.007</pub-id>
<pub-id pub-id-type="pmid">20940090</pub-id>
</element-citation>
</ref>
<ref id="R163">
<label>163</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wagner</surname>
<given-names>K.V.</given-names>
</name>
<name>
<surname>Hartmann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Labermaier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Häusl</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Harbich</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X-D.</given-names>
</name>
<name>
<surname>Santarelli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kohl</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gassen</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Matosin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Schieven</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Webhofer</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Turck</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Lindemann</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jaschke</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wettstein</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Rein</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>M.V.</given-names>
</name>
</person-group>
<article-title>Homer1/mGluR5 Activity Moderates Vulnerability to Chronic Social Stress.</article-title>
<source/>Neuropsychopharmacology
          <year>2014</year>
<volume>40</volume>
<issue>5</issue>
<fpage>1222</fpage>
<lpage>1233</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2014.308</pub-id>
<pub-id pub-id-type="pmid">25409593</pub-id>
</element-citation>
</ref>
<ref id="R164">
<label>164</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berton</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>McClung</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Dileone</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Renthal</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tsankova</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Bolanos</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Rios</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Monteggia</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Self</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress.</article-title>
<source/>Science
          <year>2006</year>
<volume>311</volume>
<issue>5762</issue>
<fpage>864</fpage>
<lpage>868</lpage>
<pub-id pub-id-type="doi">10.1126/science.1120972</pub-id>
<pub-id pub-id-type="pmid">16469931</pub-id>
</element-citation>
</ref>
<ref id="R165">
<label>165</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Razzoli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Carboni</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Andreoli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Michielin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ballottari</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arban</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Strain-specific outcomes of repeated social defeat and chronic fluoxetine treatment in the mouse.</article-title>
<source/>Pharmacol. Biochem. Behav.
          <year>2011</year>
<volume>97</volume>
<issue>3</issue>
<fpage>566</fpage>
<lpage>576</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2010.09.010</pub-id>
<pub-id pub-id-type="pmid">20863846</pub-id>
</element-citation>
</ref>
<ref id="R166">
<label>166</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsankova</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Berton</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Renthal</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Neve</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action.</article-title>
<source/>Nat. Neurosci.
          <year>2006</year>
<volume>9</volume>
<issue>4</issue>
<fpage>519</fpage>
<lpage>525</lpage>
<pub-id pub-id-type="doi">10.1038/nn1659</pub-id>
<pub-id pub-id-type="pmid">16501568</pub-id>
</element-citation>
</ref>
<ref id="R167">
<label>167</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollis</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dietz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gunjan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kabbaj</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The effects of repeated social defeat on long-term depressive-like behavior and short-term histone modifications in the hippocampus in male Sprague-Dawley rats.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>2010</year>
<volume>211</volume>
<issue>1</issue>
<fpage>69</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-010-1869-9</pub-id>
<pub-id pub-id-type="pmid">20454892</pub-id>
</element-citation>
</ref>
<ref id="R168">
<label>168</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duclot</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kabbaj</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Individual Differences in Novelty Seeking Predict Subsequent Vulnerability to Social Defeat through a Differential Epigenetic Regulation of Brain-Derived Neurotrophic Factor Expression.</article-title>
<source/>J. Neurosci.
          <year>2013</year>
<volume>33</volume>
<issue>27</issue>
<fpage>11048</fpage>
<lpage>11060</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0199-13.2013</pub-id>
<pub-id pub-id-type="pmid">23825410</pub-id>
</element-citation>
</ref>
<ref id="R169">
<label>169</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Razzoli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Roncari</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Guidi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Carboni</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Arban</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gerrard</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bacchi</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Conditioning properties of social subordination in rats: behavioral and biochemical correlates of anxiety.</article-title>
<source/>Horm. Behav.
          <year>2006</year>
<volume>50</volume>
<issue>2</issue>
<fpage>245</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="doi">10.1016/j.yhbeh.2006.03.007</pub-id>
<pub-id pub-id-type="pmid">16631758</pub-id>
</element-citation>
</ref>
<ref id="R170">
<label>170</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Razzoli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Carboni</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guidi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gerrard</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Arban</surname>
<given-names>R.</given-names>
</name>
</person-group>
<source/>Social defeat-induced contextual conditioning differentially imprints behavioral and adrenal reactivity: a time-course study in the rat.
          <year>2007</year>
</element-citation>
</ref>
<ref id="R171">
<label>171</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Razzoli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Carboni</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Arban</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Alterations of behavioral and endocrinological reactivity induced by 3 brief social defeats in rats: relevance to human psychopathology.</article-title>
<source/>Psychoneuroendocrinology
          <year>2009</year>
<volume>34</volume>
<issue>9</issue>
<fpage>1405</fpage>
<lpage>1416</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2009.04.018</pub-id>
<pub-id pub-id-type="pmid">19482436</pub-id>
</element-citation>
</ref>
<ref id="R172">
<label>172</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Avgustinovich</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Kovalenko</surname>
<given-names>I.L.</given-names>
</name>
<name>
<surname>Kudryavtseva</surname>
<given-names>N.N.</given-names>
</name>
</person-group>
<article-title>A model of anxious depression: persistence of behavioral pathology.</article-title>
<source/>Neurosci. Behav. Physiol.
          <year>2005</year>
<volume>35</volume>
<issue>9</issue>
<fpage>917</fpage>
<lpage>924</lpage>
<pub-id pub-id-type="doi">10.1007/s11055-005-0146-6</pub-id>
<pub-id pub-id-type="pmid">16270173</pub-id>
</element-citation>
</ref>
<ref id="R173">
<label>173</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>M-H.</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Berton</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Renthal</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Laplant</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lutter</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lagace</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Ghose</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Reister</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tannous</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Neve</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Chakravarty</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Eisch</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Self</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>F.S.</given-names>
</name>
<name>
<surname>Tamminga</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Gershenfeld</surname>
<given-names>H.K.</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions.</article-title>
<source/>Cell
          <year>2007</year>
<volume>131</volume>
<issue>3</issue>
<fpage>391</fpage>
<lpage>404</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2007.09.018</pub-id>
<pub-id pub-id-type="pmid">17956738</pub-id>
</element-citation>
</ref>
<ref id="R174">
<label>174</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollis</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kabbaj</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Social defeat as an animal model for depression.</article-title>
<source/>ILAR J.
          <year>2014</year>
<volume>55</volume>
<issue>2</issue>
<fpage>221</fpage>
<lpage>232</lpage>
<pub-id pub-id-type="doi">10.1093/ilar/ilu002</pub-id>
<pub-id pub-id-type="pmid">25225302</pub-id>
</element-citation>
</ref>
<ref id="R175">
<label>175</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venzala</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>García-García</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Elizalde</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Delagrange</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tordera</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Chronic social defeat stress model: behavioral features, antidepressant action, and interaction with biological risk factors.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>2012</year>
<volume>224</volume>
<issue>2</issue>
<fpage>313</fpage>
<lpage>325</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-012-2754-5</pub-id>
<pub-id pub-id-type="pmid">22707231</pub-id>
</element-citation>
</ref>
<ref id="R176">
<label>176</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Der-Avakian</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mazei-Robison</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Kesby</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Markou</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Enduring deficits in brain reward function after chronic social defeat in rats: susceptibility, resilience, and antidepressant response.</article-title>
<source/>Biol. Psychiatry
          <year>2014</year>
<volume>76</volume>
<issue>7</issue>
<fpage>542</fpage>
<lpage>549</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2014.01.013</pub-id>
<pub-id pub-id-type="pmid">24576687</pub-id>
</element-citation>
</ref>
<ref id="R177">
<label>177</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balsevich</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Namendorf</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gerlach</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Uhr</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>M.V.</given-names>
</name>
</person-group>
<article-title>The bio-distribution of the antidepressant clomipramine is modulated by chronic stress in mice: effects on behavior.</article-title>
<source/>Front. Behav. Neurosci.
          <year>2014</year>
<volume>8</volume>
<fpage>445</fpage>
<pub-id pub-id-type="doi">10.3389/fnbeh.2014.00445</pub-id>
<pub-id pub-id-type="pmid">25610380</pub-id>
</element-citation>
</ref>
<ref id="R178">
<label>178</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reber</surname>
<given-names>S.O.</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>I.D.</given-names>
</name>
</person-group>
<article-title>Defensive behavioral strategies and enhanced state anxiety during chronic subordinate colony housing are accompanied by reduced hypothalamic vasopressin, but not oxytocin, expression.</article-title>
<source/>Ann. N. Y. Acad. Sci.
          <year>2008</year>
<volume>1148</volume>
<fpage>184</fpage>
<lpage>195</lpage>
<pub-id pub-id-type="doi">10.1196/annals.1410.003</pub-id>
<pub-id pub-id-type="pmid">19120108</pub-id>
</element-citation>
</ref>
<ref id="R179">
<label>179</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uschold-Schmidt</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Peterlik</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Füchsl</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Reber</surname>
<given-names>S.O.</given-names>
</name>
</person-group>
<article-title>HPA axis changes during the initial phase of psychosocial stressor exposure in male mice.</article-title>
<source/>J. Endocrinol.
          <year>2013</year>
<volume>218</volume>
<issue>2</issue>
<fpage>193</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="doi">10.1530/JOE-13-0027</pub-id>
<pub-id pub-id-type="pmid">23720397</pub-id>
</element-citation>
</ref>
<ref id="R180">
<label>180</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Reber</surname>
<given-names>S.O.</given-names>
</name>
<name>
<surname>Botteron</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Barth</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Peterlik</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Uschold</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Männel</surname>
<given-names>D.N.</given-names>
</name>
<name>
<surname>Lechner</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Chronic psychosocial stress promotes systemic immune activation and the development of inflammatory Th cell responses.</article-title>
<source/>Brain Behav. Immun.
          <year>2010</year>
<volume>24</volume>
<issue>7</issue>
<fpage>1097</fpage>
<lpage>1104</lpage>
<pub-id pub-id-type="pmid">20451603</pub-id>
</element-citation>
</ref>
<ref id="R181">
<label>181</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caplan</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Cobb</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>French</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>White collar work load and cortisol: disruption of a circadian rhythm by job stress?</article-title>
<source/>J. Psychosom. Res.
          <year>1979</year>
<volume>23</volume>
<issue>3</issue>
<fpage>181</fpage>
<lpage>192</lpage>
<pub-id pub-id-type="pmid">573796</pub-id>
</element-citation>
</ref>
<ref id="R182">
<label>182</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yehuda</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Stress and glucocorticoid.</article-title>
<source/>Science
          <year>1997</year>
<volume>275</volume>
<issue>5306</issue>
<fpage>1662</fpage>
<lpage>1663</lpage>
<pub-id pub-id-type="pmid">9072828</pub-id>
</element-citation>
</ref>
<ref id="R183">
<label>183</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yehuda</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Sensitization of the hypothalamic-pituitary-adrenal axis in posttraumatic stress disorder.</article-title>
<source/>Ann. N. Y. Acad. Sci.
          <year>1997</year>
<volume>821</volume>
<fpage>57</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="pmid">9238194</pub-id>
</element-citation>
</ref>
<ref id="R184">
<label>184</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heim</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ehlert</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Hellhammer</surname>
<given-names>D.H.</given-names>
</name>
</person-group>
<article-title>The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders.</article-title>
<source/>Psychoneuroendocrinology
          <year>2000</year>
<volume>25</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">10633533</pub-id>
</element-citation>
</ref>
<ref id="R185">
<label>185</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veenema</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Reber</surname>
<given-names>S.O.</given-names>
</name>
<name>
<surname>Selch</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Obermeier</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>I.D.</given-names>
</name>
</person-group>
<article-title>Early life stress enhances the vulnerability to chronic psychosocial stress and experimental colitis in adult mice.</article-title>
<source/>Endocrinology
          <year>2008</year>
<volume>149</volume>
<issue>6</issue>
<fpage>2727</fpage>
<lpage>2736</lpage>
<pub-id pub-id-type="doi">10.1210/en.2007-1469</pub-id>
<pub-id pub-id-type="pmid">18308845</pub-id>
</element-citation>
</ref>
<ref id="R186">
<label>186</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peters</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Grunwald</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rümmele</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Endlicher</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lechner</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>I.D.</given-names>
</name>
<name>
<surname>Obermeier</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Reber</surname>
<given-names>S.O.</given-names>
</name>
</person-group>
<article-title>Chronic psychosocial stress increases the risk for inflammation-related colon carcino- genesis in male mice.</article-title>
<source/>Stress
          <year>2012</year>
<volume>15</volume>
<issue>4</issue>
<fpage>403</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="doi">10.3109/10253890.2011.631232</pub-id>
<pub-id pub-id-type="pmid">22044139</pub-id>
</element-citation>
</ref>
<ref id="R187">
<label>187</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eaden</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Abrams</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ekbom</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mayberry</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Colorectal cancer prevention in ulcerative colitis: a case-control study.</article-title>
<source/>Aliment. Pharmacol. Ther.
          <year>2000</year>
<volume>14</volume>
<issue>2</issue>
<fpage>145</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="pmid">10651654</pub-id>
</element-citation>
</ref>
<ref id="R188">
<label>188</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eaden</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease.</article-title>
<source/>Aliment. Pharmacol. Ther.
          <year>2003</year>
<volume>18</volume>
<issue>Suppl. 2</issue>
<fpage>15</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">12950416</pub-id>
</element-citation>
</ref>
<ref id="R189">
<label>189</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eaden</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>
<italic>Aliment.</italic> Review article: colorectal carcinoma and inflammatory bowel disease.</article-title>
<source/>Pharmacol. Ther.
          <year>2004</year>
<volume>20</volume>
<issue>Suppl. 4</issue>
<fpage>24</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2036.2004.02046.x</pub-id>
</element-citation>
</ref>
<ref id="R190">
<label>190</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Hogezand</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Eichhorn</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Choudry</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Veenendaal</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Lamers</surname>
<given-names>C.B.</given-names>
</name>
</person-group>
<article-title>Malignancies in inflammatory bowel disease: fact or fiction?</article-title>
<source/>Scand. J. Gastroenterol. Suppl.
          <year>2002</year>
<issue>236</issue>
<fpage>48</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="pmid">12408504</pub-id>
</element-citation>
</ref>
<ref id="R191">
<label>191</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cairns</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Scholefield</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Steele</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Dunlop</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>G.D.</given-names>
</name>
<name>
<surname>Eaden</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Rutter</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Atkin</surname>
<given-names>W.P.</given-names>
</name>
<name>
<surname>Saunders</surname>
<given-names>B.P.</given-names>
</name>
<name>
<surname>Lucassen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fairclough</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Woodhouse</surname>
<given-names>C.R.</given-names>
</name>
</person-group>
<article-title>Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002).</article-title>
<source/>Gut
          <year>2010</year>
<volume>59</volume>
<issue>5</issue>
<fpage>666</fpage>
<lpage>689</lpage>
<pub-id pub-id-type="doi">10.1136/gut.2009.179804</pub-id>
<pub-id pub-id-type="pmid">20427401</pub-id>
</element-citation>
</ref>
<ref id="R192">
<label>192</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duffy</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Zielezny</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Byers</surname>
<given-names>T.E.</given-names>
</name>
<name>
<surname>Weiser</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Calkins</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Ogra</surname>
<given-names>P.L.</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Relevance of major stress events as an indicator of disease activity prevalence in inflammatory bowel disease.</article-title>
<source/>Behav. Med.
          <year>1991</year>
<volume>17</volume>
<issue>3</issue>
<fpage>101</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1080/08964289.1991.9937553</pub-id>
<pub-id pub-id-type="pmid">1932843</pub-id>
</element-citation>
</ref>
<ref id="R193">
<label>193</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levenstein</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Prantera</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Varvo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Scribano</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Andreoli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Luzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Arcà</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Berto</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Milite</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Marcheggiano</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission.</article-title>
<source/>Am. J. Gastroenterol.
          <year>2000</year>
<volume>95</volume>
<issue>5</issue>
<fpage>1213</fpage>
<lpage>1220</lpage>
<pub-id pub-id-type="doi">10.1111/j.1572-0241.2000.02012.x</pub-id>
<pub-id pub-id-type="pmid">10811330</pub-id>
</element-citation>
</ref>
<ref id="R194">
<label>194</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bitton</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sewitch</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Peppercorn</surname>
<given-names>M. A.</given-names>
</name>
</person-group>
<article-title>Psychosocial determinants of
relapse in ulcerative colitis: a longitudinal study</article-title>
<source/>Am. J.Gastroenterol.
          <year>2003</year>
<volume>98</volume>
<fpage>2203</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">14572569</pub-id>
</element-citation>
</ref>
<ref id="R195">
<label>195</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slattery</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Uschold</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Magoni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bär</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Popoli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>I. D.</given-names>
</name>
<name>
<surname>Reber</surname>
<given-names>S. O.</given-names>
</name>
</person-group>
<article-title>Behavioural consequences of two chronic psychosocial stress paradigms: anxiety without depression.</article-title>
<source/>Psychoneuroendocrinology
          <year>2012</year>
<volume>37</volume>
<issue>5</issue>
<fpage>702</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">21962377</pub-id>
</element-citation>
</ref>
<ref id="R196">
<label>196</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peters</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Slattery</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Flor</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>I.D.</given-names>
</name>
<name>
<surname>Reber</surname>
<given-names>S.O.</given-names>
</name>
</person-group>
<article-title>Differential effects of baclofen and oxytocin on the increased ethanol consumption following chronic psychosocial stress in mice.</article-title>
<source/>Addict. Biol.
          <year>2013</year>
<volume>18</volume>
<issue>1</issue>
<fpage>66</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1111/adb.12001</pub-id>
<pub-id pub-id-type="pmid">23126471</pub-id>
</element-citation>
</ref>
<ref id="R197">
<label>197</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hildebrandt</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gerlach</surname>
<given-names>A.L.</given-names>
</name>
</person-group>
<article-title>Drinking motives in alcohol use disorder patients with and without social anxiety disorder.</article-title>
<source/>Anxiety Stress Coping
          <year>2014</year>
<volume>27</volume>
<issue>1</issue>
<fpage>113</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="doi">10.1080/10615806.2013.823482</pub-id>
<pub-id pub-id-type="pmid">23915169</pub-id>
</element-citation>
</ref>
<ref id="R198">
<label>198</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boger</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Auerbach</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Pechtel</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Busch</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Greenfield</surname>
<given-names>S.F.</given-names>
</name>
<name>
<surname>Pizzagalli</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Co-Occurring Depressive and Substance Use Disorders in Adolescents: An Examination of Reward Responsiveness During Treatment.</article-title>
<source/>J. Psychother. Integration
          <year>2014</year>
<volume>24</volume>
<issue>2</issue>
<fpage>109</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="doi">10.1037/a0036975</pub-id>
</element-citation>
</ref>
<ref id="R199">
<label>199</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morley</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Baillie</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Addolorato</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Leggio</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Haber</surname>
<given-names>P.S.</given-names>
</name>
</person-group>
<article-title>Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety.</article-title>
<source/>Alcohol Alcohol.
          <year>2014</year>
<fpage>654</fpage>
<lpage>660</lpage>
<pub-id pub-id-type="doi">10.1093/alcalc/agu062</pub-id>
<pub-id pub-id-type="pmid">25246489</pub-id>
</element-citation>
</ref>
<ref id="R200">
<label>200</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nyuyki</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Beiderbeck</surname>
<given-names>D.I.</given-names>
</name>
<name>
<surname>Lukas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>I.D.</given-names>
</name>
<name>
<surname>Reber</surname>
<given-names>S.O.</given-names>
</name>
</person-group>
<article-title>Chronic subordinate colony housing (CSC) as a model of chronic psychosocial stress in male rats.</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<issue>12</issue>
<fpage>e52371</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0052371</pub-id>
<pub-id pub-id-type="pmid">23300653</pub-id>
</element-citation>
</ref>
<ref id="R201">
<label>201</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maeng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zarate</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects.</article-title>
<source/>Curr. Psychiatry Rep.
          <year>2007</year>
<volume>9</volume>
<issue>6</issue>
<fpage>467</fpage>
<lpage>474</lpage>
<pub-id pub-id-type="pmid">18221626</pub-id>
</element-citation>
</ref>
<ref id="R202">
<label>202</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wierońska</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Brański</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Szewczyk</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pałucha</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Papp</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gruca</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Moryl</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Changes in the expression of metabotropic glutamate receptor 5 (mGluR5) in the rat hippocampus in an animal model of depression.</article-title>
<source/>Pol. J. Pharmacol.
          <year>2001</year>
<volume>53</volume>
<issue>6</issue>
<fpage>659</fpage>
<lpage>662</lpage>
<pub-id pub-id-type="pmid">11985342</pub-id>
</element-citation>
</ref>
<ref id="R203">
<label>203</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Connor</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Pusceddu</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>O’Leary</surname>
<given-names>O.F.</given-names>
</name>
<name>
<surname>Savignac</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Bravo</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>El Yacoubi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vaugeois</surname>
<given-names>J-M.</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Hippocampal group III mGlu receptor mRNA levels are not altered in specific mouse models of stress, depression and antidepressant action.</article-title>
<source/>Pharmacol. Biochem. Behav.
          <year>2013</year>
<volume>103</volume>
<issue>3</issue>
<fpage>561</fpage>
<lpage>567</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2012.09.017</pub-id>
<pub-id pub-id-type="pmid">23059104</pub-id>
</element-citation>
</ref>
<ref id="R204">
<label>204</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’ Connor</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Pusceddu</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Impact of early-life stress, on group III mGlu receptor levels in the rat hippocampus: effects of ketamine, electroconvulsive shock therapy and fluoxetine treatment.</article-title>
<source/>Neuropharmacology
          <year>2013</year>
<volume>66</volume>
<fpage>236</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.05.006</pub-id>
<pub-id pub-id-type="pmid">22609536</pub-id>
</element-citation>
</ref>
<ref id="R205">
<label>205</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanacora</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gueorguieva</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Epperson</surname>
<given-names>C.N.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y-T.</given-names>
</name>
<name>
<surname>Appel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rothman</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Krystal</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>G.F.</given-names>
</name>
</person-group>
<article-title>Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression.</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2004</year>
<volume>61</volume>
<issue>7</issue>
<fpage>705</fpage>
<lpage>713</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.61.7.705</pub-id>
<pub-id pub-id-type="pmid">15237082</pub-id>
</element-citation>
</ref>
<ref id="R206">
<label>206</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chamberlain</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Changes in rat serum corticosterone after treatment with metabotropic glutamate receptor agonists or antagonists.</article-title>
<source/>J. Neuroendocrinol.
          <year>2001</year>
<volume>13</volume>
<issue>8</issue>
<fpage>670</fpage>
<lpage>677</lpage>
<pub-id pub-id-type="pmid">11489083</pub-id>
</element-citation>
</ref>
<ref id="R207">
<label>207</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bradbury</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Giracello</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Holtz</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Schaffhauser</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Varney</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptor 5 antagonist-induced stimulation of hypothalamic-pituitary-adrenal axis activity: interaction with serotonergic systems.</article-title>
<source/>Neuropharmacology
          <year>2003</year>
<volume>44</volume>
<issue>5</issue>
<fpage>562</fpage>
<lpage>572</lpage>
<pub-id pub-id-type="pmid">12668042</pub-id>
</element-citation>
</ref>
<ref id="R208">
<label>208</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durand</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pampillo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Caruso</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lasaga</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Role of metabotropic glutamate receptors in the control of neuroendocrine function.</article-title>
<source/>Neuropharmacology
          <year>2008</year>
<volume>55</volume>
<issue>4</issue>
<fpage>577</fpage>
<lpage>583</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.06.022</pub-id>
<pub-id pub-id-type="pmid">18616955</pub-id>
</element-citation>
</ref>
<ref id="R209">
<label>209</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitsukawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mombereau</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lötscher</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Uzunov</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>van der Putten</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Flor</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptor subtype 7 ablation causes dysregulation of the HPA axis and increases hippocampal BDNF protein levels: implications for stress-related psychiatric disorders.</article-title>
<source/>Neuropsychopharmacology
          <year>2006</year>
<volume>31</volume>
<issue>6</issue>
<fpage>1112</fpage>
<lpage>1122</lpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1300926</pub-id>
<pub-id pub-id-type="pmid">16237391</pub-id>
</element-citation>
</ref>
<ref id="R210">
<label>210</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Livak</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Schmittgen</surname>
<given-names>T.D.</given-names>
</name>
</person-group>
<article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.</article-title>
<source/>Methods
          <year>2001</year>
<volume>25</volume>
<issue>4</issue>
<fpage>402</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id>
<pub-id pub-id-type="pmid">11846609</pub-id>
</element-citation>
</ref>
<ref id="R211">
<label>211</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bergink</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>van Megen</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Westenberg</surname>
<given-names>H.G.</given-names>
</name>
</person-group>
<article-title>Glutamate and anxiety.</article-title>
<source/>Eur. Neuropsychopharmacol.
          <year>2004</year>
<volume>14</volume>
<issue>3</issue>
<fpage>175</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="doi">10.1016/S0924-977X(03)00100-7</pub-id>
<pub-id pub-id-type="pmid">15056476</pub-id>
</element-citation>
</ref>
<ref id="R212">
<label>212</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fatemi</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Folsom</surname>
<given-names>T.D.</given-names>
</name>
<name>
<surname>Rooney</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Thuras</surname>
<given-names>P.D.</given-names>
</name>
</person-group>
<article-title>mRNA and protein expression for novel GABAA receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway.</article-title>
<source/>Transl. Psychiatry
          <year>2013</year>
<volume>3</volume>
<fpage>e271</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2013.46</pub-id>
<pub-id pub-id-type="pmid">23778581</pub-id>
</element-citation>
</ref>
<ref id="R213">
<label>213</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fatemi</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Folsom</surname>
<given-names>T.D.</given-names>
</name>
<name>
<surname>Kneeland</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Yousefi</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Liesch</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Thuras</surname>
<given-names>P.D.</given-names>
</name>
</person-group>
<article-title>Impairment of fragile X mental retardation protein-metabotropic glutamate receptor 5 signaling and its downstream cognates ras-related C3 botulinum toxin substrate 1, amyloid beta A4 precursor protein, striatal-enriched protein tyrosine phosphatase, and homer 1, in autism: a postmortem study in cerebellar vermis and superior frontal cortex.</article-title>
<source/>Mol. Autism
          <year>2013</year>
<volume>4</volume>
<issue>1</issue>
<fpage>21</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-4-21</pub-id>
<pub-id pub-id-type="pmid">23803181</pub-id>
</element-citation>
</ref>
<ref id="R214">
<label>214</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deschwanden</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Karolewicz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Feyissa</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Treyer</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ametamey</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Johayem</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Burger</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Auberson</surname>
<given-names>Y.P.</given-names>
</name>
<name>
<surname>Sovago</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stockmeier</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Buck</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hasler</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study.</article-title>
<source/>Am. J. Psychiatry
          <year>2011</year>
<volume>168</volume>
<issue>7</issue>
<fpage>727</fpage>
<lpage>734</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2011.09111607</pub-id>
<pub-id pub-id-type="pmid">21498461</pub-id>
</element-citation>
</ref>
<ref id="R215">
<label>215</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newell</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Matosin</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics.</article-title>
<source/>BMC Psychiatry
          <year>2014</year>
<volume>14</volume>
<fpage>23</fpage>
<pub-id pub-id-type="doi">10.1186/1471-244X-14-23</pub-id>
<pub-id pub-id-type="pmid">24472577</pub-id>
</element-citation>
</ref>
<ref id="R216">
<label>216</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tu</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Naisbitt</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Petralia</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Brakeman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Doan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aakalu</surname>
<given-names>V.K.</given-names>
</name>
<name>
<surname>Lanahan</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Worley</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>F Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins.</article-title>
<source/>Neuron
          <year>1999</year>
<volume>23</volume>
<issue>3</issue>
<fpage>583</fpage>
<lpage>592</lpage>
<pub-id pub-id-type="pmid">10433269</pub-id>
</element-citation>
</ref>
<ref id="R217">
<label>217</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stoop</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Conquet</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zuber</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Voronin</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Pralong</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Activation of metabotropic glutamate 5 and NMDA receptors underlies the induction of persistent bursting and associated long-lasting changes in CA3 recurrent connections.</article-title>
<source/>J. Neurosci.
          <year>2003</year>
<volume>23</volume>
<issue>13</issue>
<fpage>5634</fpage>
<lpage>5644</lpage>
<pub-id pub-id-type="pmid">12843266</pub-id>
</element-citation>
</ref>
<ref id="R218">
<label>218</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Homayoun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Stefani</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>B. W.</given-names>
</name>
<name>
<surname>Tamagan</surname>
<given-names>G. D.</given-names>
</name>
<name>
<surname>Moghaddam</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Functional Interaction Between NMDA and
mGlu5 Receptors: Effects on Working Memory, Instrumental
Learning, Motor Behaviors, and Dopamine Release.</article-title>
<source/>Neuropsychopharmacology
          <year>2004</year>
<volume>29</volume>
<issue>7</issue>
<fpage>1259</fpage>
<lpage>69.</lpage>
<pub-id pub-id-type="pmid">15010696</pub-id>
</element-citation>
</ref>
<ref id="R219">
<label>219</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collett</surname>
<given-names>V.J.</given-names>
</name>
<name>
<surname>Collingridge</surname>
<given-names>G.L.</given-names>
</name>
</person-group>
<article-title>Interactions between NMDA receptors and mGlu5 receptors expressed in HEK293 cells.</article-title>
<source/>Br. J. Pharmacol.
          <year>2004</year>
<volume>142</volume>
<issue>6</issue>
<fpage>991</fpage>
<lpage>1001</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjp.0705861</pub-id>
<pub-id pub-id-type="pmid">15210575</pub-id>
</element-citation>
</ref>
<ref id="R220">
<label>220</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turle-Lorenzo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Breysse</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Baunez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Amalric</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson’s disease.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>2005</year>
<volume>179</volume>
<issue>1</issue>
<fpage>117</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-005-2202-x</pub-id>
<pub-id pub-id-type="pmid">15726332</pub-id>
</element-citation>
</ref>
<ref id="R221">
<label>221</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pignatelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Piccinin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Molinaro</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Di Menna</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Riozzi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cannella</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Motolese</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vetere</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Catania</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Battaglia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nisticò</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Changes in mGlu5 receptor-dependent synaptic plasticity and coupling to homer proteins in the hippocampus of Ube3A hemizygous mice modeling angelman syndrome.</article-title>
<source/>J. Neurosci.
          <year>2014</year>
<volume>34</volume>
<issue>13</issue>
<fpage>4558</fpage>
<lpage>4566</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1846-13.2014</pub-id>
<pub-id pub-id-type="pmid">24672001</pub-id>
</element-citation>
</ref>
<ref id="R222">
<label>222</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geddes</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X-F.</given-names>
</name>
<name>
<surname>Newell</surname>
<given-names>K.A.</given-names>
</name>
</person-group>
<article-title>Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia.</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2011</year>
<volume>35</volume>
<issue>4</issue>
<fpage>896</fpage>
<lpage>904</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2011.02.017</pub-id>
<pub-id pub-id-type="pmid">21371516</pub-id>
</element-citation>
</ref>
<ref id="R223">
<label>223</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Tokita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamaji</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
</person-group>
<year>2012</year>
</element-citation>
</ref>
<ref id="R224">
<label>224</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weickert</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Fung</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Catts</surname>
<given-names>V.S.</given-names>
</name>
<name>
<surname>Schofield</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>L.T.</given-names>
</name>
<name>
<surname>Newell</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Pellen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X-F.</given-names>
</name>
<name>
<surname>Catts</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Weickert</surname>
<given-names>T.W.</given-names>
</name>
</person-group>
<article-title>Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia.</article-title>
<source/>Mol. Psychiatry
          <year>2013</year>
<volume>18</volume>
<issue>11</issue>
<fpage>1185</fpage>
<lpage>1192</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2012.137</pub-id>
<pub-id pub-id-type="pmid">23070074</pub-id>
</element-citation>
</ref>
<ref id="R225">
<label>225</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Therapeutic implications for NMDA receptors in mood disorders.</article-title>
<source/>Expert Rev. Neurother.
          <year>2013</year>
<volume>13</volume>
<issue>7</issue>
<fpage>735</fpage>
<lpage>737</lpage>
<pub-id pub-id-type="doi">10.1586/14737175.2013.811894</pub-id>
<pub-id pub-id-type="pmid">23898843</pub-id>
</element-citation>
</ref>
<ref id="R226">
<label>226</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Catania</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Battaglia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Copani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Barbagallo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ceña</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Sanchez-Prieto</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Spano</surname>
<given-names>P.F.</given-names>
</name>
<name>
<surname>Pizzi</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection.</article-title>
<source/>Neuropharmacology
          <year>1999</year>
<volume>38</volume>
<issue>10</issue>
<fpage>1477</fpage>
<lpage>1484</lpage>
<pub-id pub-id-type="pmid">10530809</pub-id>
</element-citation>
</ref>
<ref id="R227">
<label>227</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Battaglia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Busceti</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Molinaro</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Biagioni</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Storto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fornai</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.</article-title>
<source/>J. Neurosci.
          <year>2004</year>
<volume>24</volume>
<issue>4</issue>
<fpage>828</fpage>
<lpage>835</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3831-03.2004</pub-id>
<pub-id pub-id-type="pmid">14749427</pub-id>
</element-citation>
</ref>
<ref id="R228">
<label>228</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindemann</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jaeschke</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Michalon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Honer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Spooren</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hartung</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kolczewski</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Büttelmann</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Flament</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Diener</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gatti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Prinssen</surname>
<given-names>E.P.</given-names>
</name>
<name>
<surname>Parrott</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wettstein</surname>
<given-names>J.G.</given-names>
</name>
</person-group>
<article-title>CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2011</year>
<volume>339</volume>
<issue>2</issue>
<fpage>474</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.111.185660</pub-id>
<pub-id pub-id-type="pmid">21849627</pub-id>
</element-citation>
</ref>
<ref id="R229">
<label>229</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Michalon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sidorov</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ballard</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Ozmen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Spooren</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wettstein</surname>
<given-names>J. G.</given-names>
</name>
<name>
<surname>Jaeschke</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Lindemann</surname>
<given-names>L.</given-names>
</name>
</person-group>
<source/>Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.
          <year>2012</year>
</element-citation>
</ref>
<ref id="R230">
<label>230</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Jørgensen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>B.M.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptor 5-negative allosteric modulators for the treatment of psychiatric and neurological disorders (2009-July 2013).</article-title>
<source/>Pharm. Pat. Anal.
          <year>2013</year>
<volume>2</volume>
<issue>6</issue>
<fpage>767</fpage>
<lpage>802</lpage>
<pub-id pub-id-type="doi">10.4155/ppa.13.58</pub-id>
<pub-id pub-id-type="pmid">24237242</pub-id>
</element-citation>
</ref>
<ref id="R231">
<label>231</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaeschke</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kolczewski</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Spooren</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bitter-Stoll</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Boissin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Büttelmann</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ceccarelli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Clemann</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>David</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Funk</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Guba</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hartung</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Honer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Huwyler</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kuratli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Niederhauser</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Pähler</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>J-U.</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Prinssen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ricci</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rueher</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rueher</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Spurr</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Stoll</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tännler</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wichmann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Wettstein</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Lindemann</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a Promising Novel Medicine for Psychiatric Diseases.</article-title>
<source/>J. Med. Chem.
          <year>2015</year>
<volume>58</volume>
<issue>3</issue>
<fpage>1358</fpage>
<lpage>1371</lpage>
<pub-id pub-id-type="doi">10.1021/jm501642c</pub-id>
<pub-id pub-id-type="pmid">25565255</pub-id>
</element-citation>
</ref>
<ref id="R232">
<label>232</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Stoppel</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Heynen</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Lindemann</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jaeschke</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>M.F.</given-names>
</name>
</person-group>
<article-title>Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion.</article-title>
<source/>Nat. Neurosci.
          <year>2015</year>
<volume>18</volume>
<issue>2</issue>
<fpage>182</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="doi">10.1038/nn.3911</pub-id>
<pub-id pub-id-type="pmid">25581360</pub-id>
</element-citation>
</ref>
<ref id="R233">
<label>233</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindemann</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Scharf</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Kuennecke</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bruns</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>von Kienlin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Paehler</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Funk</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gloge</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Parrott</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Polonchuk</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Niederhauser</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Morairty</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Kilduff</surname>
<given-names>T.S.</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kolczewski</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wichmann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hartung</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Honer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Borroni</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Moreau</surname>
<given-names>J-L.</given-names>
</name>
<name>
<surname>Prinssen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Spooren</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wettstein</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Jaeschke</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Pharmacology of basimglurant (RO4917523, RG7090), a unique mGlu5 negative allosteric modulator in clinical development for depression.</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2015</year>
<volume>353</volume>
<issue>1</issue>
<fpage>213</fpage>
<lpage>233</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.114.222463</pub-id>
<pub-id pub-id-type="pmid">25665805</pub-id>
</element-citation>
</ref>
<ref id="R234">
<label>234</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pecknold</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>McClure</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Appeltauer</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wrzesinski</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Allan</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study.</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>1982</year>
<volume>2</volume>
<issue>2</issue>
<fpage>129</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="pmid">7042771</pub-id>
</element-citation>
</ref>
<ref id="R235">
<label>235</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lapierre</surname>
<given-names>Y.D.</given-names>
</name>
<name>
<surname>Tremblay</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gagnon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Monpremier</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Berliss</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Oyewumi</surname>
<given-names>L.K.</given-names>
</name>
</person-group>
<article-title>A therapeutic and discontinuation study of clobazam and diazepam in anxiety neurosis.</article-title>
<source/>J. Clin. Psychiatry
          <year>1982</year>
<volume>43</volume>
<issue>9</issue>
<fpage>372</fpage>
<lpage>374</lpage>
<pub-id pub-id-type="pmid">6126475</pub-id>
</element-citation>
</ref>
<ref id="R236">
<label>236</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porter</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Jaeschke</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Spooren</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ballard</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Büttelmann</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kolczewski</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>J-U.</given-names>
</name>
<name>
<surname>Prinssen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wichmann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mühlemann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gatti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mutel</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Malherbe</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity.</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2005</year>
<volume>315</volume>
<issue>2</issue>
<fpage>711</fpage>
<lpage>721</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.105.089839</pub-id>
<pub-id pub-id-type="pmid">16040814</pub-id>
</element-citation>
</ref>
<ref id="R237">
<label>237</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spooren</surname>
<given-names>W.P.</given-names>
</name>
<name>
<surname>Vassout</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Neijt</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gasparini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Roux</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Porsolt</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Gentsch</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents.</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2000</year>
<volume>295</volume>
<issue>3</issue>
<fpage>1267</fpage>
<lpage>1275</lpage>
<pub-id pub-id-type="pmid">11082464</pub-id>
</element-citation>
</ref>
<ref id="R238">
<label>238</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tatarczyńska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Klodzińska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chojnacka-Wójcik</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Palucha</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gasparini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist.</article-title>
<source/>Br. J. Pharmacol.
          <year>2001</year>
<volume>132</volume>
<issue>7</issue>
<fpage>1423</fpage>
<lpage>1430</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjp.0703923</pub-id>
<pub-id pub-id-type="pmid">11264235</pub-id>
</element-citation>
</ref>
<ref id="R239">
<label>239</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Need</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Baez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Witkin</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice.</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2006</year>
<volume>319</volume>
<issue>1</issue>
<fpage>254</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.106.103143</pub-id>
<pub-id pub-id-type="pmid">16803860</pub-id>
</element-citation>
</ref>
<ref id="R240">
<label>240</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gasparini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bilbe</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gomez-Mancilla</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Spooren</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>mGluR5 antagonists: discovery, characterization and drug development.</article-title>
<source/>Curr. Opin. Drug Discov. Devel.
          <year>2008</year>
<volume>11</volume>
<issue>5</issue>
<fpage>655</fpage>
<lpage>665</lpage>
</element-citation>
</ref>
<ref id="R241">
<label>241</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C.Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.X.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>D.N.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl) pyridine produces antidepressant effects in rats: role of brain-derived neurotrophic factor.</article-title>
<source/>Neuroscience
          <year>2012</year>
<volume>223</volume>
<fpage>219</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2012.08.010</pub-id>
<pub-id pub-id-type="pmid">22890078</pub-id>
</element-citation>
</ref>
<ref id="R242">
<label>242</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Nordquist</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Durkin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jaeschke</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Spooren</surname>
<given-names>W.</given-names>
</name>
</person-group>
<source/>Stress-induced hyperthermia: effects of acute and repeated dosing of MPEP.
          <year>2007</year>
</element-citation>
</ref>
<ref id="R243">
<label>243</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kłodzińska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tatarczyńska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Chojnacka-Wójcik</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Anxiolytic-like effects of group I metabotropic glutamate antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) in rats.</article-title>
<source/>Pol. J. Pharmacol.
          <year>2000</year>
<volume>52</volume>
<issue>6</issue>
<fpage>463</fpage>
<lpage>466</lpage>
<pub-id pub-id-type="pmid">11334240</pub-id>
</element-citation>
</ref>
<ref id="R244">
<label>244</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kłodzińska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brański</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pałucha</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Szewczyk</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Tatarczyńska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Chojnacka-Wójcik</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wierońska</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats.</article-title>
<source/>Neuropharmacology
          <year>2002</year>
<volume>43</volume>
<issue>2</issue>
<fpage>181</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="pmid">12213272</pub-id>
</element-citation>
</ref>
<ref id="R245">
<label>245</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brodkin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Busse</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sukoff</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Varney</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone.</article-title>
<source/>Pharmacol. Biochem. Behav.
          <year>2002</year>
<volume>73</volume>
<issue>2</issue>
<fpage>359</fpage>
<lpage>366</lpage>
<pub-id pub-id-type="pmid">12117590</pub-id>
</element-citation>
</ref>
<ref id="R246">
<label>246</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cosford</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Roppe</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tehrani</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Schweiger</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Seiders</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Chaudary</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Varney</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>[3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor.</article-title>
<source/>Bioorg. Med. Chem. Lett.
          <year>2003</year>
<volume>13</volume>
<issue>3</issue>
<fpage>351</fpage>
<lpage>354</lpage>
<pub-id pub-id-type="pmid">12565928</pub-id>
</element-citation>
</ref>
<ref id="R247">
<label>247</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klodzinska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tatarczyńska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Chojnacka-Wójcik</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cosford</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling.</article-title>
<source/>Neuropharmacology
          <year>2004</year>
<volume>47</volume>
<issue>3</issue>
<fpage>342</fpage>
<lpage>350</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2004.04.013</pub-id>
<pub-id pub-id-type="pmid">15275823</pub-id>
</element-citation>
</ref>
<ref id="R248">
<label>248</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molina-Hernández</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tellez-Alcántara</surname>
<given-names>N.P.</given-names>
</name>
<name>
<surname>Pérez-García</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Olivera-Lopez</surname>
<given-names>J.I.</given-names>
</name>
<name>
<surname>Jaramillo</surname>
<given-names>M.T.</given-names>
</name>
</person-group>
<article-title>Antidepressant-like and anxiolytic-like actions of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of male Wistar rats.</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2006</year>
<volume>30</volume>
<issue>6</issue>
<fpage>1129</fpage>
<lpage>1135</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2006.04.022</pub-id>
<pub-id pub-id-type="pmid">16759778</pub-id>
</element-citation>
</ref>
<ref id="R249">
<label>249</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pomierny-Chamioło</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Poleszak</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>NMDA but not AMPA glutamatergic receptors are involved in the antidepressant-like activity of MTEP during the forced swim test in mice.</article-title>
<source/>Pharmacol. Rep.
          <year>2010</year>
<volume>62</volume>
<issue>6</issue>
<fpage>1186</fpage>
<lpage>1190</lpage>
<pub-id pub-id-type="pmid">21273676</pub-id>
</element-citation>
</ref>
<ref id="R250">
<label>250</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tichá</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mikulecká</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mareš</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Behavioral consequences of the mGlu5 receptor antagonist MTEP in immature rats.</article-title>
<source/>Pharmacol. Biochem. Behav.
          <year>2011</year>
<volume>99</volume>
<issue>4</issue>
<fpage>619</fpage>
<lpage>625</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2011.06.007</pub-id>
<pub-id pub-id-type="pmid">21703298</pub-id>
</element-citation>
</ref>
<ref id="R251">
<label>251</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Belozertseva</surname>
<given-names>I. V</given-names>
</name>
<name>
<surname>Kos</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Popik</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Danysz</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Bespalov</surname>
<given-names>A. Y.</given-names>
</name>
</person-group>
<source/>Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests.
          <year>2007</year>
</element-citation>
</ref>
<ref id="R252">
<label>252</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pałucha</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brański</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Szewczyk</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wierońska</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Kłak</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist.</article-title>
<source/>Pharmacol. Biochem. Behav.
          <year>2005</year>
<volume>81</volume>
<issue>4</issue>
<fpage>901</fpage>
<lpage>906</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2005.06.015</pub-id>
<pub-id pub-id-type="pmid">16040106</pub-id>
</element-citation>
</ref>
<ref id="R253">
<label>253</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindsley</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Emmitte</surname>
<given-names>K.A.</given-names>
</name>
</person-group>
<article-title>Recent progress in the discovery and development of negative allosteric modulators of mGluR5.</article-title>
<source/>Curr. Opin. Drug Discov. Devel.
          <year>2009</year>
<volume>12</volume>
<issue>4</issue>
<fpage>446</fpage>
<lpage>457</lpage>
</element-citation>
</ref>
<ref id="R254">
<label>254</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Hughes</surname>
<given-names>Z. A.</given-names>
</name>
<name>
<surname>Neal</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Sukoff Rizzo</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Pulicicchio</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Lotarski</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dwyer</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Brennan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Olsen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bender</surname>
<given-names>C. N.</given-names>
</name>
<name>
<surname>Kouranova</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Andree</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Whiteside</surname>
<given-names>G. T.</given-names>
</name>
<name>
<surname>Springer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>O'Neil</surname>
<given-names>S. V.</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Schechter</surname>
<given-names>L. E.</given-names>
</name>
<name>
<surname>Dunlop</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rosenzweig-Lipson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ring</surname>
<given-names>R. H.</given-names>
</name>
</person-group>
<source/>Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression.
          <year>2013</year>
</element-citation>
</ref>
<ref id="R255">
<label>255</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vranesic</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ofner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Flor</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Bilbe</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bouhelal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Enz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Desrayaud</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McAllister</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gasparini</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>AFQ056/ mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization.</article-title>
<source/>Bioorg. Med. Chem.
          <year>2014</year>
<volume>22</volume>
<issue>21</issue>
<fpage>5790</fpage>
<lpage>5803</lpage>
<pub-id pub-id-type="doi">10.1016/j.bmc.2014.09.033</pub-id>
<pub-id pub-id-type="pmid">25316499</pub-id>
</element-citation>
</ref>
<ref id="R256">
<label>256</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Gomez-Mancilla</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>von Raison</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Apostol</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ufer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gasparini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
</person-group>
<source/>Expert Opin.
          <year>2014</year>
</element-citation>
</ref>
<ref id="R257">
<label>257</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Rascol</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gasparini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kenney</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Di Paolo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gomez-Mancilla</surname>
<given-names>B.</given-names>
</name>
</person-group>
<year>2014</year>
</element-citation>
</ref>
<ref id="R258">
<label>258</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrov</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pedros</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>de Lemos</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Pallàs</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Canudas</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Lazarowski</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Beas-Zarate</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Auladell</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Folch</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Camins</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Mavoglurant as a treatment for Parkinson’s disease.</article-title>
<source/>Expert Opin. Investig. Drugs
          <year>2014</year>
<volume>23</volume>
<issue>8</issue>
<fpage>1165</fpage>
<lpage>1179</lpage>
<pub-id pub-id-type="doi">10.1517/13543784.2014.931370</pub-id>
</element-citation>
</ref>
<ref id="R259">
<label>259</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quiroz</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Tamburri</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Deptula</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Banken</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Beyer</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Fontoura</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Santarelli</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomised, double-blind, placebo-controlled study.</article-title>
<source/>Eur. Neuropsychopharmacol.
          <year>2015</year>
<volume>24</volume>
<fpage>S468</fpage>
<pub-id pub-id-type="doi">10.1016/S0924-977X(14)70748-5</pub-id>
</element-citation>
</ref>
<ref id="R260">
<label>260</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michalon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bruns</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Risterucci</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Honer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ballard</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Ozmen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jaeschke</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wettstein</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>von Kienlin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Künnecke</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lindemann</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice.</article-title>
<source/>Biol. Psychiatry
          <year>2014</year>
<volume>75</volume>
<issue>3</issue>
<fpage>189</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2013.05.038</pub-id>
<pub-id pub-id-type="pmid">23910948</pub-id>
</element-citation>
</ref>
<ref id="R261">
<label>261</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodrigues</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>E.P.</given-names>
</name>
<name>
<surname>Farb</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Schafe</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>LeDoux</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>The group I metabotropic glutamate receptor mGluR5 is required for fear memory formation and long-term potentiation in the lateral amygdala.</article-title>
<source/>J. Neurosci.
          <year>2002</year>
<volume>22</volume>
<issue>12</issue>
<fpage>5219</fpage>
<lpage>5229</lpage>
<pub-id pub-id-type="pmid">12077217</pub-id>
</element-citation>
</ref>
<ref id="R262">
<label>262</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fendt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptors are involved in amygdaloid plasticity.</article-title>
<source/>Eur. J. Neurosci.
          <year>2002</year>
<volume>15</volume>
<issue>9</issue>
<fpage>1535</fpage>
<lpage>1541</lpage>
<pub-id pub-id-type="pmid">12028364</pub-id>
</element-citation>
</ref>
<ref id="R263">
<label>263</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riedel</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Casabona</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Platt</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Macphail</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Fear conditioning-induced time- and subregion-specific increase in expression of mGlu5 receptor protein in rat hippocampus.</article-title>
<source/>Neuropharmacology
          <year>2000</year>
<volume>39</volume>
<issue>11</issue>
<fpage>1943</fpage>
<lpage>1951</lpage>
<pub-id pub-id-type="pmid">10963738</pub-id>
</element-citation>
</ref>
<ref id="R264">
<label>264</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Page</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Szeliga</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gasparini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Blockade of the mGlu5 receptor decreases basal and stress-induced cortical norepinephrine in rodents.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>2005</year>
<volume>179</volume>
<issue>1</issue>
<fpage>240</fpage>
<lpage>246</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-005-2142-5</pub-id>
<pub-id pub-id-type="pmid">15717212</pub-id>
</element-citation>
</ref>
<ref id="R265">
<label>265</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tatarczyńska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kłodzińska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kroczka</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chojnacka-Wójcik</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>2001</year>
<volume>158</volume>
<issue>1</issue>
<fpage>94</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="doi">10.1007/s002130100798</pub-id>
<pub-id pub-id-type="pmid">11685389</pub-id>
</element-citation>
</ref>
<ref id="R266">
<label>266</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steckler</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Van Dyck</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Van Craenendonck</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mateus</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Langlois</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lesage</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Prickaerts</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial Water maze task.</article-title>
<source/>Behav. Brain Res.
          <year>2005</year>
<volume>164</volume>
<issue>1</issue>
<fpage>52</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2005.05.010</pub-id>
<pub-id pub-id-type="pmid">16043241</pub-id>
</element-citation>
</ref>
<ref id="R267">
<label>267</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varty</surname>
<given-names>G.B.</given-names>
</name>
<name>
<surname>Grilli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Forlani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fredduzzi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Grzelak</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Guthrie</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Hodgson</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>S.X.</given-names>
</name>
<name>
<surname>Nicolussi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pond</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Hunter</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Higgins</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Reggiani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bertorelli</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>2005</year>
<volume>179</volume>
<issue>1</issue>
<fpage>207</fpage>
<lpage>217</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-005-2143-4</pub-id>
<pub-id pub-id-type="pmid">15682298</pub-id>
</element-citation>
</ref>
<ref id="R268">
<label>268</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rorick-Kehn</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>McKinzie</surname>
<given-names>D.L.</given-names>
</name>
</person-group>
<article-title>Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>2005</year>
<volume>183</volume>
<issue>2</issue>
<fpage>226</fpage>
<lpage>240</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-005-0169-2</pub-id>
<pub-id pub-id-type="pmid">16175401</pub-id>
</element-citation>
</ref>
<ref id="R269">
<label>269</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Satow</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Maehara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ise</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hikichi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fukushima</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tanak</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kawamoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ohta</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 anatagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2008</year>
<volume>326</volume>
<issue>2</issue>
<fpage>577</fpage>
<lpage>586</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.108.138107</pub-id>
<pub-id pub-id-type="pmid">18487514</pub-id>
</element-citation>
</ref>
<ref id="R270">
<label>270</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nielsen</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Macphail</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Riedel</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Class I mGlu receptor antagonist 1-aminoindan-1,5-dicarboxylic acid blocks contextual but not cue conditioning in rats.</article-title>
<source/>Eur. J. Pharmacol.
          <year>1997</year>
<volume>326</volume>
<issue>2-3</issue>
<fpage>105</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="pmid">9196260</pub-id>
</element-citation>
</ref>
<ref id="R271">
<label>271</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simonyi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Serfozo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Shelat</surname>
<given-names>P.B.</given-names>
</name>
<name>
<surname>Dopheide</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Coulibaly</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Schachtman</surname>
<given-names>T.R.</given-names>
</name>
</person-group>
<article-title>Differential roles of hippocampal metabotropic glutamate receptors 1 and 5 in inhibitory avoidance learning.</article-title>
<source/>Neurobiol. Learn. Mem.
          <year>2007</year>
<volume>88</volume>
<issue>3</issue>
<fpage>305</fpage>
<lpage>311</lpage>
<pub-id pub-id-type="doi">10.1016/j.nlm.2007.04.012</pub-id>
<pub-id pub-id-type="pmid">17548216</pub-id>
</element-citation>
</ref>
<ref id="R272">
<label>272</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Geum</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Blockade of amygdala metabotropic glutamate receptor subtype 1 impairs fear extinction.</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2007</year>
<volume>355</volume>
<issue>1</issue>
<fpage>188</fpage>
<lpage>193</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2007.01.125</pub-id>
<pub-id pub-id-type="pmid">17292864</pub-id>
</element-citation>
</ref>
<ref id="R273">
<label>273</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gil-Sanz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Delgado-García</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Fairén</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gruart</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Involvement of the mGluR1 receptor in hippocampal synaptic plasticity and associative learning in behaving mice.</article-title>
<source/>Cereb. Cortex
          <year>2008</year>
<volume>18</volume>
<issue>7</issue>
<fpage>1653</fpage>
<lpage>1663</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/bhm193</pub-id>
<pub-id pub-id-type="pmid">18024992</pub-id>
</element-citation>
</ref>
<ref id="R274">
<label>274</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conquet</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bashir</surname>
<given-names>Z.I.</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Daniel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ferraguti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bordi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Franz-Bacon</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Reggiani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Matarese</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Condé</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1.</article-title>
<source/>Nature
          <year>1994</year>
<volume>372</volume>
<issue>6503</issue>
<fpage>237</fpage>
<lpage>243</lpage>
<pub-id pub-id-type="doi">10.1038/372237a0</pub-id>
<pub-id pub-id-type="pmid">7969468</pub-id>
</element-citation>
</ref>
<ref id="R275">
<label>275</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aiba</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Stanton</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>G.D.</given-names>
</name>
<name>
<surname>Herrup</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zwingman</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Tonegawa</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice.</article-title>
<source/>Cell
          <year>1994</year>
<volume>79</volume>
<issue>2</issue>
<fpage>377</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="pmid">7954803</pub-id>
</element-citation>
</ref>
<ref id="R276">
<label>276</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aiba</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Herrup</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rosenmund</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Tonegawa</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Reduced hippocampal long-term potentiation and context-specific deficit in associative learning in mGluR1 mutant mice.</article-title>
<source/>Cell
          <year>1994</year>
<volume>79</volume>
<issue>2</issue>
<fpage>365</fpage>
<lpage>375</lpage>
<pub-id pub-id-type="pmid">7954802</pub-id>
</element-citation>
</ref>
<ref id="R277">
<label>277</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Lesage</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Steckler</surname>
<given-names>T.</given-names>
</name>
</person-group>
<source/>Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness.
          <year>2010</year>
</element-citation>
</ref>
<ref id="R278">
<label>278</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Wheeler</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Ornstein</surname>
<given-names>P.L.</given-names>
</name>
<name>
<surname>Schoepp</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>[3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain.</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2001</year>
<volume>298</volume>
<issue>2</issue>
<fpage>453</fpage>
<lpage>460</lpage>
<pub-id pub-id-type="pmid">11454905</pub-id>
</element-citation>
</ref>
<ref id="R279">
<label>279</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wierońska</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Legutko</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dudys</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Olfactory bulbectomy and amitriptyline treatment influences mGlu receptors expression in the mouse brain hippocampus.</article-title>
<source/>Pharmacol. Rep.
          <year>2008</year>
<volume>60</volume>
<issue>6</issue>
<fpage>844</fpage>
<lpage>855</lpage>
<pub-id pub-id-type="pmid">19211976</pub-id>
</element-citation>
</ref>
<ref id="R280">
<label>280</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matrisciano</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Caruso</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Orlando</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Marchiafava</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Battaglia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gruber</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Melchiorri</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tatarelli</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Girardi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mathè</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats.</article-title>
<source/>Neuropharmacology
          <year>2008</year>
<volume>55</volume>
<issue>4</issue>
<fpage>525</fpage>
<lpage>531</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.05.014</pub-id>
<pub-id pub-id-type="pmid">18590921</pub-id>
</element-citation>
</ref>
<ref id="R281">
<label>281</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feyissa</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Woolverton</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Miguel-Hidalgo</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Kyle</surname>
<given-names>P.B.</given-names>
</name>
<name>
<surname>Hasler</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Stockmeier</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Iyo</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Karolewicz</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression.</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2010</year>
<volume>34</volume>
<issue>2</issue>
<fpage>279</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2009.11.018</pub-id>
<pub-id pub-id-type="pmid">19945495</pub-id>
</element-citation>
</ref>
<ref id="R282">
<label>282</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monn</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Valli</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Massey</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Salhoff</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>B.G.</given-names>
</name>
<name>
<surname>Howe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Alt</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Rhodes</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Robey</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Griffey</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Tizzano</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Kallman</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Helton</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Schoepp</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties.</article-title>
<source/>J. Med. Chem.
          <year>1997</year>
<volume>40</volume>
<issue>4</issue>
<fpage>528</fpage>
<lpage>537</lpage>
<pub-id pub-id-type="doi">10.1021/jm9606756</pub-id>
<pub-id pub-id-type="pmid">9046344</pub-id>
</element-citation>
</ref>
<ref id="R283">
<label>283</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Linden</surname>
<given-names>A-M.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Bergeron</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schoepp</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions.</article-title>
<source/>Neuropsychopharmacology
          <year>2004</year>
<volume>29</volume>
<issue>3</issue>
<fpage>502</fpage>
<lpage>513</lpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1300321</pub-id>
<pub-id pub-id-type="pmid">14694349</pub-id>
</element-citation>
</ref>
<ref id="R284">
<label>284</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Linden</surname>
<given-names>A-M.</given-names>
</name>
<name>
<surname>Shannon</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Baez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Koester</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schoepp</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>2005</year>
<volume>179</volume>
<issue>1</issue>
<fpage>284</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-004-2098-x</pub-id>
<pub-id pub-id-type="pmid">15619115</pub-id>
</element-citation>
</ref>
<ref id="R285">
<label>285</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Rorick-Kehn</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Perkins</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Knitowski</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>B. G.</given-names>
</name>
<name>
<surname>Schoepp</surname>
<given-names>D. D.</given-names>
</name>
<name>
<surname>McKinzie</surname>
<given-names>D. L.</given-names>
</name>
</person-group>
<year>2006</year>
</element-citation>
</ref>
<ref id="R286">
<label>286</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rorick-Kehn</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>B.G.</given-names>
</name>
<name>
<surname>Burkey</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Calligaro</surname>
<given-names>D.O.</given-names>
</name>
<name>
<surname>Marek</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Nisenbaum</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Catlow</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Kingston</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Giera</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Herin</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Monn</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>McKinzie</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Schoepp</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid.</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2007</year>
<volume>321</volume>
<issue>1</issue>
<fpage>308</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.106.110809</pub-id>
<pub-id pub-id-type="pmid">17204749</pub-id>
</element-citation>
</ref>
<ref id="R287">
<label>287</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schoepp</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Gaydos</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Potter</surname>
<given-names>W.Z.</given-names>
</name>
</person-group>
<article-title>LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress.</article-title>
<source/>Stress
          <year>2003</year>
<volume>6</volume>
<issue>3</issue>
<fpage>189</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="doi">10.1080/1025389031000146773</pub-id>
<pub-id pub-id-type="pmid">13129812</pub-id>
</element-citation>
</ref>
<ref id="R288">
<label>288</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matrisciano</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Panaccione</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Zusso</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Giusti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tatarelli</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Iacovelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mathé</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Gruber</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Girardi</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: a new strategy to shorten the latency of antidepressant medication?</article-title>
<source/>Mol. Psychiatry
          <year>2007</year>
<volume>12</volume>
<issue>8</issue>
<fpage>704</fpage>
<lpage>706</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4002005</pub-id>
<pub-id pub-id-type="pmid">17653204</pub-id>
</element-citation>
</ref>
<ref id="R289">
<label>289</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matrisciano</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zusso</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Panaccione</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Turriziani</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Caruso</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Iacovelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Noviello</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Togna</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Melchiorri</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Debetto</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tatarelli</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Battaglia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Giusti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Girardi</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Synergism between fluoxetine and the mGlu2/3 receptor agonist, LY379268, in an <italic>in vitro</italic> model for antidepressant drug-induced neurogenesis.</article-title>
<source/>Neuropharmacology
          <year>2008</year>
<volume>54</volume>
<issue>2</issue>
<fpage>428</fpage>
<lpage>437</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2007.10.020</pub-id>
<pub-id pub-id-type="pmid">18082849</pub-id>
</element-citation>
</ref>
<ref id="R290">
<label>290</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Wierońska</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Stachowicz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Brański</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pałucha-Poniewiera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<source/>On the mechanism of anti-hyperthermic effects of LY379268 and LY487379, group II mGlu receptors activators, in the stress-induced hyperthermia in singly housed mice.
          <year>2012</year>
</element-citation>
</ref>
<ref id="R291">
<label>291</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fell</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Svensson</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>B.G.</given-names>
</name>
<name>
<surname>Schoepp</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo [3.1.0]hexane-4,6-dicarboxylic acid (LY404039).</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2008</year>
<volume>326</volume>
<issue>1</issue>
<fpage>209</fpage>
<lpage>217</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.108.136861</pub-id>
<pub-id pub-id-type="pmid">18424625</pub-id>
</element-citation>
</ref>
<ref id="R292">
<label>292</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woolley</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Pemberton</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Bate</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Corti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>D.N.</given-names>
</name>
</person-group>
<article-title>The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>2008</year>
<volume>196</volume>
<issue>3</issue>
<fpage>431</fpage>
<lpage>440</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-007-0974-x</pub-id>
<pub-id pub-id-type="pmid">18057917</pub-id>
</element-citation>
</ref>
<ref id="R293">
<label>293</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trabanco</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Cid</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Lavreysen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Macdonald</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Tresadern</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Progress in the developement of positive allosteric modulators of the metabotropic glutamate receptor 2.</article-title>
<source/>Curr. Med. Chem.
          <year>2011</year>
<volume>18</volume>
<issue>1</issue>
<fpage>47</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="pmid">21110815</pub-id>
</element-citation>
</ref>
<ref id="R294">
<label>294</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trabanco</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Cid</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>mGluR2 positive allosteric modulators: a patent review (2009 - present).</article-title>
<source/>Expert Opin. Ther. Pat.
          <year>2013</year>
<volume>23</volume>
<issue>5</issue>
<fpage>629</fpage>
<lpage>647</lpage>
<pub-id pub-id-type="doi">10.1517/13543776.2013.777043</pub-id>
<pub-id pub-id-type="pmid">23452205</pub-id>
</element-citation>
</ref>
<ref id="R295">
<label>295</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fell</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Witkin</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Falcone</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Katner</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rorick-Kehn</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Overshiner</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Rasmussen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chaney</surname>
<given-names>S.F.</given-names>
</name>
<name>
<surname>Benvenga</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Marlow</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Luecke</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Wafford</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Seidel</surname>
<given-names>W.F.</given-names>
</name>
<name>
<surname>Edgar</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Quets</surname>
<given-names>A.T.</given-names>
</name>
</person-group>
<article-title>Felder, Christian C.; Wang, X.; Heinz, B. A.; Nikolayev, A.; Kuo, M.-S.; Mayhugh, D.; Khilevich, A.; Zhang, D.; Ebert, P. J.; Eckstein, J. A.; Ackermann, B. L.; Swanson, S. P.; Catlow, J. T.; Dean, R. A.; Jackson, K.; Tauscher-Wisniewski, S.; Marek, G. J.; Schkeryantz, J. M.; Svensson, K. A. N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes.</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2011</year>
<volume>336</volume>
<issue>1</issue>
<fpage>165</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.110.172957</pub-id>
<pub-id pub-id-type="pmid">20947638</pub-id>
</element-citation>
</ref>
<ref id="R296">
<label>296</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Malchow</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Falkai</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.</article-title>
<source/>Eur. Arch. Psychiatry Clin. Neurosci.
          <year>2013</year>
<volume>263</volume>
<issue>5</issue>
<fpage>367</fpage>
<lpage>377</lpage>
<pub-id pub-id-type="doi">10.1007/s00406-013-0399-y</pub-id>
<pub-id pub-id-type="pmid">23455590</pub-id>
</element-citation>
</ref>
<ref id="R297">
<label>297</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hopkins</surname>
<given-names>C.R.</given-names>
</name>
</person-group>
<article-title>Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia?</article-title>
<source/>ACS Chem. Neurosci.
          <year>2013</year>
<volume>4</volume>
<issue>2</issue>
<fpage>211</fpage>
<lpage>213</lpage>
<pub-id pub-id-type="doi">10.1021/cn400023y</pub-id>
<pub-id pub-id-type="pmid">23421671</pub-id>
</element-citation>
</ref>
<ref id="R298">
<label>298</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galici</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>C.K.</given-names>
</name>
<name>
<surname>Hemstapat</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Echemendia</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>de Paulis</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Conn</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2006</year>
<volume>318</volume>
<issue>1</issue>
<fpage>173</fpage>
<lpage>185</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.106.102046</pub-id>
<pub-id pub-id-type="pmid">16608916</pub-id>
</element-citation>
</ref>
<ref id="R299">
<label>299</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hirota</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shimazaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kawashima</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yoshimizu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yasuhara</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sakagami</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Okuyama</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nakazato</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.</article-title>
<source/>Neuropharmacology
          <year>2004</year>
<volume>46</volume>
<issue>4</issue>
<fpage>457</fpage>
<lpage>467</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2003.10.009</pub-id>
<pub-id pub-id-type="pmid">14975669</pub-id>
</element-citation>
</ref>
<ref id="R300">
<label>300</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pałucha-Poniewiera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wierońska</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Brański</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Stachowicz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>On the mechanism of the
antidepressant-like action of group II mGlu receptor antagonist,
MGS0039.</article-title>
<source/>Psychopharmacology (Berl).
          <year>2010</year>
<volume>212</volume>
<issue>4</issue>
<fpage>523</fpage>
<lpage>35.</lpage>
<pub-id pub-id-type="pmid">20703449</pub-id>
</element-citation>
</ref>
<ref id="R301">
<label>301</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshimizu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shimazaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chaki</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>2006</year>
<volume>186</volume>
<issue>4</issue>
<fpage>587</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-006-0390-7</pub-id>
<pub-id pub-id-type="pmid">16612616</pub-id>
</element-citation>
</ref>
<ref id="R302">
<label>302</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Kawasaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ago</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yano</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Araki</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Washida</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Onoe</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nakazato</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Baba</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Takuma</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Matsuda</surname>
<given-names>T.</given-names>
</name>
</person-group>
<source/>Increased binding of cortical and hippocampal group II metabotropic glutamate receptors in isolation-reared mice.
          <year>2011</year>
</element-citation>
</ref>
<ref id="R303">
<label>303</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Ago</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yano</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Araki</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hiramatsu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kita</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kawasaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Onoe</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nakazato</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Baba</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Takuma</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Matsuda</surname>
<given-names>T.</given-names>
</name>
</person-group>
<year>2013</year>
</element-citation>
</ref>
<ref id="R304">
<label>304</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iijima</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shimazaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chaki</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Effects of metabotropic glutamate 2/3 receptor antagonists in the stress-induced hyperthermia test in singly housed mice.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>2007</year>
<volume>190</volume>
<issue>2</issue>
<fpage>233</fpage>
<lpage>239</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-006-0618-6</pub-id>
<pub-id pub-id-type="pmid">17102982</pub-id>
</element-citation>
</ref>
<ref id="R305">
<label>305</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimazaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Iijima</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chaki</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test.</article-title>
<source/>Eur. J. Pharmacol.
          <year>2004</year>
<volume>501</volume>
<issue>1-3</issue>
<fpage>121</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2004.08.016</pub-id>
<pub-id pub-id-type="pmid">15464070</pub-id>
</element-citation>
</ref>
<ref id="R306">
<label>306</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bespalov</surname>
<given-names>A.Y.</given-names>
</name>
<name>
<surname>van Gaalen</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Sukhotina</surname>
<given-names>I.A.</given-names>
</name>
<name>
<surname>Wicke</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mezler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schoemaker</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression.</article-title>
<source/>Eur. J. Pharmacol.
          <year>2008</year>
<volume>592</volume>
<issue>1-3</issue>
<fpage>96</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2008.06.089</pub-id>
<pub-id pub-id-type="pmid">18634781</pub-id>
</element-citation>
</ref>
<ref id="R307">
<label>307</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campo</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kalinichev</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lambeng</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>El Yacoubi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Royer-Urios</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Legrand</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Parron</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Girard</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bessif</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Poli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vaugeois</surname>
<given-names>J-M.</given-names>
</name>
<name>
<surname>Le Poul</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Celanire</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression.</article-title>
<source/>J. Neurogenet.
          <year>2011</year>
<volume>25</volume>
<issue>4</issue>
<fpage>152</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="doi">10.3109/01677063.2011.627485</pub-id>
<pub-id pub-id-type="pmid">22091727</pub-id>
</element-citation>
</ref>
<ref id="R308">
<label>308</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dwyer</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Lepack</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Duman</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure.</article-title>
<source/>J. Mol. Psychiatry
          <year>2013</year>
<volume>1</volume>
<issue>1</issue>
<fpage>15</fpage>
<pub-id pub-id-type="doi">10.1186/2049-9256-1-15</pub-id>
<pub-id pub-id-type="pmid">25408908</pub-id>
</element-citation>
</ref>
<ref id="R309">
<label>309</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Celanire</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sebhat</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Wichmann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gatti</surname>
<given-names>S.</given-names>
</name>
</person-group>
<year>2015</year>
</element-citation>
</ref>
<ref id="R310">
<label>310</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schoepp</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Jane</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Monn</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Pharmacological agents acting at subtypes of metabotropic glutamate receptors.</article-title>
<source/>Neuropharmacology
          <year>1999</year>
<volume>38</volume>
<issue>10</issue>
<fpage>1431</fpage>
<lpage>1476</lpage>
<pub-id pub-id-type="pmid">10530808</pub-id>
</element-citation>
</ref>
<ref id="R311">
<label>311</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Semyanov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kullmann</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Modulation of GABAergic signaling among interneurons by metabotropic glutamate receptors.</article-title>
<source/>Neuron
          <year>2000</year>
<volume>25</volume>
<issue>3</issue>
<fpage>663</fpage>
<lpage>672</lpage>
<pub-id pub-id-type="pmid">10774733</pub-id>
</element-citation>
</ref>
<ref id="R312">
<label>312</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drew</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>V.A.</given-names>
</name>
<name>
<surname>Vaughan</surname>
<given-names>C.W.</given-names>
</name>
</person-group>
<article-title>Glutamate spillover modulates GABAergic synaptic transmission in the rat midbrain periaqueductal grey via metabotropic glutamate receptors and endocannabinoid signaling.</article-title>
<source/>J. Neurosci.
          <year>2008</year>
<volume>28</volume>
<issue>4</issue>
<fpage>808</fpage>
<lpage>815</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4876-07.2008</pub-id>
<pub-id pub-id-type="pmid">18216189</pub-id>
</element-citation>
</ref>
<ref id="R313">
<label>313</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macinnes</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Duty</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Group III metabotropic glutamate receptors act as hetero-receptors modulating evoked GABA release in the globus pallidus in vivo.</article-title>
<source/>Eur. J. Pharmacol.
          <year>2008</year>
<volume>580</volume>
<issue>1-2</issue>
<fpage>95</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2007.10.030</pub-id>
<pub-id pub-id-type="pmid">18035348</pub-id>
</element-citation>
</ref>
<ref id="R314">
<label>314</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farazifard</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.H.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptors modulate glutamatergic and GABAergic synaptic transmission in the central nucleus of the inferior colliculus.</article-title>
<source/>Brain Res.
          <year>2010</year>
<volume>1325</volume>
<fpage>28</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2010.02.021</pub-id>
<pub-id pub-id-type="pmid">20153735</pub-id>
</element-citation>
</ref>
<ref id="R315">
<label>315</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guimarães-Souza</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Calaza</surname>
<given-names>K.C.</given-names>
</name>
</person-group>
<article-title>Selective activation of group III metabotropic glutamate receptor subtypes produces different patterns of γ-aminobutyric acid immunoreactivity and glutamate release in the retina.</article-title>
<source/>J. Neurosci. Res.
          <year>2012</year>
<volume>90</volume>
<issue>12</issue>
<fpage>2349</fpage>
<lpage>2361</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.23123</pub-id>
<pub-id pub-id-type="pmid">22987212</pub-id>
</element-citation>
</ref>
<ref id="R316">
<label>316</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Summa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Di Prisco</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Grilli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Usai</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Marchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pittaluga</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Presynaptic mGlu7 receptors control GABA release in mouse hippocampus.</article-title>
<source/>Neuropharmacology
          <year>2013</year>
<volume>66</volume>
<fpage>215</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.04.020</pub-id>
<pub-id pub-id-type="pmid">22564442</pub-id>
</element-citation>
</ref>
<ref id="R317">
<label>317</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>I-S.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptors inhibit GABA release in rat histamine neurons.</article-title>
<source/>Neurosci. Lett.
          <year>2014</year>
<volume>579</volume>
<fpage>106</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2014.07.022</pub-id>
<pub-id pub-id-type="pmid">25062585</pub-id>
</element-citation>
</ref>
<ref id="R318">
<label>318</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tatarczyńska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pałucha</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Szewczyk</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chojnacka-Wójcik</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wierońska</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Anxiolytic- and antidepressant-like effects of group III metabotropic glutamate agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in rats.</article-title>
<source/>Pol. J. Pharmacol.
          <year>2002</year>
<volume>54</volume>
<issue>6</issue>
<fpage>707</fpage>
<lpage>710</lpage>
<pub-id pub-id-type="pmid">12866729</pub-id>
</element-citation>
</ref>
<ref id="R319">
<label>319</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stachowicz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kłodzińska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Palucha-Poniewiera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Neuville</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<source/>The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems.
          <year>2009</year>
</element-citation>
</ref>
<ref id="R320">
<label>320</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pałucha</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tatarczyńska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Brański</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Szewczyk</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wierońska</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Kłak</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chojnacka-Wójcik</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats.</article-title>
<source/>Neuropharmacology
          <year>2004</year>
<volume>46</volume>
<issue>2</issue>
<fpage>151</fpage>
<lpage>159</lpage>
<pub-id pub-id-type="pmid">14680755</pub-id>
</element-citation>
</ref>
<ref id="R321">
<label>321</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kłak</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pałucha</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brański</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sowa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats.</article-title>
<source/>Amino Acids
          <year>2007</year>
<volume>32</volume>
<issue>2</issue>
<fpage>169</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.1007/s00726-006-0316-z</pub-id>
<pub-id pub-id-type="pmid">16868652</pub-id>
</element-citation>
</ref>
<ref id="R322">
<label>322</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stachowicz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kłak</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kłodzińska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chojnacka-Wojcik</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats.</article-title>
<source/>Eur. J. Pharmacol.
          <year>2004</year>
<volume>498</volume>
<issue>1-3</issue>
<fpage>153</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2004.07.001</pub-id>
<pub-id pub-id-type="pmid">15363989</pub-id>
</element-citation>
</ref>
<ref id="R323">
<label>323</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niswender</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>C. K.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Marlo</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>de Paulis</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Days</surname>
<given-names>E. L.</given-names>
</name>
<name>
<surname>Nalywajko</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Ayala</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lindsley</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Conn</surname>
<given-names>P. J.</given-names>
</name>
</person-group>
<article-title>Opposing roles of mGluR8 in measures of anxiety involving
non-social and social challenges.</article-title>
<source/>Behav. Brain Res
          <year>2011</year>
<volume>221</volume>
<issue>1</issue>
<fpage>50</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="pmid">21382421</pub-id>
</element-citation>
</ref>
<ref id="R324">
<label>324</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duvoisin</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Villasana</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Winder</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Raber</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Opposing roles of mGluR8 in measures of anxiety involving non-social and social challenges.</article-title>
<source/>Behav. Brain Res.
          <year>2011</year>
<volume>221</volume>
<issue>1</issue>
<fpage>50</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2011.02.049</pub-id>
<pub-id pub-id-type="pmid">21382421</pub-id>
</element-citation>
</ref>
<ref id="R325">
<label>325</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sławińska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wierońska</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Stachowicz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pałucha-Poniewiera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Uberti</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Bacolod</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Doller</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Anxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu<sub>4</sub> receptor.</article-title>
<source/>Neuropharmacology
          <year>2013</year>
<volume>66</volume>
<fpage>225</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.05.001</pub-id>
<pub-id pub-id-type="pmid">22634361</pub-id>
</element-citation>
</ref>
<ref id="R326">
<label>326</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalinichev</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Le Poul</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Boléa</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Girard</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Campo</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Fonsi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Royer-Urios</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Browne</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Uslaner</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Raber</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Duvoisin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bate</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>I.J.</given-names>
</name>
<name>
<surname>Poli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Celanire</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders.</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2014</year>
<volume>350</volume>
<issue>3</issue>
<fpage>495</fpage>
<lpage>505</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.114.214437</pub-id>
<pub-id pub-id-type="pmid">24947466</pub-id>
</element-citation>
</ref>
<ref id="R327">
<label>327</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Haley</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Duvoisin</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Raber</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Measures of anxiety, sensorimotor function, and memory in male and female mGluR4−/− mice.</article-title>
<source/>Behav. Brain Res.
          <year>2012</year>
<volume>229</volume>
<issue>1</issue>
<fpage>21</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2011.12.037</pub-id>
<pub-id pub-id-type="pmid">22227508</pub-id>
</element-citation>
</ref>
<ref id="R328">
<label>328</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Iancu</surname>
<given-names>O.D.</given-names>
</name>
<name>
<surname>Acher</surname>
<given-names>F.C.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Eiwaz</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Duvoisin</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Raber</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Role of mGluR4 in acquisition of fear learning and memory.</article-title>
<source/>Neuropharmacology
          <year>2013</year>
<volume>66</volume>
<fpage>365</fpage>
<lpage>372</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.07.038</pub-id>
<pub-id pub-id-type="pmid">22884897</pub-id>
</element-citation>
</ref>
<ref id="R329">
<label>329</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Linden</surname>
<given-names>A-M.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>B.G.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Shannon</surname>
<given-names>H.E.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Köster</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Baez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schoepp</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor.</article-title>
<source/>Neuropharmacology
          <year>2002</year>
<volume>43</volume>
<issue>2</issue>
<fpage>251</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="pmid">12213279</pub-id>
</element-citation>
</ref>
<ref id="R330">
<label>330</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duvoisin</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pfankuch</surname>
<given-names>T.F.</given-names>
</name>
<name>
<surname>O’Connor</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gayet-Primo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Quraishi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Raber</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Increased measures of anxiety and weight gain in mice lacking the group III metabotropic glutamate receptor mGluR8.</article-title>
<source/>Eur. J. Neurosci.
          <year>2005</year>
<volume>22</volume>
<issue>2</issue>
<fpage>425</fpage>
<lpage>436</lpage>
<pub-id pub-id-type="doi">10.1111/j.1460-9568.2005.04210.x</pub-id>
<pub-id pub-id-type="pmid">16045496</pub-id>
</element-citation>
</ref>
<ref id="R331">
<label>331</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Linden</surname>
<given-names>A-M.</given-names>
</name>
<name>
<surname>Baez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bergeron</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schoepp</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>Increased c-Fos expression in the centromedial nucleus of the thalamus in metabotropic glutamate 8 receptor knockout mice following the elevated plus maze test.</article-title>
<source/>Neuroscience
          <year>2003</year>
<volume>121</volume>
<issue>1</issue>
<fpage>167</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="pmid">12946709</pub-id>
</element-citation>
</ref>
<ref id="R332">
<label>332</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Duvoisin</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Pfankuch</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Grabell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chhajlani</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>D. G.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Raber</surname>
<given-names>J.</given-names>
</name>
</person-group>
<source/>Acute pharmacological modulation of mGluR8 reduces measures of anxiety.
          <year>2010</year>
</element-citation>
</ref>
<ref id="R333">
<label>333</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Fendt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Imobersteg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Peterlik</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chaperon</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mattes</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wittmann</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Olpe</surname>
<given-names>H.-R.</given-names>
</name>
<name>
<surname>Mosbacher</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vranesic</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>van der Putten</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>McAllister</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Flor</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Gee</surname>
<given-names>C. E.</given-names>
</name>
</person-group>
<year>2013</year>
</element-citation>
</ref>
<ref id="R334">
<label>334</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raber</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Duvoisin</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Novel metabotropic glutamate receptor 4 and glutamate receptor 8 therapeutics for the treatment of anxiety.</article-title>
<source/>Expert Opin. Investig. Drugs
          <year>2014</year>
<volume>24</volume>
<issue>4</issue>
<fpage>519</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="doi">10.1517/13543784.2014.986264</pub-id>
</element-citation>
</ref>
<ref id="R335">
<label>335</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masugi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yokoi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shigemoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Muguruma</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sansig</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>van der Putten</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamate receptor subtype 7 ablation causes deficit in fear response and conditioned taste aversion.</article-title>
<source/>J. Neurosci.
          <year>1999</year>
<volume>19</volume>
<issue>3</issue>
<fpage>955</fpage>
<lpage>963</lpage>
<pub-id pub-id-type="pmid">9920659</pub-id>
</element-citation>
</ref>
<ref id="R336">
<label>336</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>P.H.</given-names>
</name>
<name>
<surname>Neijt</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Sansig</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Flor</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>van Der Putten</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7.</article-title>
<source/>Eur. J. Neurosci.
          <year>2003</year>
<volume>17</volume>
<issue>11</issue>
<fpage>2409</fpage>
<lpage>2417</lpage>
<pub-id pub-id-type="pmid">12814372</pub-id>
</element-citation>
</ref>
<ref id="R337">
<label>337</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Mitsukawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ofner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nozulak</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pescott</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Lukic</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Stoehr</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mombereau</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>McAllister</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>van der Putten</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Flor</surname>
<given-names>P. J.</given-names>
</name>
</person-group>
<source/>A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo.
          <year>2005</year>
</element-citation>
</ref>
<ref id="R338">
<label>338</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fendt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Thakker</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Jacobson</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mitsukawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Maier</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Natt</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hüsken</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>P.H.</given-names>
</name>
<name>
<surname>McAllister</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Hoyer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>van der Putten</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Flor</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity.</article-title>
<source/>Mol. Psychiatry
          <year>2008</year>
<volume>13</volume>
<issue>10</issue>
<fpage>970</fpage>
<lpage>979</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4002073</pub-id>
<pub-id pub-id-type="pmid">17712315</pub-id>
</element-citation>
</ref>
<ref id="R339">
<label>339</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Siegl</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Flor</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Fendt</surname>
<given-names>M.</given-names>
</name>
</person-group>
<source/>Amygdaloid metabotropic glutamate receptor subtype 7 is involved in the acquisition of conditioned fear.
          <year>2008</year>
</element-citation>
</ref>
<ref id="R340">
<label>340</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Dobi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sartori</surname>
<given-names>S. B.</given-names>
</name>
<name>
<surname>Busti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Van der Putten</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Singewald</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shigemoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ferraguti</surname>
<given-names>F.</given-names>
</name>
</person-group>
<source/>Neural substrates for the distinct effects of presynaptic group III metabotropic glutamate receptors on extinction of contextual fear conditioning in mice.
          <year>2013</year>
</element-citation>
</ref>
<ref id="R341">
<label>341</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palucha</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Klak</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Branski</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>van der Putten</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Flor</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Activation of the mGlu7 receptor elicits antidepressant-like effects in mice.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>2007</year>
<volume>194</volume>
<issue>4</issue>
<fpage>555</fpage>
<lpage>562</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-007-0856-2</pub-id>
<pub-id pub-id-type="pmid">17622518</pub-id>
</element-citation>
</ref>
<ref id="R342">
<label>342</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pałucha-Poniewiera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brański</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lenda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The antidepressant-like action of metabotropic glutamate 7 receptor agonist N,N’-bis(diphenylmethyl)-1,2-ethanediamine (AMN082) is serotonin-dependent.</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2010</year>
<volume>334</volume>
<issue>3</issue>
<fpage>1066</fpage>
<lpage>1074</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.110.169730</pub-id>
<pub-id pub-id-type="pmid">20562216</pub-id>
</element-citation>
</ref>
<ref id="R343">
<label>343</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Pałucha-Poniewiera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<source/>A selective mGlu7 receptor antagonist MMPIP reversed antidepressant-like effects of AMN082 in rats.
          <year>2013</year>
</element-citation>
</ref>
<ref id="R344">
<label>344</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bradley</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Uslaner</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Flick</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Groover</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Hutson</surname>
<given-names>P.H.</given-names>
</name>
</person-group>
<article-title>The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling.</article-title>
<source/>Pharmacol. Biochem. Behav.
          <year>2012</year>
<volume>101</volume>
<issue>1</issue>
<fpage>35</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2011.11.006</pub-id>
<pub-id pub-id-type="pmid">22138407</pub-id>
</element-citation>
</ref>
<ref id="R345">
<label>345</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stachowicz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Brañski</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kłak</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>van der Putten</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Flor</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Andrzej</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Selective activation of metabotropic  G-protein-coupled glutamate 7 receptor elicits anxiolytic-like effects in mice by modulating GABAergic neurotransmission.</article-title>
<source/>Behav. Pharmacol
          <year>2008</year>
<volume>19</volume>
<issue>5-6</issue>
<fpage>597</fpage>
<lpage>603</lpage>
<pub-id pub-id-type="pmid">18690114</pub-id>
</element-citation>
</ref>
<ref id="R346">
<label>346</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palazzo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Maione</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Neugebauer</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Group III mGluR7 and mGluR8 in the amygdala differentially modulate nocifensive and affective pain behaviors.</article-title>
<source/>Neuropharmacology
          <year>2008</year>
<volume>55</volume>
<issue>4</issue>
<fpage>537</fpage>
<lpage>545</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.05.007</pub-id>
<pub-id pub-id-type="pmid">18533199</pub-id>
</element-citation>
</ref>
<ref id="R347">
<label>347</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>O’Connor</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Thakker</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Schmutz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>van der Putten</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hoyer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Flor</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J. F.</given-names>
</name>
</person-group>
<source/>Adult siRNA-induced knockdown of mGlu7 receptors reduces anxiety in the mouse.
          <year>2013</year>
</element-citation>
</ref>
<ref id="R348">
<label>348</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pelkey</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lavezzari</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Roche</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>McBain</surname>
<given-names>C.J.</given-names>
</name>
</person-group>
<article-title>mGluR7 undergoes rapid internalization in response to activation by the allosteric agonist AMN082.</article-title>
<source/>Neuropharmacology
          <year>2007</year>
<volume>52</volume>
<issue>1</issue>
<fpage>108</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2006.07.020</pub-id>
<pub-id pub-id-type="pmid">16914173</pub-id>
</element-citation>
</ref>
<ref id="R349">
<label>349</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sukoff Rizzo</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dollings</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M-Y.</given-names>
</name>
<name>
<surname>Di</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Platt</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Neal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dwyer</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Bender</surname>
<given-names>C.N.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lock</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kowal</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kramer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Randall</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Huselton</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vishwanathan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tse</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Butera</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ring</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Rosenzweig-Lipson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>Z.A.</given-names>
</name>
<name>
<surname>Dunlop</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise?</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2011</year>
<volume>338</volume>
<issue>1</issue>
<fpage>345</fpage>
<lpage>352</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.110.177378</pub-id>
<pub-id pub-id-type="pmid">21508084</pub-id>
</element-citation>
</ref>
<ref id="R350">
<label>350</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalinichev</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rouillier</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Girard</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Royer-Urios</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bournique</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Finn</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Charvin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Campo</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Le Poul</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mutel</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Poli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Neale</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Salt</surname>
<given-names>T.E.</given-names>
</name>
<name>
<surname>Lütjens</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization.</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2013</year>
<volume>344</volume>
<issue>3</issue>
<fpage>624</fpage>
<lpage>636</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.112.200915</pub-id>
<pub-id pub-id-type="pmid">23257312</pub-id>
</element-citation>
</ref>
<ref id="R351">
<label>351</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Connor</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>The effects of mGlu<sub>7</sub> receptor modulation in behavioural models sensitive to antidepressant action in two mouse strains.</article-title>
<source/>Behav. Pharmacol.
          <year>2013</year>
<volume>24</volume>
<issue>2</issue>
<fpage>105</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="doi">10.1097/FBP.0b013e32835efc78</pub-id>
<pub-id pub-id-type="pmid">23455446</pub-id>
</element-citation>
</ref>
<ref id="R352">
<label>352</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Hikichi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Murai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Okuda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Maehara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Satow</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ise</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nishino</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Takehana</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ohta</surname>
<given-names>H.</given-names>
</name>
</person-group>
<year>2010</year>
</element-citation>
</ref>
<ref id="R353">
<label>353</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gee</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Peterlik</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Neuhäuser</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bouhelal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kaupmann</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Laue</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Uschold-Schmidt</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Feuerbach</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zimmermann</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ofner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>van der Putten</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fendt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vranesic</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Glatthar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Flor</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Blocking metabotropic glutamate receptor subtype 7 (mGlu7) via the Venus flytrap domain (VFTD) inhibits amygdala plasticity, stress, and anxiety-related behavior.</article-title>
<source/>J. Biol. Chem.
          <year>2014</year>
<volume>289</volume>
<issue>16</issue>
<fpage>10975</fpage>
<lpage>10987</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M113.542654</pub-id>
<pub-id pub-id-type="pmid">24596089</pub-id>
</element-citation>
</ref>
<ref id="R354">
<label>354</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Shyn</surname>
<given-names>S. I.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kraft</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Potash</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Knowles</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Weissman</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Garriock</surname>
<given-names>H A</given-names>
</name>
<name>
<surname>Yokoyama</surname>
<given-names>J S</given-names>
</name>
<name>
<surname>McGrath</surname>
<given-names>P J</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>E J</given-names>
</name>
<name>
<surname>Scheftner</surname>
<given-names>W A</given-names>
</name>
<name>
<surname>Coryell</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>W B</given-names>
</name>
<name>
<surname>Jancic</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gejman</surname>
<given-names>P V</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>A R</given-names>
</name>
<name>
<surname>Holmans</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Slager</surname>
<given-names>S L</given-names>
</name>
<name>
<surname>Levinson</surname>
<given-names>D F</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>S. P.</given-names>
</name>
</person-group>
<source/>Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies.
          <year>2011</year>
</element-citation>
</ref>
<ref id="R355">
<label>355</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamilton</surname>
<given-names>S.P.</given-names>
</name>
</person-group>
<article-title>A new lead from genetic studies in depressed siblings: assessing studies of chromosome 3.</article-title>
<source/>Am. J. Psychiatry
          <year>2011</year>
<volume>168</volume>
<issue>8</issue>
<fpage>783</fpage>
<lpage>789</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2011.11060835</pub-id>
<pub-id pub-id-type="pmid">21813496</pub-id>
</element-citation>
</ref>
<ref id="R356">
<label>356</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pałucha-Poniewiera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brański</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wierońska</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Stachowicz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sławińska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The antidepressant-like action of mGlu5 receptor antagonist, MTEP, in the tail suspension test in mice is serotonin dependent.</article-title>
<source/>Psychopharmacology (Berl.)
          <year>2014</year>
<volume>231</volume>
<issue>1</issue>
<fpage>97</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-013-3206-6</pub-id>
<pub-id pub-id-type="pmid">23958941</pub-id>
</element-citation>
</ref>
<ref id="R357">
<label>357</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Ago</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hiramatsu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ishihama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hazama</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hayata-Takano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shintani</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kawasaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Onoe</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nakazato</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Baba</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Takuma</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Matsuda</surname>
<given-names>T.</given-names>
</name>
</person-group>
<year>2013</year>
</element-citation>
</ref>
<ref id="R358">
<label>358</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harvey</surname>
<given-names>B.H.</given-names>
</name>
<name>
<surname>Shahid</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: focus on pharmacology and preclinical translational models.</article-title>
<source/>Pharmacol. Biochem. Behav.
          <year>2012</year>
<volume>100</volume>
<issue>4</issue>
<fpage>775</fpage>
<lpage>800</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2011.06.014</pub-id>
<pub-id pub-id-type="pmid">21708184</pub-id>
</element-citation>
</ref>
<ref id="R359">
<label>359</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Füchsl</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>I.D.</given-names>
</name>
<name>
<surname>Reber</surname>
<given-names>S.O.</given-names>
</name>
</person-group>
<article-title>Stress resilience: a low-anxiety genotype protects male mice from the consequences of chronic psychosocial stress.</article-title>
<source/>Endocrinology
          <year>2014</year>
<volume>155</volume>
<issue>1</issue>
<fpage>117</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="doi">10.1210/en.2013-1742</pub-id>
<pub-id pub-id-type="pmid">24169562</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Fig. (1)</label>
<caption>
<p>
<bold>Schematic representation of mGlu receptors at the synapse.</bold> In general, group I mGlu subtypes are localized postsynaptically, whereas group II and III receptors are localized mainly in presynaptic locations. While the mGlu7 receptor subtype is localized in the active zone, mGlu subtypes 2, 3, 4, and 8 are generally found in perisynaptic locations on the presynapse. Group II and III receptors modulate  the release of glutamate (right, red circles) or 4-aminobutanoic acid, GABA (left, blue circles). At the postsynaptic terminal, the ionotropic (2R)-2-(methylamino)butanedioic acid (NMDA)-, 2-amino-3-(5-methyl-3-oxo-2,3-dihydro-1,2-oxazol-4-yl)propanoic acid (AMPA)- and (2S,3S,4S)-3-(carboxylatomethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylate (kainate, KA)-receptors respond to glutamate with increases in intracellular sodium or calcium, promoting cell excitability. Group I mGlus signal <italic>via</italic> G<sub>q/11</sub> proteins to increase diacylglycerol (DAG) and phosphatidylinositol (PI). Importantly, mGlu5 and NMDA receptors are closely linked to each other <italic>via</italic> Shank, Homer and PSD-95 (postsynaptic density-95) proteins. Postsynaptic mGlu2/3 and GABA<sub>B</sub> receptors couple to cAMP inhibition. Instead, GABA<sub>A</sub> chloride channels modulate intracellular chloride levels. Expression of mGlu3 and mGlu5 on glial cells has emerged as another key site for regulation of synaptic activity, however, the consequences of receptor activation on these cells and the exact signaling pathways are presently not well understood.</p>
</caption>
<graphic xlink:href="CN-14-514_F1"></graphic>
</fig>
<fig id="F2" position="float">
<label>Fig. (2)</label>
<caption>
<p>
<bold>Schematic illustration of the experimental design of the chronic social defeat stress (CSDS) (A) and the chronic subordinate colony housing (CSC) (B) paradigms in mice. (A)</bold> In this CSDS procedure, which lasts for 21 days, experimental animals are introduced to a larger male resident mouse until defeat is achieved. Subsequently, the animals spend 24 h in the same cage, only divided by a holed metal or transparent partition, which only allows sensory but no physical contact. Stressed animals are exposed to a new resident every day to minimize a potential habituation effect. Control mice remain single-housed and unstressed in their home cages for the course of the experiment. Typically, during the last week of the paradigm, all behavioral tests are performed (OF, EPM test, acute stress response test; see [<xref ref-type="bibr" rid="R163">162</xref>, <xref ref-type="bibr" rid="R164">163</xref>]). (B) In the CSC paradigm, male mice weighing 19-21 g are housed singly for one week before they are assigned to the single-housed control (SHC) or the CSC group in a weight-matched manner. In order to induce chronic psychosocial stress, CSC mice are housed together with a larger dominant male for 19 consecutive days. In detail, four experimental CSC mice are put into the homecage of resident (1) on day 1 of CSC, resulting in immediate subordination of the four intruder CSC mice. The latter are then housed together with this dominant resident (1) for 7 consecutive days. On day 8, and again on day 15 of CSC, the four experimental CSC mice are transferred into the homecages of resident (2) (day 8) and resident (3) (day 15), respectively, in order to avoid habituation. On day 19, CSC and SHC mice are usually tested for their innate or physiological anxiety and on day 20 immunological and physiological parameter are assessed.</p>
</caption>
<graphic xlink:href="CN-14-514_F2"></graphic>
</fig>
<fig id="F3" position="float">
<label>Fig. (3)</label>
<caption>
<p>
<bold>Summary of the main effects of chronic psychosocial stress in male mice induced by 19 days of chronic subordinate colony housing (CSC) on behavioral, immunological and physiological parameters.</bold> Compared with single-housed controls (SHC), CSC mice show affective and somatic changes and develop decreased glucocorticoid (GC) signaling. Thus, the CSC paradigm represents a promising animal model to mimic diseases in which decreased GC signaling is a core feature and to unravel the underlying mechanisms of stress-related pathology in humans. Abbreviations: EPM, elevated plus-maze; LDB, light-dark box; EPF, elevated platform; OF, open field; SPAT, social preference/avoidance test; mes LN cells, mesenterial lymph node cells; ACTH, adrenocorticotropic hormone; CORT, corticosterone; LPS, lipopolysaccharide; Th2, T helper 2; adapted from [<xref ref-type="bibr" rid="R41">41</xref>].</p>
</caption>
<graphic xlink:href="CN-14-514_F3"></graphic>
</fig>
<fig id="F4" position="float">
<label>Fig. (4)</label>
<caption>
<p>
<bold>Changes in relative gene expression of distinct mGlu receptors in three different brain regions (PFC, hypothalamus and hippocampus) that occur in response to 19 days of chronic subordinate colony housing (CSC).</bold> As a representative for group I, mGlu5 mRNA, for group II, mGlu2 and mGlu3 mRNA, and for group III, mGlu7 mRNA regulation was assessed relative to expression of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in comparison to respective SHC mice (set at 100%). Total RNA was isolated using Trizol reagent according to the manufacturer's instructions (Peqlab, Erlangen, Germany). RNA was re-suspended in 20 μL of RNase free water and its concentration and quality were analyzed spectrophotometrically (NanoDrop Spectrophotometer, Peqlab, Erlangen, Germany). cDNA was prepared from 500 ng of total RNA in a 20 µL final reverse transcription reaction mixture (using Superscript III; Invitrogen, Karlsruhe, Germany). Quantitative PCR was performed using the SYBR<sup>®</sup> Green Master Mix on an ABI 7500 Fast Sequence Detection System (Applied Biosystems, Darmstadt, Germany), with a thermocycler profile of 95°C (20 sec), followed by 40 cycles of 95°C (3 sec), 60°C (30 sec). Amplification of mGlu2, mGlu3, mGlu5 and mGlu7 receptor cDNA was carried out employing the following primers. mGlu2-forward: 5’-CGTGTCCGTCAGCCTCAGT-3’, mGlu2-reverse: 5’-TGGCTCACCACGACGTTCTTCTG-3’; mGlu3-forward: 5’-TGTGATGGTGTCTGTGTGGCT-3’, mGlu3-reverse: 5’-GTTTCCCGCTTCTCTGGCA-3’; mGlu5-forward: 5’-TGTGTACCTTCTGCC TCATTGC-3’, mGlu5-reverse: 5’-GGAGAGAGACCGATGCCAATT-3’; mGlu7-forward: 5’-GCAGAAGGAGCCATCACCAT-3’, mGlu7-reverse: 5’-GTCCGGGATGTGAAGTAAGCA-3’; GAPDH-forward: 5’-TGTGTCCGTCGTGGATCTGA-3’, GAPDH-reverse: 5’-CCTGC TTCACCACCTTCTTGA-3’. Samples were prepared in triplicates and changes in gene expression were determined with the 2<sup>-ΔΔCT</sup> method [<xref ref-type="bibr" rid="R211">210</xref>]. Arrows indicate either no change (), downregulation () or upregulation () of relative gene expression of respective mGlu mRNA levels in CSC compared to SHC mice. Student’s <italic>t</italic>-test, following <italic>p</italic>-value determination: (1); <italic>p</italic> = 0.07, increase from 100% (SHC) to approximately 180% (CSC). (2); <italic>p</italic> &lt; 0.03, decrease from 100% (SHC) to approximately 50% (CSC).</p>
</caption>
<graphic xlink:href="CN-14-514_F4"></graphic>
</fig>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<title>A summary of mGlu receptor pharmacology focusing on the selection of animal models of acute and chronic stress as detailed in this manuscript (see above).</title>
</caption>
<table frame="border" rules="all" width="100%">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" scope="col" valign="middle">
<bold>Drug</bold>
</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="middle">
<bold>Action</bold>
</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="middle">
<bold>Animal Model(s)</bold>
</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="middle">
<bold>Effect(s)</bold>
</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="middle">
<bold>Reference(s)</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">Fenobam</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu5 NAM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Porter <italic>et al.</italic>, 2005 [<xref ref-type="bibr" rid="R237">236</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">MPEP</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu5 NAM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH, EPM, FST, TST, LH</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic, antidepressant-like</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Spooren <italic>et al.</italic>, 2000 [<xref ref-type="bibr" rid="R238">237</xref>]; Nordquist <italic>et al.</italic>, 2007 [<xref ref-type="bibr" rid="R243">242</xref>]; Garparini <italic>et al.</italic>, 2008 [<xref ref-type="bibr" rid="R241">240</xref>]; Liu <italic>et al.</italic>, 2012 [<xref ref-type="bibr" rid="R242">241</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">MTEP</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu5 NAM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH, EPM, FST, TST</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic, antidepressant-like</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Klodzinska <italic>et al.</italic>, 2004 [<xref ref-type="bibr" rid="R248">247</xref>]; Palucha <italic>et al.</italic>, 2005 [<xref ref-type="bibr" rid="R253">252</xref>]; Molina-Herandez <italic>et al.</italic>, 2006 [<xref ref-type="bibr" rid="R249">248</xref>]; Pomierny-Chamioło <italic>et al.</italic>, 2010 [<xref ref-type="bibr" rid="R250">249</xref>]; Ticha <italic>et al.</italic>, 2011 [<xref ref-type="bibr" rid="R251">250</xref>]; Palucha-Poniewiera <italic>et al.</italic>, 2014 [<xref ref-type="bibr" rid="R357">356</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">GRN-529</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu5 NAM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH, FST, TST</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic, antidepressant-like</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Hughes <italic>et al.</italic>, 2013 [<xref ref-type="bibr" rid="R255">254</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">AFQ056/ mavoglurant</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu5 NAM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Vranesic <italic>et al.</italic>, 2014 [<xref ref-type="bibr" rid="R256">255</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">Basimglurant</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu5 NAM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Jaeschke <italic>et al.</italic>, 2015 [<xref ref-type="bibr" rid="R232">231</xref>]; Lindemann <italic>et al.</italic>, 2015 [<xref ref-type="bibr" rid="R234">233</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">CTEP</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu5 NAM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH, CSDS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic, antidepressant-like: reversal of CSDS-induced reduction of locomotion and anhedonia</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Lindemann <italic>et al.</italic>, 2011 [<xref ref-type="bibr" rid="R229">228</xref>]; Wagner <italic>et al.</italic>, 2014 [<xref ref-type="bibr" rid="R164">163</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">LY354740</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu2/3 agonist</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH, EPM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Linden <italic>et al.</italic>, 2004 [<xref ref-type="bibr" rid="R284">283</xref>]; Rorick-Kehn <italic>et al.</italic>, 2005, 2006 [<xref ref-type="bibr" rid="R269">268</xref>, <xref ref-type="bibr" rid="R286">285</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">LY379268</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu2/3 agonist</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH, FST</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic, antidepressant-like</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Matrisciano <italic>et al.</italic>, 2007 [<xref ref-type="bibr" rid="R289">288</xref>]; Satow <italic>et al.</italic>, 2008 [<xref ref-type="bibr" rid="R270">269</xref>]; Wieronska <italic>et al.</italic>, 2012 [<xref ref-type="bibr" rid="R291">290</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">THIIC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu2 PAM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH, FST</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic, antidepressant-like</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Fell <italic>et al.</italic>, 2011 [<xref ref-type="bibr" rid="R296">295</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">LY487379</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu2 PAM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Wieronska <italic>et al.</italic>, 2012 [<xref ref-type="bibr" rid="R291">290</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">BINA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu2 PAM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH, EPM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Galici <italic>et al.</italic>, 2006 [<xref ref-type="bibr" rid="R299">298</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">MGS0039</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu2/3 antagonist</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH, FST, TST, LH</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic, antidepressant-like</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Chaki <italic>et al.</italic>, 2004 [<xref ref-type="bibr" rid="R300">299</xref>]; Yoshimizu <italic>et al.</italic>, 2006 [<xref ref-type="bibr" rid="R302">301</xref>]; Iijima <italic>et al.</italic>, 2007 [<xref ref-type="bibr" rid="R305">304</xref>]; Palucha-Poniewiera <italic>et al.</italic>, 2010 [<xref ref-type="bibr" rid="R301">300</xref>]; Ago <italic>et al.</italic>, 2013 [<xref ref-type="bibr" rid="R358">357</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">LY341495</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu2/3 preferring antagonist</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH, FST, TST, CMS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic, antidepressant-like: reversal of CMS-induced anhedonia</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Chaki <italic>et al.</italic>, 2004 [<xref ref-type="bibr" rid="R300">299</xref>]; Iijima <italic>et al.</italic>, 2007 [<xref ref-type="bibr" rid="R305">304</xref>]; Bespalov <italic>et al.</italic>, 2008 [<xref ref-type="bibr" rid="R307">306</xref>]; Ago <italic>et al.</italic>, 2013 [<xref ref-type="bibr" rid="R358">357</xref>]; Dwyer <italic>et al.</italic>, 2013 [<xref ref-type="bibr" rid="R309">308</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">RO4491533</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu2/3 NAM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">FST, TST</td>
<td align="center" colspan="1" rowspan="1" valign="middle">antidepressant-like</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Campo <italic>et al.</italic>, 2011 [<xref ref-type="bibr" rid="R308">307</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">ACPT-I</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu4/6/7/8 agonist</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH, EPM, FST</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic, antidepressant-like</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Tatarczynska <italic>et al.</italic>, 2002 [<xref ref-type="bibr" rid="R319">318</xref>]; Stachowicz <italic>et al.</italic>, 2009 [<xref ref-type="bibr" rid="R320">319</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">PHCCC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu4 PAM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">FST</td>
<td align="center" colspan="1" rowspan="1" valign="middle">antidepressant-like (in combination with ACPT-I)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Klak <italic>et al.</italic>, 2007 [<xref ref-type="bibr" rid="R322">321</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">Lu AF21934</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu4 PAM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Slawinska <italic>et al.</italic>, 2013 [<xref ref-type="bibr" rid="R326">325</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">ADX88178</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu4 PAM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">EPM, FST</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic, antidepressant-like</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Kalinichev <italic>et al.</italic>, 2014 [<xref ref-type="bibr" rid="R327">326</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">DCPG</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu8 agonist</td>
<td align="center" colspan="1" rowspan="1" valign="middle">EPM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Duvoisin <italic>et al.</italic>, 2010 [<xref ref-type="bibr" rid="R333">332</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">AMN082</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu7 agonist</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH, EPM, FST, TST</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic, antidepressant-like</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Palucha <italic>et al.</italic>, 2007 [<xref ref-type="bibr" rid="R342">341</xref>]; Stachowicz <italic>et al.</italic>, 2008 [<xref ref-type="bibr" rid="R346">345</xref>]; Palazzo <italic>et al.</italic>, 2008 [<xref ref-type="bibr" rid="R347">346</xref>]; Bradley <italic>et al.</italic>, 2012 [<xref ref-type="bibr" rid="R345">344</xref>]; O’Connor and Cryan, 2013 [<xref ref-type="bibr" rid="R352">351</xref>]; Palucha-Poniewiera <italic>et al.</italic>, 2010, 2013, 2014 [<xref ref-type="bibr" rid="R72">72</xref>, <xref ref-type="bibr" rid="R343">342</xref>, <xref ref-type="bibr" rid="R344">343</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">ADX71743</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu7 NAM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">EPM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Kalinichev <italic>et al.</italic>, 2013 [<xref ref-type="bibr" rid="R351">350</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="middle">XAP044</td>
<td align="center" colspan="1" rowspan="1" valign="middle">mGlu7 antagonist</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SIH, EPM, TST</td>
<td align="center" colspan="1" rowspan="1" valign="middle">anxiolytic, antidepressant-like</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Gee <italic>et al.</italic>, 2014 [<xref ref-type="bibr" rid="R354">353</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>